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1.	  The	  need	  for	  updated	  guidance	  
These	  guidelines	  provide	  updated,	  GRADE-­‐based	  recommendations	  on	  the	  use	  of	  vaccines	  in	  HIV-­‐
positive	  adults.	  Several	  factors	  have	  made	  the	  updating	  of	  HIV-­‐specific	  vaccination	  guidelines	  
important:	  effective	  antiretroviral	  therapy	  (ART)	  has	  substantially	  modified	  the	  natural	  history	  of	  HIV	  
infection,	  vaccination	  practices	  are	  evolving,	  and	  a	  large	  number	  of	  novel	  vaccines	  are	  becoming	  
available	  in	  clinical	  care.	  The	  update	  contains	  important	  new	  guidance	  regarding	  the	  use	  of	  new	  
vaccines	  against	  human	  papillomavirus	  (HPV),	  shingles	  (herpes	  zoster),	  and	  pneumococcus.	  Further	  
key	  updates	  are	  related	  to	  the	  use	  of	  hepatitis	  B,	  meningococcus,	  and	  pertussis	  vaccines.	  
	  
Compared	  with	  HIV-­‐negative	  individuals,	  HIV-­‐positive	  adults	  often	  have	  an	  increased	  risk	  of	  infection	  
or	   experience	   more	   severe	   morbidity	   following	   exposure	   to	   vaccine-­‐preventable	   diseases,	   and	  
therefore	   a	   lower	   threshold	   for	   extending	   indications	   and	   offering	   vaccination	  may	   be	   appropriate	  
relative	  to	  the	  general	  population.	   Improved	  health	  and	  prognosis	  mean	  that	  HIV-­‐positive	  adults	  are	  
also	   increasingly	   likely	   to	  engage	   in	   travel	  or	  occupations	   that	   carry	   a	   risk	  of	   exposure	   to	   infectious	  
agents,	  and	  these	  otherwise	  healthy	  individuals	  should	  not	  be	  denied	  protection	  or	  engagement	  with	  
such	   activities	   if	   evidence	   indicates	   vaccination	   is	   safe	   and	   immunogenic.	   Immune	   responses	   to	  
vaccination	   are	   often	   sub-­‐optimal	   in	  HIV-­‐positive	   patients,	   and	  while	   these	   improve	  with	  ART,	   they	  
often	  remain	  lower	  and	  decline	  more	  rapidly	  than	  in	  HIV-­‐negative	  individuals.	  However,	  many	  of	  these	  
vaccines	   still	   afford	   protection	   and	   for	   some	   vaccines	   it	   is	   possible	   to	   improve	   immunogenicity	   by	  
offering	   modified	   vaccine	   schedules,	   with	   higher	   or	   more	   frequent	   doses,	   without	   compromising	  
safety.	  	  
	  
Non-­‐replicating	  vaccines	  (e.g.,	  whole	  inactivated,	  polysaccharide,	  conjugated,	  and	  subunit	  vaccines,	  or	  
virus-­‐like	  particles)	  can	  be	  used	  safely	  in	  HIV-­‐positive	  persons,	  whereas	  replicating	  (live)	  vaccines	  have	  
traditionally	  been	  contraindicated.	  However,	  ART-­‐induced	  Immunorestoration	  reduces	  the	  risk	  of	  
adverse	  events,	  in	  many	  cases	  shifting	  the	  risk-­‐benefit	  ratio	  in	  favour	  of	  vaccination,	  whereby	  the	  risk	  
of	  disease	  with	  natural	  infection	  becomes	  greater	  than	  the	  risk	  of	  live	  vaccine-­‐related	  adverse	  events.	  
Important	  examples	  of	  replicating	  vaccines	  that	  can	  be	  used	  in	  HIV-­‐positive	  persons	  with	  good	  
immunity	  include	  those	  for	  measles,	  mumps	  and	  rubella	  (MMR),	  varicella-­‐zoster	  virus	  (VZV),	  and	  
yellow	  fever.	  For	  vaccinated	  individuals,	  the	  importance	  of	  infection	  avoidance	  and	  infection	  control	  
should	  continue	  to	  be	  emphasised.	  
	  
It	   is	   envisaged	   that	   the	  HIV	   specialist	   should	  provide	  overall	   guidance	  on	  vaccine	  use	  and	  enlist	   the	  
help	   of	   primary	   care	   physicians	   for	   vaccine	   administration.	   Education	   of	   health	   care	   providers	   and	  
good	   communication	   are	   key	   requirements	   to	   ensure	   successful	   implementation	   of	   this	   guidance.	  
Despite	  evidence	  that	  HIV-­‐positive	  persons	  benefit	  from	  vaccination,	  there	  are	  persisting	  perceptions	  
about	  disease	   incidence	   and	   burden,	   and	   vaccine	   effectiveness	   and	   safety,	  which	   affect	   vaccination	  
practices	   among	   health	   professionals	   caring	   for	  HIV-­‐positive	  patients.	   It	   is	   hoped	   that	   this	   guidance	  
will	  help	  overcoming	  such	  barriers.	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Key	  points:	  Vaccination	  of	  HIV-­‐positive	  adults	  
• High	  risk	  of	  infection	   Lowers	  threshold	  for	  vaccination	  
• High	  risk	  of	  severe	  disease	  	  
Lowers	  threshold	  for	  vaccination	  	  
Extends	  indications	  for	  vaccination	  
• Improved	  prognosis	  
Allows	  engagement	  with	  exposure-­‐prone	  occupations	  and	  travel	  
Increases	  the	  likely	  impact	  of	  vaccine-­‐preventable	  infections	  
• Immunorestoration	  
Improves	  vaccine	  immunogenicity	  	  
Overcomes	  traditional	  contraindications	  to	  replicating	  vaccines	  
• Reduced	  immunogenicity	   May	  be	  overcome	  with	  higher	  and	  more	  frequent	  vaccine	  doses	  
• Perceptions	   Create	  barriers	  to	  effective	  vaccination	  
• Evolving	  knowledge	  	   Requires	  education	  of	  health	  care	  professionals	  and	  effective	  communication	  between	  primary	  and	  specialist	  care	  providers	  
	  
2.	  How	  to	  use	  the	  guidelines	  
• The	   guidelines	   are	  meant	   to	   highlight	   specific	   aspects	   of	   vaccine	   use	   that	   are	   relevant	   to	   HIV-­‐
positive	   adults.	   They	   are	   intended	   to	  be	   complementary	   to	  national	   guidance	   available	   through	  
The	   Green	   Book	   [www.gov.uk/government/collections/immunisation-­‐against-­‐infectious-­‐disease-­‐
the-­‐green-­‐book],	   to	  which	   readers	   should	   refer	   for	   the	   latest	   information	   on	   available	   vaccines	  
and	  vaccination	  procedures	  in	  the	  United	  Kingdom	  (UK)	  
• For	  epidemiological	  information	  relevant	  to	  the	  use	  of	  travel-­‐related	  vaccines,	  the	  reader	  is	  invited	  
to	  consult	  guidance	  for	  health	  professionals	  available	  through	  the	  National	  Travel	  Health	  Network	  
and	  Centre	   [www.nathnac.org/ds/map_world.aspx].	  Country-­‐specific	   information	  for	   travellers	   is	  
also	  available	  from	  Public	  Health	  England	  [www.gov.uk/government/organisations/public-­‐health-­‐
england];	   Health	   Protection	   Scotland	   [www.hps.scot.nhs.uk];	   Travax	   [www.travax.nhs.uk];	   and	  
FitForTravel	  [www.fitfortravel.nhs.uk]	  
• Table	  1	  summarises	  the	  recommendations	  contained	  in	  the	  guidelines.	  The	  reader	  should	  refer	  to	  
the	  individual	  chapters	  for	  details	  	  
	  
3.	  General	  principles	  	  
	  
Replicating	  (live)	  vaccines:	  	  
• HIV-­‐positive	  adults	  with	  CD4	  counts	  <200	  cells/μL	  must	  not	  be	  given	  replicating	  vaccines	  due	  to	  a	  
potential	   risk	   of	   vaccine-­‐associated	   disease;	   when	   indicated,	   vaccination	   should	   be	   postponed	  
until	  the	  CD4	  cell	  count	  has	  improved	  on	  ART	  (refer	  to	  individual	  chapters	  for	  details)	  
• HIV-­‐positive	   adults	   with	   a	   CD4	   count	   of	   200-­‐350	   cells/μL	   have	   moderate	   immunodeficiency.	  
Clinical	  judgment	  should	  be	  used	  to	  guide	  the	  use	  of	  replicating	  vaccines	  in	  these	  patients.	  Where	  
exposure	   is	   likely,	   natural	   infection	   often	   carries	   a	   greater	   risk	   of	   adverse	   outcomes	   than	  
vaccination;	   a	   suppressed	   plasma	   HIV-­‐1	   RNA	   (“viral”)	   load	   on	   ART	   increases	   the	   safety	   and	  
immunogenicity	  of	  vaccination	  in	  this	  group	  
• The	  co-­‐administration	  of	  multiple	  replicating	  vaccines	  is	  not	  recommended	  in	  HIV-­‐positive	  adults	  
due	   to	   uncertainties	   over	   safety,	   immunogenicity,	   and	   efficacy.	   An	   interval	   of	   at	   least	   4	   weeks	  
between	  vaccinations	  is	  recommended	  [1D]	  
• Regardless	  of	  the	  CD4	  cell	  count,	  contraindications	  to	  the	  use	  of	  replicating	  vaccines	  that	  apply	  to	  
the	  general	  population	   (e.g.,	   in	   relation	  to	   the	  use	  of	   immunosuppressive	  therapy)	  also	  apply	   to	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5	  
HIV-­‐positive	   patients.	   The	   reader	   should	   refer	   to	   The	   Green	   Book	   for	   details	  
[www.gov.uk/government/collections/immunisation-­‐against-­‐infectious-­‐disease-­‐the-­‐green-­‐book]	  
• Replicating	   vaccines	   (except	   Yellow	   Fever)	   should	   be	   administered	   at	   least	   14	   days	   before	   or	   3	  
months	   after	   the	   administration	   of	   antibody-­‐containing	   blood	   products,	   because	   passively	  
acquired	  antibodies	  may	  interfere	  with	  the	  response	  to	  the	  vaccine	  
	  
Patients	  with	  CD4	  counts	  <200	  cells/μL:	  	  
• Replicating	  (live)	  vaccines	  are	  contraindicated	  
• Responses	  to	  non-­‐replicating	  vaccines	  are	  reduced.	  Depending	  on	  the	  level	  of	  risk,	  consideration	  
may	  be	   given	   to	  delaying	   vaccination	  until	   the	  CD4	   cell	   count	  has	   recovered	  with	  ART.	  Because	  
responses	   to	   vaccination	  are	  observed	   in	   a	   substantial	   proportion	  of	   patients	  with	   low	  CD4	   cell	  
counts	  however,	   the	  potential	  benefit	  of	   vaccination	   should	  not	  be	  denied	   to	  persons	  at	   risk	  of	  
exposure.	   If	   indicated,	   the	   vaccine	   course	   can	   be	   repeated	   following	   immunoreconstitution	   on	  
ART	  rather	  than	  postponed	  [1C]	  
	  
Travel	  vaccines:	  	  
• Destination,	   itinerary,	   length	   of	   stay,	   and	   planned	   activities	  must	   be	   considered	   equally	   in	   HIV-­‐
positive	   and	   HIV-­‐negative	   travellers	   when	   recommending	   vaccination.	   However,	   the	  
consequences	  of	  not	  administering	  an	  indicated	  vaccine	  may	  be	  more	  severe	  in	  people	  with	  HIV	  
• HIV-­‐positive	  vaccine	  recipients	  should	  be	  advised	  that	  the	  levels	  and	  duration	  of	  vaccine-­‐induced	  
protection	  might	   be	   reduced	   relative	   to	   HIV-­‐negative	   individuals.	   The	   importance	   of	   additional	  
measures	   of	   protection	   (e.g.,	   hand	   washing,	   against	   insect	   bites,	   food	   hygiene)	   should	   be	  
emphasised	  
	  
Effects	  of	  vaccination	  on	  viral	  load:	  
• Transient,	   clinically	   non-­‐significant	   increases	   in	   viral	   load	   have	   been	   reported	   in	   HIV-­‐positive	  
persons	   after	   the	   administration	   of	   several	   vaccines.	   Concerns	   related	   to	   the	   induction	   of	   HIV	  
replication	  are	  counterbalanced	  by	  the	  benefit	  of	  vaccination,	  and	  do	  not	  preclude	  vaccination	  
	  
	  General	  contraindications:	  
• As	   a	   general	   rule,	   vaccines	   are	   contraindicated	   in	   persons	   with	   a	   history	   of	   previous	   severe	  
adverse	   reaction	   or	   allergy	   to	   the	   vaccine	   or	   its	   components.	   In	   addition,	   persons	   with	   acute	  
moderate	   or	   severe	   febrile	   illness	   should	   not	   usually	   be	   vaccinated	   until	   their	   symptoms	   have	  
abated	  
• Non-­‐replicating	   vaccines	   may	   be	   used	   in	   pregnancy	   and	   during	   breastfeeding	   if	   there	   is	   a	  
significant	  risk	  of	  infection	  or	  other	  clinical	  indication.	  Replicating	  vaccines	  are	  contraindicated	  in	  
pregnancy,	  although	  in	  most	  cases	  the	  theoretical	  risk	  to	  the	  developing	  foetus	  is	  expected	  to	  be	  
low	  
	  
4.	  Sources	  of	  evidence	  
Available	  evidence	  was	  obtained	  from	  published	  peer-­‐reviewed	  studies	  and	  from	  studies	  presented	  at	  
international	   conferences	   in	   the	   last	   two	   years.	   In	   addition,	   the	   following	  websites	  were	   consulted:	  
The	   Green	   Book	   [www.gov.uk/government/collections/immunisation-­‐against-­‐infectious-­‐disease-­‐the-­‐
green-­‐book];	   the	   Centers	   for	   Disease	   Control	   &	   Prevention	  
[www.cdc.gov/vaccines/hcp/acip-­‐recs/index.html];	   and	   the	   World	   Health	   Organization	   [WHO;	  
www.who.int/en].	   The	   following	   US	   guidelines	   were	   also	   reviewed:	   Recommendations	   from	   the	  
Centers	   for	  Disease	  Control	  and	  Prevention,	   the	  National	   Institutes	  of	  Health,	  and	   the	  HIV	  Medicine	  
Association	   of	   the	   Infectious	   Diseases	   Society	   of	   America:	   Guidelines	   for	   the	   Prevention	   and	  
Treatment	   of	   Opportunistic	   Infections	   in	   HIV-­‐Infected	   Adults	   and	   Adolescent	   (updated	   April	   2015)	  
[aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf];	   Hibberd	   PL.	   Immunizations	   in	   HIV-­‐infected	  
patients.	  UpToDate	  May	  2015	  [www.uptodate.com]	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5.	  Summary	  of	  the	  modified	  GRADE	  system	  	  
BHIVA	   revised	  and	  updated	   the	  association’s	   guideline	  development	  manual	   in	  2011	   [1].	   BHIVA	  has	  
adopted	   the	   modified	   Grading	   of	   Recommendations	   Assessment,	   Development	   and	   Evaluation	  
(GRADE)	   system	   for	   the	   assessment,	   evaluation,	   and	   grading	   of	   evidence	   and	   the	   development	   of	  
recommendations	   [2,3].	   Strong	   recommendations	   are	   graded	   1	   A-­‐D.	   Weak	   recommendations	   are	  
suggestions	   graded	  2	  A-­‐D.	   Clinicians	   should	   follow	  a	   strong	   recommendation	  unless	   there	   is	   a	   clear	  
rationale	  for	  an	  alternative	  approach.	  Consensus	  opinion	  on	   good	   practice	   is	   indicated	   as	   GPP	   (Good	  
Practice	  Point).	  
Summary	  modified	  GRADE	  system	  
Grade	  Quality	  of	  
evidence	  
Benefits,	  source	  of	  evidence,	  impact	  of	  further	  research,	  recommendation	  
1A	   High	  	   • Benefits	  clearly	  outweigh	  risks	  and	  burdens,	  or	  vice	  versa	  
• Consistent	  evidence	  from	  well	  performed	  randomised,	  controlled	  trials	  or	  
overwhelming	  evidence	  of	  some	  other	  form	  
• Further	  research	  is	  unlikely	  to	  change	  confidence	  in	  estimate	  of	  benefits	  and	  risks	  
• Strong	  recommendations,	  can	  apply	  to	  most	  patients	  in	  most	  circumstances	  
without	  reservation	  
1B	  	   Moderate	  	  • Benefits	  clearly	  outweigh	  risks	  and	  burdens,	  or	  vice	  versa	  	  
• Evidence	  from	  randomised,	  controlled	  trials	  with	  important	  limitations	  
(inconsistent	  results,	  methods	  flaws,	  indirect	  or	  imprecise),	  or	  very	  strong	  
evidence	  of	  some	  other	  research	  design	  
• Further	  research	  may	  impact	  on	  confidence	  in	  the	  estimate	  of	  benefits	  and	  risks	  
• Strong	  recommendation	  and	  applies	  to	  most	  patients	  	  
1C	  	   Low	  	   • Benefits	  appear	  to	  outweigh	  risks	  and	  burdens,	  or	  vice	  versa	  	  
• Evidence	  from	  observational	  studies,	  unsystematic	  clinical	  experience,	  or	  from	  
randomised,	  controlled	  trials	  with	  serious	  flaws	  
• Any	  estimate	  of	  effect	  is	  uncertain.	  Strong	  recommendation,	  and	  applies	  to	  most	  
patients.	  Some	  of	  the	  evidence	  base	  supporting	  the	  recommendation	  is,	  however,	  
of	  low	  quality	  
1D	  	   Very	  low	  	   • Benefits	  appear	  to	  outweigh	  risks	  and	  burdens,	  or	  vice	  versa	  
• Evidence	  limited	  to	  case	  studies	  
• Strong	  recommendation	  based	  mainly	  on	  case	  studies	  and	  expert	  judgment	  
2A	  	  
	  
High	  	   • Benefits	  closely	  balanced	  with	  risks	  and	  burdens	  
• Consistent	  evidence	  from	  well	  performed	  randomised,	  controlled	  trials	  or	  
overwhelming	  evidence	  of	  some	  other	  form	  
• Further	  research	  is	  unlikely	  to	  change	  confidence	  in	  estimate	  of	  benefits	  and	  risks	  
• Weak	  recommendation,	  best	  action	  may	  differ	  depending	  on	  circumstances,	  
patients,	  or	  societal	  values	  
2B	  	   Moderate	   • Benefits	  closely	  balanced	  with	  risks	  and	  burdens,	  some	  uncertainly	  in	  the	  
estimates	  of	  benefits,	  risks	  and	  burdens	  
• Evidence	  from	  randomised,	  controlled	  trials	  with	  important	  limitations	  
(inconsistent	  results,	  methods	  flaws,	  indirect	  or	  imprecise)	  
• Further	  research	  may	  change	  the	  estimate	  of	  benefits	  and	  risks	  
• Weak	  recommendation,	  alternative	  approaches	  likely	  to	  be	  better	  for	  some	  
patients	  under	  some	  circumstances	  
2C	  	   Low	   • Uncertainty	  in	  the	  estimates	  of	  benefits,	  risks,	  and	  burdens;	  benefits	  may	  be	  
closely	  balanced	  with	  risks	  and	  burdens	  
• Evidence	  from	  observational	  studies,	  unsystematic	  clinical	  experience,	  or	  from	  
randomised,	  controlled	  trials	  with	  serious	  flaws	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   GH,	   Oxman	   AD,	   Kunz	   R	   et	   al.	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   from	   evidence	   to	   recommendations.	   BMJ	   2008;336:	  
1049-­‐51.	  	  
3.	   The	   Grading	   of	   Recommendations	   Assessment,	   Development	   and	   Evaluation	   (short	   GRADE)	  
Working	  Group.	  www.gradeworkinggroup.org	  	  
	  
• Any	  estimate	  of	  effect	  is	  uncertain	  
• Weak	  recommendation;	  other	  alternatives	  may	  be	  reasonable	  
2D	  	   Very	  low	   • Uncertainty	  in	  the	  estimates	  of	  benefits,	  risks,	  and	  burdens;	  benefits	  may	  be	  
closely	  balanced	  with	  risks	  and	  burdens	  
• Evidence	  limited	  to	  case	  studies	  and	  expert	  judgment	  
• Very	  weak	  recommendation;	  other	  alternatives	  may	  be	  equally	  reasonable	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TABLE 1. SUMMARY OF RECOMMENDATIONS 
Infection/Disease	   Vaccine	   Replicating	   Primary	  course	   Indication	   Notes	  
Vaccines	  with	  broad	  indications	  in	  adults	  
Hepatitis	  B	   Subunit	  	   No	   4	  doses	   All	  non-­‐immune	   Engerix	  B/HBvaxPRO	  40µg;	  Fendrix	  20µg	  
Influenza	  	   Inactivated	   No	   1	  dose	   All	  yearly	   Quadrivalent	  vaccine	  preferred	  	  
Pneumococcus	   Conjugated	  	   No	   1	  dose	   All	  once	   PCV-­‐13	  	  
Human	  papilloma	  virus	   VLP	   No	   3	  doses	   Age	  and	  gender	  related	   4vHPV	  or	  9vHPV	  preferred	  
Hepatitis	  A	   Inactivated	   No	   2-­‐3	  doses	   At	  risk	  	   3	  doses	  if	  CD4	  counts	  <350	  cells/μL	  
Meningococcus	  	   Conjugated	  	   No	   2	  doses	   Age	  related,	  at	  risk	   MenC,	  MenACWY	  
Meningococcus	  	   Recombinant	  protein	  +	  OMV	  	   No	   2	  doses	   Age	  related,	  at	  risk	   MenB	  
Pertussis	  	   Acellular	  multicomponent	   No	   1	  dose	   Pregnant	  women	   Given	  as	  combined	  dTaP/IPV	  vaccine	  
Pneumococcus	   Polysaccharide	  	   No	   1	  dose	   At	  risk,	  once	   PPV-­‐23	  
Measles,	  Mumps,	  Rubella	   Live	  attenuated	   Yes	   2	  doses	   All	  non-­‐immune	   Given	  as	  combined	  MMR	  vaccine,	  CD4	  >200	  cells/µL	  
Varicella	  (chickenpox)	   Live	  attenuated	   Yes	   2	  doses	   All	  non-­‐immune	   CD4	  >200	  cells/µL	  
Herpes	  zoster	  (shingles)	   Live	  attenuated	   Yes	   1	  dose	   All	  VZV	  IgG+,	  age	  related	   CD4	  >200	  cells/µL	  
Vaccines	  with	  predominantly	  travel-­‐related	  indications	  in	  adults	  
Cholera	  	   Inactivated	  +	  subunit	   No	   2	  doses	   Selective	  use	   WC/rBs,	  oral	  administration	  	  
Japanese	  encephalitis	   Vero	  cell-­‐derived	  inactivated	   No	   2	  doses	   	   	  
Tick-­‐borne	  encephalitis	  	   Inactivated	   No	   3-­‐4	  doses	   	   	  
Tetanus	   	  Toxoid	   No	   1	  dose	   	   Given	  as	  combined	  Td/IPV	  vaccine	  
Diphtheria	   	  Toxoid	  	   No	   1	  dose	   	   Given	  as	  combined	  Td/IPV	  vaccine	  
Poliovirus	   	  Inactivated	   No	   1	  dose	   	   Given	  as	  combined	  Td/IPV	  vaccine	  
Rabies	   Cell-­‐culture	  derived	   No	   3	  doses	   	   5	  doses	  for	  post-­‐exposure	  prophylaxis	  
Typhoid	  	   Polysaccharide	   No	   1	  dose	   	   ViCPS,	  parenteral	  
Yellow	  Fever	   Live	  attenuated	   Yes	   1	  dose	   	   <60	  years;	  CD4	  >200	  cells/μL	  
Vaccines	  with	  selected	  indications	  for	  at	  risk	  adults	  
Anthrax	   Filtrate	  of	  bacterial	  proteins	   No	   4	  doses	   Occupational	  	   AVP	  
Haemophilus	  Influenzae	  B	   Conjugated	   No	   1	  dose	   At	  risk	   Given	  as	  combined	  vaccines	  -­‐	  	  Hib/MenC	  
Smallpox	  	   MVA	   No	   2	  doses	   Occupational	  
Not	  preferred	  and	  contraindicated	  vaccines	  
Hepatitis	  A/B	   	   No	   	   Not	  preferred	   Reduced	  immunogenicity	  	  
Hepatitis	  A/typhoid	   	   No	   	   Not	  preferred	   Reduced	  HAV	  immunogenicity	  
Influenza	  	   Live	  attenuated	   Yes	   	   Contraindicated	   Intranasal	  
Smallpox	  live	  	   Vaccinia	  virus	   Yes	   	   Contraindicated	   May	  be	  considered	  if	  CD4	  >200	  cells/µL	  
Tuberculosis	   BCG	   Yes	   	   Contraindicated	   	  
Typhoid	  	   Live	  attenuated	   Yes	   	   Contraindicated	   Oral	  administration	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VLP=	   Virus-­‐like	   particle;	   OVM=Outer	   membrane	   vesicles;	   Td/IPV=	   Tetanus/diphtheria/Inactivated	   Poliovirus;	   dTaP/IPV	   =	   diphtheria/Tetanus/acellular	  
Pertussis/Inactivated	   Poliovirus;	   VZV=	   Varicella	   Zoster	   Virus;	   AVP=Anthrax	   Vaccine	   Precipitated;	   MVA=Modified	   Vaccinia	   Ankara;	   ViCPS=	   Vi	   capsular	  
polysaccharide	  vaccine	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1.	   Infection	  and	  disease:	  Bacillus	  anthracis	   is	  a	  toxin-­‐producing	  gram-­‐positive	  bacterium	  transmitted	  
through	   spores	   that	   can	  be	   found	   in	  animal	  products	  and	  can	   remain	  viable	   in	   the	  environment	   for	  
years.	   The	   infection	   occurs	   primarily	   in	   herbivorous	  mammals.	   Human	   infection	   is	   rare	   and	   occurs	  
almost	   exclusively	   after	   contact	   with	   infected	   animals	   or	   animal	   products.	   Person-­‐to-­‐person	  
transmission	  may	  occur	  through	  contact	  with	  skin	  lesions	  but	  is	  unusual	  [1].	  The	  disease	  may	  present	  
as	  one	  of	  three	  syndromes:	  cutaneous	  (50%	  of	  cases,	  rare	  mortality);	  respiratory	  (50%	  mortality);	  and	  
gastrointestinal	  (very	  rare,	  25-­‐60%	  mortality).	  Meningitis	  may	  occur	  and	  is	  usually	  fatal.	  Provided	  it	  is	  
recognized	  early,	  anthrax	  can	  be	  treated	  effectively	  with	  antibiotics.	  	  
	  
2.	   Epidemiology:	   Anthrax	   occurs	   in	   Asia,	   Africa,	   and	   parts	   of	   Europe	   and	   the	   Americas.	   In	   the	   UK,	  
human	   anthrax	   is	   rare	   and	   is	   seen	   almost	   entirely	   as	   an	   occupational	   disease	   in	   persons	   handling	  
imported	   animal	   products	   or	   working	   with	   infected	   animals.	   Cases	   have	   been	   reported	   in	   abattoir	  
workers,	  tannery/leather	  workers,	  farm	  workers,	  butchers,	  engineers,	  textile	  workers,	  and	  bone	  meal	  
workers.	  	  
	  
3.	  Anthrax	  in	  HIV-­‐positive	  people:	   It	  is	  not	  known	  whether	  the	  natural	  history	  of	  anthrax	  is	  modified	  
by	  HIV	  infection.	  
	  
4.	  Anthrax	   vaccine:	  The	  British	  vaccine	   -­‐	  Anthrax	  Vaccine	  Precipitated	   (AVP)	   -­‐	   is	  non-­‐replicating	  and	  
contains	  a	  cell-­‐free	  filtrate	  of	  B.	  anthracis	  proteins.	  The	  product	  licence	  (PL	  1511/0058)	  is	  held	  by	  the	  
UK	  Department	  of	  Health.	  The	  anthrax	  vaccine	  adsorbed	  (AVA)	  is	  licensed	  for	  use	  in	  humans	  In	  the	  US.	  
AVP	   is	  given	  by	  parenteral	  administration.	  There	  have	  been	  no	   formal	  efficacy	   trials	  with	  AVP.	  Data	  
from	   the	  UK	   and	  US	   suggest	   that	   anthrax	   vaccination	  prevents	   disease	   [2,3].	   Anthrax	   vaccination	   is	  
considered	   safe	   [4-­‐13].	   Injection	   site	   reactions	   occur	   in	   47%	   of	   AVP	   recipients	   [4].	   Follow-­‐up	   data	  
ranging	  from	  3	  to	  6	  years	  show	  no	  overall	  adverse	  health	  effects	  following	  receipt	  of	  AVP	  [10].	  	  
	  
General	  indications:	  Anthrax	  vaccination	  is	  indicated	  in	  those	  with	  a	  significant	  risk	  of	  exposure.	  In	  the	  
UK,	  it	  is	  available	  to	  the	  Department	  of	  Health	  for	  occupational	  health	  purposes	  and	  to	  the	  Ministry	  of	  
Defence	  to	  protect	  service	  personnel	  from	  the	  use	  of	  anthrax	  as	  a	  biological	  weapon.	  	  
	  
5.	  Anthrax	  vaccine	   in	  HIV-­‐positive	  adults:	  No	  data	  are	  available	  on	  the	  immunogenicity,	  safety,	  and	  
efficacy	  of	  anthrax	  vaccination	  in	  HIV-­‐positive	  persons.	  	  
	  
6.	  Post-­‐exposure	  prophylaxis:	  Following	  a	  credible	  or	  confirmed	  exposure	  to	  anthrax,	  post-­‐exposure	  
prophylaxis	   consists	  of	   antibiotic	   therapy	   (e.g.,	   oral	   ciprofloxacin)	   and	  may	  also	   include	   the	  vaccine.	  
Vaccination	   is	   recommended	   because	   of	   the	   uncertainty	   of	   when	   or	   if	   the	   inhaled	   spores	   may	  
germinate.	  Advice	  must	  be	  obtained	  from	  Public	  Health	  England	  or	  other	  appropriate	  agencies.	  	  
	  
7.	  Recommendations	  for	  HIV-­‐positive	  adults	  
• We	  recommend	  that	  HIV-­‐positive	  adults	  at	  significant	  risk	  of	  anthrax	  exposure	  (typically	  through	  
occupation)	  be	  offered	  vaccination	  in	  accordance	  with	  general	  indications,	  and	  regardless	  of	  CD4	  
count,	  ART	  use,	  and	  viral	  load	  [1D]	  
o We	   recommend	   a	   primary	   vaccine	   course	   consisting	   of	   4	   parental	   doses	   of	   the	   non-­‐
replicating	  AVP	  vaccine	  given	  at	  0,	  3	  weeks,	  6	  weeks,	  and	  6	  months,	  with	  a	  booster	  dose	  
given	  annually	  to	  those	  at	  continued	  risk	  [1D]	  
Draft	  BHIVA	  guidelines	  on	  the	  use	  of	  vaccines	  in	  HIV-­‐positive	  adults	  2015	  
 
Consultation	  draft	  	   	   	  
 
11	  
o We	  recommend	  that	  patients	  with	  CD4	  count	  <200	  cells/μL	  be	  counselled	  about	  potential	  
non-­‐response	   to	   vaccination	   and	   managed	   accordingly.	   Deferred	   or	   repeat	   vaccination	  
may	  be	  indicated	  following	  Immunorestoration	  on	  ART	  [1D]	  
• We	  recommend	  that	  following	  a	  credible	  or	  confirmed	  exposure	  to	  anthrax,	  HIV-­‐positive	  contacts	  
receive	   post-­‐exposure	   prophylaxis	   with	   antibiotic	   therapy	   and	   vaccination	   in	   accordance	   with	  
standard	  recommendations	  [1D]	  
	  
References	  
1. Holty	  JE,	  Bravata	  DM,	  Liu	  H,	  et	  al.	  A	  century	  of	  inhalational	  Anthrax	  cases	  from	  1900	  to	  2005.	  Ann	  
Intern	  Med	  2006;144:270-­‐80.	  
2. Brachman	  PS,	  Gold	  H,	  Plotkin	  SA	  et	  al.	  Field	  evaluation	  of	  a	  human	  anthrax	  vaccine.	  Am	  J	  Public	  
Health	  1962;52:632-­‐45.	  
3. Hambleton	   P,	   Carman	   JA,	   Melling	   J.	   Anthrax:	   the	   disease	   in	   relation	   to	   vaccines.	   Vaccine	  
1984;2:125-­‐32.	  
4. Hayes	   SC,	  World	  MJ.	   Adverse	   reactions	   to	   anthrax	   immunisation	   in	   a	  military	   field	   hospital.	   J	   R	  
Army	  Med	  Corps	  2000;146:191-­‐5.	  
5. Sato	   PA,	   Reed	   RJ,	   Smith	   TC,	   Wang	   L.	   Monitoring	   anthrax	   vaccine	   safety	   in	   US	   military	   service	  
members	   on	   active	   duty:	   surveillance	   of	   1998	   hospitalizations	   in	   temporal	   association	   with	  
anthrax	  immunization.	  Vaccine	  2002;20:2369-­‐74.	  
6. Enstone	  JE,	  Wale	  MC,	  Nguyen-­‐Van-­‐Tam	  JS,	  Pearson	  JC.	  Adverse	  medical	  events	   in	  British	  service	  
personnel	  following	  anthrax	  vaccination.	  Vaccine	  2003;	  21:1348-­‐54.	  
7. Lange	   JL,	   Lesikar	   SE,	   Rubertone	   MV,	   Brundage	   JF.	   Comprehensive	   systematic	   surveillance	   for	  
adverse	  effects	  of	  anthrax	  vaccine	  adsorbed,	  US	  Armed	  Forces,	  1998-­‐2000.	  Vaccine	  2003;21:1620-­‐
8.	  
8. Hunter	   D,	   Zoutman	   D,	   Whitehead	   J,	   Hutchings	   J,	   Mac-­‐Donald	   K.	   Health	   effects	   of	   anthrax	  
vaccination	  in	  the	  Canadian	  forces.	  Mil	  Med	  2004;169:833-­‐8.	  
9. Niu	   MT,	   Ball	   R,	   Woo	   EJ,	   Burwen	   DR,	   Knippen	   M,	   Braun	   MM.	   Adverse	   events	   after	   anthrax	  
vaccination	  reported	  to	  the	  Vaccine	  Adverse	  Event	  Reporting	  System	  (VAERS),	  1990-­‐2007.	  Vaccine	  
2009;27:290-­‐7.	  
10. Murphy	  D,	  Marteau	  TM,	  Wessely	  S.	  A	  longitudinal	  study	  of	  UK	  military	  personnel	  offered	  anthrax	  
vaccination:	   informed	   choice,	   symptom	   reporting,	   uptake	   and	   pre-­‐vaccination	   health.	   Vaccine	  
2012;30:1094-­‐100.	  
11. Sulsky	   SI,	   Luippold	   R,	   Garman	   P,	   et	   al.	   Disability	   among	   US	   Army	   Veterans	   vaccinated	   against	  
anthrax.	  Vaccine	  2012;30:6150-­‐6.	  
12. Stewart	   B,	   Rose	   CE,	   Tokars	   JI,	   et	   al.	   Health-­‐related	   quality	   of	   life	   in	   the	   CDC	   Anthrax	   Vaccine	  
Adsorbed	  Human	  Clinical	  Trial.	  Vaccine	  2012;30:5875-­‐9.	  	  	  
13. Ryan	  MA,	   Smith	   TC,	   Sevick	   CJ,	   et	   al.	   Birth	   defects	   among	   infants	   born	   to	  women	  who	   received	  
anthrax	  vaccine	  in	  pregnancy.	  Am	  J	  Epidemiol	  2008;168:434-­‐42.	  
	  
	   	  
Draft	  BHIVA	  guidelines	  on	  the	  use	  of	  vaccines	  in	  HIV-­‐positive	  adults	  2015	  
 





1.	   Infection	   and	   disease:	  Vibrio	   cholerae	   is	   a	   non-­‐invasive	   toxin-­‐secreting	   gram-­‐negative	   bacterium	  
that	  colonises	  the	  small	  bowel.	  Classification	  into	  over	  200	  serogroups	  is	  based	  on	  the	  O	  antigen	  of	  the	  
lipopolysaccharide.	  Cholera	  epidemics	  are	  caused	  by	  the	  O1	  serogroup	  and	  more	  recently	  by	  the	  O139	  
serogroup	  in	  South	  and	  South-­‐East	  Asia	  [1].	  Infection	  is	  acquired	  primarily	  by	  consuming	  contaminated	  
water	   or	   food;	   person-­‐to-­‐person	   transmission	   is	   rare.	   Man	   is	   the	   only	   known	   host.	   The	   disease	   is	  
characterised	   by	   sudden	   onset	   of	   profuse	  watery	   diarrhoea	   and	   responds	   to	   fluid-­‐	   and	   electrolyte-­‐
replacement	  therapy	  [1-­‐2].	  In	  extreme	  cases,	  hypotension	  and	  death	  can	  occur	  within	  6-­‐8	  hours	  of	  the	  
onset	   of	   symptoms.	   Approximately	   80%	   of	   infected	   people	   have	   mild	   diarrhoea	   or	   may	   be	  
asymptomatic.	  Persons	  with	  underlying	  gastrointestinal	  disease	  may	  be	  at	  increased	  risk	  of	  disease.	  
	  
2.	   Epidemiology: Seven	   cholera	   pandemics	   have	   been	   recorded	   throughout	   history.	   The	   latest	  
started	  in	  1961	  and	  is	  still	  ongoing	  in	  over	  50	  countries	  in	  regions	  of	  Asia,	  the	  Middle	  East,	  Africa,	  and	  
Central	  and	  Latin	  America,	  with	  an	  estimated	  3	  million	  cases	  each	  year	  [3].	  Large	  outbreaks	  are	  usually	  
caused	   by	   a	   contaminated	  water	   supply.	   In	   developed	   countries	   cases	   are	   reported	   sporadically	   in	  
travellers,	  with	  an	  overall	  risk	  of	  5	  cases	  per	  100,000	  travellers	  to	  all	  destinations	  [4].	  Cholera	  is	  rare	  
among	   UK	   travellers,	   and	   seen	   predominantly	   among	   those	   who	   visit	   the	   Indian	   subcontinent.	  
Travellers	  who	  follow	  usual	  tourist	  itineraries,	  use	  standard	  tourist	  accommodation,	  and	  observe	  food	  
safety	   recommendations	  while	   in	   countries	   reporting	  cholera	  are	  at	   little	   risk.	  The	   risk	   increases	   for	  
long-­‐term	  travellers	  and	  for	  those	  who	  drink	  untreated	  water,	  eat	  poorly	  cooked	  or	  raw	  seafood,	  or	  
live	   in	  unsanitary	  conditions	   in	  disease-­‐endemic	  areas	   (e.g.	  aid	  workers	  assisting	   in	  disaster	   relief	  or	  
refugee	   camps	   and	   adventurous	   backpackers	   travelling	   to	   remote	   areas)	   [4].	   Currently,	   no	   country	  
requires	  proof	  of	  vaccination	  against	  cholera	  as	  a	  condition	  for	  entry.	  Local	  authorities,	  however,	  may	  
require	  documentation	  of	  vaccination.	  
	  
3.	   Cholera	   in	   HIV-­‐positive	   people:	   In	   cholera-­‐endemic	   areas,	   HIV	   infection	   is	   associated	   with	   an	  
increased	  risk	  for	  cholera	  [5].	  The	  risk	  of	  severe	  disease	  may	  be	  increased	  by	  immunodeficiency.	  
	  
4.	  Cholera	  vaccine:	  Several	  non-­‐replicating	  oral	  cholera	  vaccines	  are	  available	  internationally	  [6].	  The	  
WC/rBs	   vaccine	   available	   in	   the	   UK	   contains	   inactivated	   Inaba	   and	   Ogawa	   strains	   of	   V.	   cholerae	  
serotype	  O1,	  together	  with	  recombinant	  B-­‐subunit	  of	  the	  cholera	  toxin	  produced	  in	  Inaba	  strains	  of	  V.	  
cholerae	  serotype	  O1.	  The	  replicating,	  live	  attenuated	  CVD	  103-­‐HgR	  vaccine,	  which	  has	  been	  tested	  in	  
HIV-­‐positive	  adults	  in	  Mali	  [7],	  is	  currently	  unavailable.	  In	  healthy	  persons,	  oral	  cholera	  vaccines	  given	  
as	  two	  oral	  doses	  1-­‐6	  weeks	  apart	  confer	  65-­‐86%	  protection,	  starting	  10	  days	  after	  the	  second	  dose,	  
and	   lasting	   for	   up	   to	   2	   years	   [8-­‐14].	   Interestingly,	   there	   is	   evidence	   of	   herd	   protection	   from	   some	  
vaccine	  campaigns	  [12,15].	  The	  WC/rBS	  vaccine	  does	  not	  confer	  protection	  against	  V.	  cholerae	  O139.	  
WC/rBS	   appears	   to	   provide	   modest	   protection	   against	   travellers'	   diarrhoea	   caused	   by	   heat-­‐labile	  
toxin-­‐producing	  Escherichia	  coli	  during	  the	  first	  3	  months	  following	  vaccination	  [4].	  However,	  use	  for	  
the	   specific	   prevention	   of	   travellers’	   diarrhoea	   is	   not	   recommended.	   There	   are	   no	   major	   safety	  
concerns	  with	   the	  WC/rBS	   vaccine	   in	   immunocompetent	   individuals	   from	   endemic	   or	   non-­‐endemic	  
countries	   [9-­‐11,13,18].	   The	   vaccine	   may	   cause	   occasional	   gastrointestinal	   symptoms.	   Systemic	  
symptoms	  have	  been	  reported	  rarely	  [4].	  
	  
General	   indications:	  Cholera	  vaccine	   is	  not	   indicated	   for	  most	   travellers,	  but	   is	   considered	   for	   those	  
who	  are	  unable	  to	  take	  adequate	  precautions	  in	  highly	  endemic	  or	  epidemic	  V.	  cholerae	  01	  settings.	  
These	   include	   those	   assisting	   in	   disaster	   relief	   or	   refugee	   camps;	   and	   visitors	   to	   remote	   areas	  with	  
limited	  access	   to	  healthcare	  where	   there	  are	  outbreaks.	  The	  vaccine	   should	  not	  be	  co-­‐administered	  
with	  other	  oral	  vaccines.	  
	  
5.	  Cholera	  vaccine	  in	  HIV-­‐positive	  adults:	  There	  have	  been	  no	  published	  reports	  of	  the	  efficacy	  of	  the	  
WC/rBS	   vaccine	   in	   HIV-­‐positive	   travellers.	   A	   study	   conducted	   in	   Beira,	   Mozambique	   showed	   72%	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protection	  in	  a	  population	  including	  approximately	  25%	  HIV-­‐positive	  persons	  [14].	  HIV-­‐positive	  adults	  
with	  CD4	  counts	  <100	  cells/μL	  may	  be	  expected	  to	  respond	  poorly	  to	  oral	  cholera	  vaccines,	  whereas	  
those	   with	   CD4	   counts	   >100	   cells/	   μL	   show	   improved	   responses	   after	   two	   doses	   [16].	   Intestinal	  
immunogenicity	   may	   be	   preserved	   [17].	   Duration	   of	   immunity	   is	   unknown.	   The	   vaccine	   is	   well	  
tolerated	  in	  HIV-­‐positive	  people	  [14,16].	  	  
	  
6.	  Recommendations	  for	  HIV-­‐positive	  adults	  
• We	  recommend	  that	  HIV-­‐positive	  adults	  at	  significant	  risk	  of	  cholera	  exposure	  (typically	  through	  
specific	   travel)	   be	   offered	   vaccination	   in	   accordance	  with	   general	   indications,	   and	   regardless	   of	  
CD4	  count,	  ART	  use,	  and	  viral	  load	  [1B]	  
o We	   recommend	   a	   primary	   vaccine	   course	   consisting	   of	   2	   oral	   doses	   of	   the	   non-­‐
replicating	   WC/rBS	   vaccine	   given	   1-­‐6	   weeks	   apart	   and	   at	   least	   1	   week	   prior	   to	  
exposure.	  If	  >6	  weeks	  elapse	  between	  doses,	  the	  primary	  course	  should	  be	  restarted	  
[1B]	  
o We	  recommend	  a	  single	  booster	  dose	  after	  2	  years	  if	  continued	  protection	  is	  required.	  
If	   >2	   years	   elapse	   after	   completion	   of	   the	   primary	   vaccine	   course,	   the	   full	   course	  
should	  be	  repeated	  [1B]	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1.	   Infection	   and	   disease:	   Diphtheria	   is	   caused	   by	   toxigenic	   strains	   of	   the	   gram-­‐positive	   bacteria	  
Corynebacterium	  diphtheriae	   and	  Corynebacterium	  ulcerans,	   and	   affects	   the	   upper	   respiratory	   tract	  
and	  occasionally	  the	  skin.	  The	  infection	  is	  transmitted	  via	  airborne	  droplets,	  generally	  requiring	  close	  
contact	  with	   symptomatic	  patients	  or	   asymptomatic	   carriers.	  Alternative	  modes	  of	   transmission	  are	  
direct	   contact	  with	   skin	   lesions	  or	   infected	  cattle	  and	  other	   farm	  animals	   (C.	  ulcerans).	  Rare	  human	  
cases	   have	   been	   associated	   with	   the	   consumption	   of	   raw	   unpasteurized	   dairy	   products.	   Life-­‐
threatening	  complications	  include	  cardiac	  failure	  and	  paralysis.	  	  
	  	  
2.	  Epidemiology:	  Both	  C.	  diphtheriae	  and	  C.	  ulcerans	  cause	  diphtheria	   in	  the	  UK.	  Since	  the	  1990s,	  C.	  
ulcerans	  has	  been	  the	  predominant	  cause	  of	   infection	  resulting	   in	  sporadic	  deaths	  [1].	  As	  a	  result	  of	  
successful	  vaccination	  programmes,	  the	  circulation	  of	  C.	  diphtheria	  has	  virtually	  ceased	  in	  the	  UK.	  The	  
majority	   of	   cases	   are	   now	  mild	   infections	   in	   partially	   immunised	   individuals,	   or	   in	   adults	   that	   have	  
been	   fully	   immunised	  but	  have	  waning	   immunity.	   Susceptibility	   to	  diphtheria	   increases	  with	   age.	   In	  
the	  UK,	  approximately	  50%	  of	  adults	  >30	  years	  of	  age	  are	  estimated	  to	  be	  susceptible	  to	  diphtheria	  [2].	  
Diphtheria	  cases	  continue	  to	  be	  reported	   from	   India,	  South-­‐east	  Asia,	  South	  America,	  Africa,	   former	  
Soviet	   States,	   and	   Eastern	   Europe;	   thus	   there	   is	   potential	   for	   exposure	   through	   travel,	   and	   re-­‐
introduction	  of	  C.	  diphtheriae	  into	  the	  UK	  may	  also	  occur	  through	  immigration	  from	  these	  regions.	  	  
	  
3.	   Diphtheria	   in	   HIV-­‐positive	   people:	   It	   is	   not	   known	   whether	   the	   natural	   history	   of	   diphtheria	   is	  
modified	  by	  HIV	  infection.	  
	  
4.	   Diphtheria	   vaccine:	   The	  diphtheria	   vaccine	   is	   non-­‐replicating	   and	   is	  made	   from	   cell-­‐free	   purified	  
toxin	   extracted	   from	   C.	   diphtheriae	   and	   converted	   into	   diphtheria	   toxoid.	   The	   vaccine	   is	   given	   to	  
adults	   in	   combination	   with	   tetanus	   toxoid	   and	   inactivated	   polio	   vaccine	   (Td/IPV)	   in	   a	   preparation	  
containing	  a	   lower	  dosage	  of	  diphtheria	  toxoid	  than	  preparations	  designed	  for	  use	  in	  childhood.	  The	  
vaccine	   is	   given	   by	   parenteral	   administration.	   The	   diphtheria	   vaccine	   induces	   protective	   antitoxin	  
levels	   in	   95%	   of	   recipients	   after	   three	   doses,	   and	   shows	   a	   clinical	   efficacy	   of	   over	   97%	   [3,4].	   The	  
vaccine	   is	  well	   tolerated.	   Injection	  site	  reactions	  are	  common	  but	  usually	  self-­‐limited	  and	  may	  occur	  
more	   frequently	   following	   subsequent	   doses.	   Fever	   and	   other	   systemic	   reactions	   are	   uncommon.	  
Severe	  systemic	  reactions	  are	  rare.	  	  
	  
General	  indications:	  The	  aim	  of	  the	  UK	  national	  vaccination	  programme	  is	  to	  ensure	  that	  all	  individuals	  
receive	   at	   least	   5	   vaccine	   doses.	   Td/IPV	   is	   recommended	   for	   vaccination	   of	   those	   aged	   ≥10	   years.	  
Adults	  who	  are	  either	  unvaccinated	  or	  have	  an	  uncertain	   vaccination	  history	   are	   advised	   to	   receive	  
primary	  immunization	  with	  three	  vaccine	  doses	  at	  either	  monthly	  intervals	  or	  at	  0,	  1-­‐2	  months,	  and	  6-­‐
12	  months.	   Two	   further	   doses	   are	   scheduled	   5	   and	   10	   years	   after	   the	   last	   dose.	   Adults	   who	   have	  
received	  partial	  vaccination	  are	  advised	  to	  receive	  the	  remaining	  doses,	  regardless	  of	  the	  interval	  since	  
the	   last	   dose	   and	   type	   of	   vaccine	   previously	   received.	   It	   is	   also	   recommended	   that	   travellers	   to	  
epidemic	  and	  endemic	  areas	  should	  ensure	  they	  are	  fully	  vaccinated.	  	  
	  
5.	   Diphtheria	   vaccine	   in	   HIV-­‐positive	   adults:	   Limited	  data	   exist	   on	   the	   immunogenicity	   and	   clinical	  
efficacy	  of	  the	  diphtheria	  vaccine	  in	  HIV-­‐positive	  adults.	  Vaccine	  responses	  may	  be	  reduced	  compared	  
to	   HIV-­‐negative	   persons,	   especially	   in	   those	   with	   advanced	   disease	   and	   low	   CD4	   cell	   counts,	   but	  
improve	  with	  ART	  [5-­‐8].	  No	  increased	  risk	  of	  side	  effects	  or	  adverse	  reactions	  to	  vaccination	  has	  been	  
reported	  in	  individuals	  with	  HIV	  infection.	  
	  
6.	  Post-­‐exposure	  prophylaxis:	  Contacts	  of	  a	  case	  or	  a	  carrier	  of	  C.	  diphtherium	  or	  C.	  ulcerans	  require	  
antibiotic	  prophylaxis	  (e.g.,	  erythromycin).	  Fully	  immunised	  individuals	  also	  receive	  a	  single	  reinforcing	  
dose	  of	  the	  vaccine;	  others	  are	  offered	  to	  complete	  the	  vaccine	  course.	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7.	  Recommendations	  for	  HIV-­‐positive	  adults	  
• We	   recommend	   that	  HIV-­‐positive	   adults	   that	   require	   vaccination	   against	   diphtheria,	   tetanus,	   or	  
polio	   be	   given	   the	   parenteral	   Td/IPV	   vaccine	   in	   accordance	   with	   general	   indications,	   and	  
regardless	  of	  CD4	  cell	  count,	  ART	  use,	  and	  viral	  load	  [1B]	  
o We	   recommend	   that	   individuals	   who	   are	   either	   unvaccinated	   or	   have	   an	   uncertain	  
vaccination	   history	   receive	   3	   vaccine	   doses	   at	   1	  month	   interval,	   followed	   by	   2	   booster	  
doses	   after	   5	   and	   10	   years;	   partially	   vaccinated	   individuals	   should	   complete	   the	   5-­‐dose	  
vaccine	  course	  [1B]	  
o We	  recommend	  that	  fully	  vaccinated	  individuals	  (5	  doses)	  receive	  a	  booster	  dose	  every	  10	  
years	  if	  at	  risk	  of	  exposure,	  typically	  through	  travel	  [1C]	  
• We	  recommend	  that	  individuals	  who	  may	  be	  occupationally	  exposed	  to	  diphtheria	  (e.g.	  laboratory	  
workers)	   be	   tested	   for	   diphtheria	   antibodies	   3	   months	   after	   vaccination	   to	   confirm	   protective	  
immunity,	  and	  be	  revaccinated	  if	  required	  [1C]	  
• We	   recommend	   that	   following	   a	   credible	   or	   confirmed	   exposure	   to	   diphtheria,	   HIV-­‐positive	  
contacts	  receive	  post-­‐exposure	  prophylaxis	  with	  antibiotic	  therapy	  and	  vaccination	  in	  accordance	  
with	  standard	  recommendations	  [1C]	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HAEMOPHILUS INFLUENZAE SEROTYPE b  
	  
1.	   Infection	   and	   disease:	   Haemophilus	   influenzae	   is	   a	   gram-­‐negative	   coccobacillus	   that	   can	   cause	  
invasive	  disease	  in	  young	  children	  and	  in	  people	  with	  predisposing	  conditions	  [1-­‐3].	  Hib	  can	  colonise	  
the	  nasopharynx	   in	  the	  absence	  of	  symptoms.	  Transmission	  occurs	  through	  respiratory	  droplets	  and	  
close	   contact	   with	   a	   case	   or	   a	   carrier.	   Invasive	   disease	   is	   usually	   caused	   by	   one	   of	   6	   encapsulated	  
serotypes	  (a-­‐f),	  and	  less	  commonly	  by	  encapsulated	  non-­‐typable	  strains.	  Serotype	  b	  (Hib)	  is	  the	  most	  
virulent	   strain	   and,	   prior	   to	   the	   introduction	   of	   routine	   vaccination,	   was	   responsible	   for	   >80%	   of	  
invasive	   infections,	   (primarily	  meningitis)	   among	   children	  <5	   years	  of	   age.	  Non-­‐encapsulated	   strains	  
(ncHi)	   mainly	   cause	   respiratory	   disease;	   invasive	   ncHi	   disease	   is	   uncommon	   and	   usually	   occurs	   in	  
pregnant	  women,	  newborns,	  and	  individuals	  with	  underlying	  conditions	  (immunosuppression,	  chronic	  
respiratory	  disease,	  head	  trauma,	  or	  neurological	  disease)	  [4].	  Risk	  factors	  for	  invasive	  Hib	  disease	  are	  
similar	   to	   those	   associated	   with	   other	   encapsulated	   bacteria.	   Patients	   with	   anatomic	   or	   functional	  
asplenia	  and	  those	  with	  complement	  deﬁciencies	  are	  at	  an	  increased	  risk	  of	  disease.	  	  
	  
2.	  Epidemiology:	  Hib	  remains	  one	  of	  the	  major	  vaccine-­‐preventable	  causes	  of	  morbidity	  and	  mortality	  
worldwide	   [5].	   In	   industrialised	   countries,	   the	   introduction	   of	   Hib	   conjugate	   vaccines	   into	   national	  
childhood	  vaccination	  programmes	  over	   the	  past	   two	  decades	  has	  resulted	   in	  a	  sustained	  decline	   in	  
the	   incidence	   of	   invasive	   Hib	   infections	   across	   all	   age-­‐groups,	   through	   a	   combination	   of	   direct	   and	  
indirect	  (herd)	  protection	  [6,7].	  In	  England	  and	  Wales,	  invasive	  Hib	  disease	  is	  now	  infrequent	  [8].	  Most	  
cases	   occur	   in	   adults	   who	   typically	   present	   with	   pneumonia	   and	   often	   have	   pre-­‐existing	   medical	  
conditions,	  with	  an	  overall	  case-­‐fatality	  rate	  of	  9%	  [8].	  Average	  vaccine	  coverage	  remains	  suboptimal	  
in	  many	  developing	  countries	  [9].	  	  
	  
3.	   Haemophilus	   influenzae	   in	   HIV-­‐positive	   adults:	   In	   HIV-­‐positive	   adults,	   the	   risk	   of	   invasive	   H.	  
influenzae	  disease	  is	  increased	  compared	  to	  the	  general	  population	  [10,11].	  In	  one	  study,	  cumulative	  
incidence	   reached	   79.6/100,000	   among	  men	  with	   AIDS	   aged	   20-­‐49	   years;	   however,	   only	   a	   third	   of	  
cases	  were	  due	  to	  the	  Hib	  serotype	   indicating	  that	  the	  Hib	  vaccine	  would	  not	  be	  protective.	   [10].	   In	  
countries	  with	  established	  Hib	   vaccination	  programmes	   such	  as	   the	  UK,	   invasive	  Hib	  disease	   is	  now	  
uncommon	  among	  people	  with	  HIV	  [8].	  	  
	  
4.	  Hib	  vaccine:	  The	  Hib	  vaccine	  is	  non-­‐replicating	  and	  contains	  capsular	  polysaccharide	  conjugated	  to	  
a	  protein	  (e.g.,	  tetanus	  toxoid).	   It	   is	  typically	  part	  of	  multivalent	  vaccines	  for	  use	  in	  infants,	   including	  
the	   diphtheria/tetanus/acellular	   pertussis/inactivated	   polio/Hib	   vaccine	   (DTaP/IPV/Hib)	   and	   the	  
Hib/meningococcal	   group	   C	   vaccine	   (Hib/MenC).	   The	   vaccine	   is	   given	   by	   parenteral	   administration.	  	  
The	  Hib	  vaccine	   is	  highly	   immunogenic	  and	  efficacious	   in	  children	   [3,5,6,12];	   it	  only	  protects	  against	  
invasive	  Hib	  disease	   and	  offers	  no	  protection	   against	   other	   serotypes	  or	   against	   ncHi.	  Although	   the	  
duration	  of	  protection	  is	  unknown,	  no	  booster	  doses	  are	  routinely	  recommended	  after	  12	  months	  of	  
age.	   The	   vaccine	   is	   well	   tolerated.	   Injection	   site	   reactions	   occur	   in	   5-­‐30%	   of	   recipients.	   Systemic	  
reactions	  are	  infrequent.	  	  
	  
General	   indications:	  The	  objective	  of	   the	  UK	  Hib	  vaccination	  programme	   is	   to	  protect	   all	   individuals	  
<10	  years	  of	  age	  and	  older	  individuals	  at	  elevated	  risk	  from	  invasive	  Hib	  disease,	  including	  individuals	  
who	  develop	  asplenia	  or	  splenic	  dysfunction	  or	  when	  complement	  deficiency	  is	  diagnosed.	  	  
	  
5.	  Hib	  vaccine	  in	  HIV-­‐positive	  adults:	  The	  vaccine	  has	  been	  shown	  to	  induce	  protective	  antibodies	  in	  
HIV-­‐positive	  children	  [13-­‐16]	  and	  adults	  [17-­‐19].	  The	  magnitude	  and	  longevity	  of	  responses	  are	  related	  
to	  the	  CD4	  cells	  count	  and	  can	  be	  reduced	  relative	  to	  HIV-­‐negative	   individuals.	  Clinical	  effectiveness	  
may	  also	  be	   reduced	  by	  HIV	   infection.	   In	   South	  Africa,	   47%	  of	   children	  who	  developed	   invasive	  Hib	  
disease	   during	   2003-­‐2009	   despite	   being	   fully	   immunised	  with	   the	   conjugate	   Hib	   vaccine	  were	   HIV-­‐
positive	  [20].	  No	  safety	  concerns	  have	  emerged	  in	  HIV-­‐positive	  vaccine	  recipients.	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6.	  Post-­‐exposure	  prophylaxis:	  Household	  contacts	  of	  a	  Hib	  case	  are	  given	  antibiotic	  prophylaxis	  (e.g.,	  
rifampicin),	  regardless	  of	  their	  immunization	  status,	  starting	  as	  soon	  as	  the	  index	  case	  is	  diagnosed.	  
	  
7.	  Recommendations	  for	  HIV-­‐positive	  adults	  
• Hib	   vaccination	   is	   not	   recommended	   routinely	   in	   HIV-­‐positive	   adults,	   including	   patients	   who	  
develop	   Hib	   disease.	   We	   recommend	   however	   that	   HIV-­‐positive	   adults	   with	   asplenia,	   splenic	  
dysfunction	  or	   complement	   deficiency	   (including	   those	   receiving	   complement	   inhibitor	   therapy)	  
receive	  1	  parental	  dose	  of	  a	  Hib-­‐containing	  vaccine	  (e.g.,	  Hib/MenC	  in	  the	  UK)	  whether	  or	  not	  they	  
were	  immunised	  previously,	  and	  regardless	  of	  CD4	  count,	  ART	  use,	  and	  viral	  load	  [1B]	  
• We	   recommend	   that	   HIV-­‐positive	   adults	  who	   are	   household	   contacts	   of	   a	   Hib	   case	   are	   offered	  
antibiotic	  prophylaxis	  in	  accordance	  with	  standard	  recommendations	  [1C]	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1.	   Infection	   and	   disease:	  Hepatitis	   A	   virus	   (HAV)	   is	   transmitted	   faeco-­‐orally	   through	   close	   personal	  
contact,	  contaminated	  food	  and	  water,	  and	  rarely	  through	  blood	  exposure.	  Person-­‐to-­‐person	  spread	  is	  
the	   most	   common	   method	   of	   transmission	   in	   developed	   countries.	   There	   is	   evidence	   that	   the	  
infection	  may	  be	   spread	  during	   sexual	   contact	   in	  men	  who	  have	   sex	  with	  men	   (MSM)	   [1].	   Infection	  
may	   be	   asymptomatic,	   but	   severity	   tends	   to	   increase	  with	   age.	   Jaundice	   occurs	   in	   10%	   of	   children	  
below	  the	  age	  of	  6	  years,	  40-­‐50%	  of	  older	  children	  and	  70-­‐80%	  of	  adults.	  Fulminant	  hepatitis	   is	  rare	  
(<1%	   overall)	   and	   predominantly	   occurs	   in	   older	   age	   groups,	   but	   carries	   a	   45%	   risk	   of	   mortality.	  
Patients	  with	  chronic	  liver	  disease	  are	  at	  risk	  of	  severe	  complications	  [2].	  Although	  approximately	  15%	  
of	   cases	   show	   prolonged	   or	   relapsing	   symptoms,	   chronic	   HAV	   infection	   is	   not	   known	   to	   occur.	  
Infection	  is	  followed	  by	  lifelong	  immunity.	  	  
	  
2.	   Epidemiology:	  HAV	  prevalence	   is	   low	   in	  northern	  and	  Western	  Europe,	  North	  America,	  Australia,	  
New	   Zealand	   and	   Japan,	   and	   intermediate	   to	   high	   in	   Mexico,	   Central	   and	   South	   America,	   the	  
Caribbean,	  Africa,	  Asia	  and	  Eastern	  Europe.	  In	  the	  UK,	  those	  at	  risk	  for	  infection	  include:	  	  
• Household	  and	  sexual	  contacts	  of	  infected	  persons	  
• Travellers	  to	  countries	  where	  HAV	  is	  common	  
• Men	  who	  have	  sex	  with	  men	  
• Injecting	  and	  non-­‐injecting	  drug	  users	  
• Individuals	  at	  risk	  of	  infection	  during	  outbreaks	  
• Those	  with	  occupational	  exposure	  to	  HAV	  (e.g.	  laboratory	  workers,	  sewage	  workers)	  
• Persons	  with	  haemophilia	  
• Persons	  with	  special	  needs	  living	  in	  residential	  institutions,	  and	  their	  carers	  
	  
3.	  Hepatitis	  A	  in	  HIV-­‐positive	  adults:	  Hepatitis	  A	  does	  not	  appear	  to	  be	  worse	  in	  HIV-­‐positive	  patients	  
when	  compared	  to	  HIV-­‐negative	  persons,	  although	  HAV	  viraemia	  may	  be	  prolonged	  [3,4].	  
	  
4.	   Hepatitis	   A	   vaccine:	   The	   HAV	   vaccine	   is	   non-­‐replicating	   and	   contains	   whole	   inactivated	   virus.	  
Combined	  hepatitis	  A/hepatitis	  B	  and	  hepatitis	  A/typhoid	   vaccines	  are	  also	  available.	  The	  vaccine	   is	  
given	   by	   parenteral	   administration.	   The	   standard	   vaccine	   course	   comprises	   two	   doses	   given	   6-­‐12	  
months	   apart.	   In	   healthy	   persons,	   the	   HAV	   vaccine	   is	   highly	   immunogenic	   and	   efficacious,	   without	  
safety	  concerns.	  Protective	   levels	  of	  antibodies	  develop	   in	  97-­‐100%	  of	   individuals	  within	  1	  month	  of	  
the	   first	   dose	   and	   in	   virtually	   100%	   after	   the	   second	   dose.	   The	   level	   of	   protection	   against	   clinical	  
hepatitis	   is	   79-­‐100%	  after	   a	   single	  dose.	   The	   combined	  hepatitis	  A/hepatitis	  B	   vaccine	   is	   also	  highly	  
efficacious	   in	  health	   individuals.	  Successful	   immunization	   is	   thought	  to	  confer	  protection	  for	  at	   least	  
10	  years	  and	  possibly	  for	  life	  [5,6].	  	  
	  
General	  indications:	  The	  HAV	  vaccine	  is	  indicated	  for	  persons	  at	  risk	  of	  exposure	  (listed	  above).	  	  
	  
5.	   HAV	   vaccine	   in	   HIV-­‐positive	   adults:	  The	   rate,	  magnitude,	  and	   longevity	  of	   immune	   responses	   to	  
HAV	  vaccination	  are	  generally	  reduced	  in	  HIV-­‐positive	  persons,	  although	  they	  improve	  with	  increasing	  
CD4	   cells	   counts	   and	   viral	   load	   suppression	   on	   ART	   [7-­‐13].	   Less	   than	   half	   of	   vaccine	   recipients	  
experience	  seroconversion	  after	  a	  single	  vaccine	  dose;	  responses	  increase	  to	  over	  70%	  after	  two	  doses,	  
while	  remaining	  lower	  than	  those	  measured	  in	  HIV-­‐negative	  adults.	  Further	  increasing	  the	  number	  of	  
vaccine	   doses	   improves	   antibody	   levels	   and	   the	   longevity	   of	   response	   but	   does	   not	   significantly	  
improve	   overall	   seroconversion	   rates.	   In	   a	   randomised	   study,	   HIV-­‐positive	   adults	   were	   assigned	   to	  
receive	  either	  2	  (0	  and	  6	  months)	  or	  3	  (0,	  1,	  and	  6	  months)	  HAV	  vaccine	  doses.	  At	  week	  28	  after	  the	  
first	   vaccine	   dose,	   seroconversion	   rates	   were	   72%	   vs.	   88%	   respectively	   in	   the	   observed	   analysis	  
(p=0.06);	   the	   3-­‐dose	   group	   had	   significantly	   higher	   antibody	   titres	   at	   week	   28	   and	   week	   72	   [7].	  
Multivariate	   analysis	   indicated	   that	   absence	   of	   tobacco	   smoking	   was	   an	   independent	   predictor	   of	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response	  to	  HAV	  vaccine	  (OR	  2.92;	  95%	  CI	  1.07,	  7.97;	  p=0.04).	  A	  prospective	  cohort	  study	  compared	  
responses	  between	  HIV-­‐positive	  MSM	  receiving	  two	  (0	  and	  6	  months)	  or	   three	  (0,	  1,	  and	  6	  months)	  
doses	   of	   HAV	   vaccine	   and	   HIV-­‐negative	   MSM	   receiving	   two	   vaccine	   doses	   [12].	   At	   week	   48,	   HAV	  
seroconversion	  rates	  were	  76%,	  78%,	  and	  89%	  respectively.	  In	  HIV-­‐positive	  MSM,	  antibody	  titres	  were	  
significantly	  higher	  with	  3	  doses	  than	  2	  doses.	  Responses	  to	  HAV	  vaccination	  also	  appear	  to	  be	  higher	  
with	  the	  monovalent	  HAV	  vaccine	  than	  for	  the	  combined	  HAV/HBV	  vaccine,	  particularly	  with	  low	  CD4	  
cells	   counts	   and	   detectable	   viral	   load,	   and	   among	   patients	   not	   completing	   the	   vaccine	   course	   [13].	  
Most	  patients	  with	  high	  CD4	  cell	   counts	   show	  a	  durable	   response	  during	  up	   to	  5	  years	  of	   follow-­‐up	  
after	   HAV	   vaccination	   [14].	   The	   HAV	   vaccine	   is	   safe	   and	   well	   tolerated	   in	   HIV-­‐positive	   individuals,	  
including	   those	   receiving	   three	   vaccine	   doses	   over	   6	  months	   [7,13].	   Injection	   site	   reactions	   are	   the	  
most	  frequent	  side	  effect.	  	  
	  
6.	   Post-­‐exposure	   prophylaxis:	   Following	   a	   high-­‐risk	   contact	   (e.g.	   in	   the	   household	   setting	   or	   other	  
intimate	  contact)	  HAV	  vaccine	  plus	  human	  normal	   immunoglobulin	   (HNIG)	  given	   intramuscularly	   (at	  
different	   sites)	  within	  14	  days	  of	  exposure	   can	  prevent	  or	  attenuate	  disease	   in	   susceptible	  persons.	  
Efficacy	  beyond	  14	  days	  of	  exposure	  is	  unknown;	  disease	  may	  be	  attenuated	  rather	  than	  prevented.	  In	  
HIV-­‐negative	   people	   the	   clinical	   efficacy	   of	   prophylaxis	   is	   in	   the	   range	   47-­‐87%	   [15,16].	   Early	  
vaccination	  alone	  (without	  HNIG)	  seems	  equally	  effective	  in	  HIV-­‐negative	  people.	  There	  are	  no	  data	  on	  
the	  efficacy	  of	  post-­‐exposure	  prophylaxis	  in	  HIV-­‐positive	  persons.	  	  
	  
7.	  Recommendations	  for	  HIV-­‐positive	  adults	  
• We	  recommend	  that	  HIV-­‐positive	  adults	  at	  risk	  of	  hepatitis	  A	  exposure	  (see	  risk	  groups)	  be	  offered	  
vaccination	  with	  the	  monovalent	  HAV	  vaccine	  [1A]	  
o Patients	   with	   CD4	   counts	   >350	   cells/μL	   should	   be	   offered	   2	   vaccine	   doses	   at	   0	   and	   6	  
months	  [1A]	  
o Patients	   with	   CD4	   counts	   <350	   cells/μL	   should	   receive	   3	   vaccine	   doses	   at	   0,	   1,	   and	   6	  
months	  in	  order	  to	  increase	  antibody	  levels	  and	  longevity,	  especially	  if	  they	  are	  likely	  to	  be	  
at	  continued	  risk	  of	  exposure	  [1C]	  
o Pre-­‐vaccination	   testing	   for	   evidence	   of	   HAV	   immunity	   may	   be	   cost-­‐effective	   in	   some	  
clinical	   settings:	   screening	   may	   target	   those	   who	   were	   born	   in	   or	   lived	   for	   extensive	  
periods	   in	   geographic	   areas	   that	   have	   a	   high	   to	   intermediate	   HAV	   endemicity,	   MSM,	  
injecting	  drug	  users,	  and	  those	  aged	  >50	  years	  [GPP]	  
• We	  recommend	  that	  patients	  at	  continued	  risk	  of	  exposure	  receive	  a	  boosting	  vaccine	  dose	  every	  
10	  years	  [1C]	  
• We	   recommend	   that	   in	   circumstance	   where	   a	   profoundly	   immunocompromised	   patient	   (CD4	  
count	   <200	   cell/μL)	   must	   be	   protected	   from	   likely	   exposure	   to	   HAV,	   HNIG	  may	   be	   considered	  
alongside	  the	  vaccine	  for	  temporary	  (~3	  weeks)	  pre-­‐exposure	  prophylaxis	  [1D]	  
• We	   recommend	   that	   following	   a	   significant	   exposure,	   HIV-­‐positive	   contacts	   who	   are	   HAV	  
seronegative	  receive	  post-­‐exposure	  prophylaxis	  with	  the	  HAV	  vaccine,	  with	  the	  first	  dose	  given	  as	  
soon	  as	  possible	  and	  within	  14	  days	  of	  exposure;	  if	  the	  CD4	  count	  is	  <200	  cells/μL	  they	  should	  also	  
receive	  HNIG	  [1C].	  	  
o While	   HAV	   serostatus	   should	   be	   determined	   if	   unknown,	   prophylaxis	   should	   not	   be	  
delayed	  while	  waiting	  for	  the	  results	  [GPP]	  	  
o We	  suggest	  that	  in	  some	  circumstances	  post-­‐exposure	  prophylaxis	  may	  be	  considered	  up	  
to	  28	  days	  after	  the	  contact	  [2D]	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1.	   Infection	   and	   disease:	   The	   hepatitis	   B	   virus	   (HBV)	   is	   transmitted	   through	   sexual	   intercourse,	  
percutaneous	  and	  parenteral	  exposure	  to	  blood	  and	  infected	  body	  ﬂuids,	  and	  vertically	  from	  mother	  
to	  child.	  The	  severity	  of	  acute	  infection	  varies	  from	  asymptomatic	  to	  fulminant	  hepatitis.	  After	  primary	  
infection,	  HBV	  persists	  in	  90%	  of	  infants	  infected	  perinatally,	  25-­‐50%	  of	  children	  aged	  1-­‐5	  years	  and	  1-­‐
5%	  of	   immunocompetent	  adults	  and	  older	   children.	  Chronic	   infection	  can	   lead	   to	   liver	   cirrhosis	  and	  
hepatocellular	  carcinoma.	  	  
	  
2.	   Epidemiology:	   Based	   on	   the	   prevalence	   of	   the	   infection,	   three	   geographical	   categories	   can	   be	  
identiﬁed:	  low	  prevalence	  (<2%),	  intermediate	  prevalence	  (2-­‐8%),	  and	  high	  prevalence	  (>8%).	  Regions	  
of	   low	   prevalence	   include	   Western,	   Northern	   and	   Central	   Europe,	   North	   America,	   and	   Australia.	  
Worldwide,	   the	   risk	   of	   infection	   is	   increased	   in	   injecting	  drug	  users	   (IDUs),	  men	  who	  have	   sex	  with	  
men	  (MSM),	  those	  with	  multiple	  sexual	  partners,	  household	  and	  other	  close	  contacts	  of	  HBV-­‐infected	  
persons,	  those	  receiving	  blood	  or	  blood	  products,	  patients	  and	  staff	  of	  haemodialysis	  centres,	  people	  
sharing	   unsterile	   medical	   and	   dental	   equipment,	   people	   providing	   and	   receiving	   acupuncture	   and	  
tattooing	  with	  unsterile	  devices,	  healthcare	  workers,	  staff	  and	  residents	  of	  residential	  accommodation	  
for	   those	  with	  mental	   disabilities,	   and	   travellers	   to	   areas	  of	   high	  or	   intermediate	  HBV	  prevalence	   if	  
engaging	   in	   exposure-­‐prone	   activities	   (including	   undertaking	   relief	   aid	   work	   and/or	   participating	   in	  
contact	  sports).	  	  
	  
3.	  HBV	   in	  HIV-­‐positive	   adults:	  Both	  the	  risk	  of	  HBV	   infection	  and	  that	  of	  chronicity	  are	   increased	   in	  
HIV-­‐seropositive	   persons	   [1].	   Chronic	   HBV	   infection	   is	   found	   in	   5-­‐10%	   of	   HIV-­‐positive	   persons	  
worldwide	  and	  co-­‐infected	  persons	  show	  increased	  rates	  of	  progression	  to	  cirrhosis	  and	   liver	  cancer	  
and	  a	  higher	  mortality	  than	  persons	  with	  either	  infection	  alone	  [2].	  	  
	  
4.	  Hepatitis	  B	   vaccine:	  The	  yeast-­‐derived	  HBV	  vaccine	   is	  prepared	  with	  biosynthetic	  surface	  antigen	  
made	  using	  recombinant	  technology.	  There	  is	  also	  a	  combined	  hepatitis	  A/hepatitis	  B	  vaccine.	  Newly	  
developed	  pre-­‐S/S	  HBV	  vaccines	  are	  under	  evaluation	  and	  may	  in	  the	  future	  play	  a	  role	  in	  improving	  
vaccine	  response	  rates	  in	  special	  risk	  groups	  including	  HIV-­‐positive	  patients	  [3,	  4].	  The	  vaccine	  is	  given	  
by	  parenteral	  administration.	  In	  HIV-­‐negative	  adults,	  the	  schedule	  of	  administration	  can	  be:	  Typical	  (3	  
doses	  at	  0,	  1,	  and	  6	  months);	  Accelerated	  (4	  doses	  at	  0,	  1,	  2,	  and	  12	  months);	  or	  Ultra-­‐rapid	  (4	  doses	  at	  
0,	  7-­‐10	  days,	  21	  days,	   and	  12	  months).	  Approximately	  80-­‐90%	  of	  healthy	  young	  adults	  achieve	  HBV	  
surface	  antibody	  (HBsAb)	   levels	  >10	   IU/L	  after	  a	  complete	  vaccine	  course.	  Antibody	   levels	  >100	   IU/L	  
are	   regarded	  as	   ideal	  whereas	  a	   level	  <10	   IU/L	   is	   classiﬁed	  as	  non-­‐response	   [5].	  Factors	   that	   reduce	  
responses	  to	  HBV	  vaccination	  include	  age	  >40	  years,	  obesity,	  female	  gender,	  haemodialysis,	  smoking,	  
and	  immunocompromise,	  including	  HIV	  infection.	  	  
	  
HBsAb	   levels	   decline	   over	   time	   after	   successful	   vaccination.	   After	   20	   years,	   18-­‐37%	   of	   adults	   have	  
HBsAb	   levels	   >10	   IU/L	   [6,7].	   There	   is	   some	   evidence	   that	   protective	   immunity	   is	   still	   present	   even	  
though	  HBsAb	   levels	  have	  fallen	  <10	   IU/L.	   Infection	  may	  occur,	  but	   it	   is	  mostly	   transient	   [7-­‐10].	   In	  a	  
study	   from	   the	   Gambia,	   adolescents	   and	   young	   adults	   vaccinated	   in	   infancy	   showed	   a	   risk	   of	   HBV	  
infection,	  but	   this	  did	  not	  usually	   result	   in	   a	   chronic	   infection	   [7].	   Time	   since	   vaccination	  and	  a	   low	  
peak	   HBsAb	   response	   were	   the	   strongest	   risk	   factors	   for	   HBV	   infection.	   There	   is	   limited	   evidence	  
regarding	   the	  need	   for	  booster	   vaccine	  doses	   in	  healthy	   individuals.	  UK	  guidelines	   recommend	   that	  
persons	  at	  ongoing	  risk	  receive	  a	  single	  booster	  5	  years	  after	  completion	  of	  the	  primary	  vaccine	  course.	  	  
	  
General	   indications:	   In	   the	  UK	  HBV	  vaccination	   is	  offered	   to	   individuals	  who	  are	  at	   increased	   risk	  of	  
infection	   or	   severe	   disease.	   The	   groups	   include	   IDUs,	   individuals	   who	   change	   sexual	   partners	  
frequently	  (e.g.,	  sexual	  workers),	  MSM,	  close	  contacts	  of	  people	  with	  HBV	  infection,	  families	  adopting	  
children	   from	   countries	   with	   a	   high	   or	   intermediate	   HBV	   prevalence,	   foster	   carers,	   individuals	  
receiving	  regular	  blood	  or	  blood	  products	  and	  their	  carers,	  patients	  with	  chronic	  renal	  failure,	  patients	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24	  
with	  chronic	  liver	  disease,	  Inmates	  of	  custodial	   institutions,	  Individuals	  in	  residential	  accommodation	  
for	   those	   with	   learning	   difficulties,	   people	   travelling	   to	   or	   going	   to	   reside	   in	   areas	   of	   high	   or	  
intermediate	  prevalence,	  and	  individuals	  at	  occupational	  risk.	  	  
	  
5.	  HBV	  vaccine	   in	  HIV-­‐positive	  adults:	  HBV	  vaccination	  signiﬁcantly	  reduces	  the	  risk	  of	   incident	  HBV	  
infection	   in	  HIV-­‐positive	   persons,	   and	   also	   reduces	   the	   risk	   of	   a	   newly	   acquired	   infection	   becoming	  
chronic	   [11].	   HIV	   infection	   however	   affects	   responses	   to	   HBV	   vaccination,	   reducing	   HBsAb	  
seroconversion	   rates,	   and	   HBsAb	   levels	   and	   longevity	   [12-­‐16].	   After	   standard	   vaccination,	   rates	   of	  
HBsAb	   seroconversion	   (>10	   IU/L)	   range	   between	   7%	   and	   88%,	   and	   correlate	   strongly	  with	   CD4	   cell	  
counts	   and	   viral	   load	   [12-­‐21].	   Strategies	   to	   improve	   responses	   have	   included	   revaccination	   of	   non-­‐
responders	  once	  the	  viral	  load	  is	  suppressed	  on	  ART	  and	  the	  CD4	  count	  is	  >350-­‐500	  cells/μL,	  and	  the	  
use	  of	   larger	  and	  more	  frequent	  vaccine	  doses	  [19-­‐23].	  When	  using	  yeast-­‐based	  HBV	  vaccines,	  high-­‐
dose	   vaccination	   improves	  HBsAb	   responses	   in	  HIV-­‐positive	   people.	   A	   systematic	   review	   and	  meta-­‐
analysis	  of	  five	  studies	  including	  a	  total	  of	  883	  patients	  compared	  HBsAb	  response	  with	  high-­‐dose	  (40	  
μg)	  vs.	  standard-­‐dose	  (20	  or	  10	  μg	  depending	  on	  vaccine	  type)	  vaccination	  [22].	  High-­‐dose	  vaccination	  
increased	  response	  rates	  with	  a	  pooled	  OR	  of	  1.96	  (95%	  CI	  1.47,	  2.61).	  With	  four	  studies	  that	  included	  
only	  vaccine-­‐naive	  patients	  the	  OR	  was	  1.82	  (95%	  CI	  1.35,	  2.47).	  No	  study	  heterogeneity	  was	  found.	  
An	  open-­‐label,	  multicentre,	  randomized	  trial	  of	  patients	  with	  CD4	  counts	  >200	  cell/μL	  evaluated	  three	  
HBV	  vaccination	  strategies:	  a.	  Three	  standard-­‐dose	  (20	  μg)	  intramuscular	  administrations	  at	  0,	  1,	  and	  6	  
months	   (n=145);	   b.	   Four	   high-­‐dose	   (40	   μg)	   intramuscular	   administrations	   at	   0,	   1,	   2,	   and	   6	  months	  
(n=148);	  and	  c.	  Four	  low-­‐dose	  (4	  μg)	  intradermal	  administrations	  at	  0,	  1,	  2,	  and	  6	  months	  (n=144)	  [20].	  
Response	  rates	  (HBsAb	  ≥10	  IU/L)	  4	  weeks	  after	  the	  last	  vaccine	  dose	  in	  patients	  who	  received	  at	  least	  
1	  vaccine	  dose	  (missing	  HBsAb	  titre	  =	  non-­‐responder)	  was	  65%	  (95%	  CI	  56%-­‐72%)	  in	  group	  a	  vs.	  82%	  
(77%-­‐88%)	   in	  group	  b	   (p<0.001)	  and	  77%	   (69%-­‐84%)	   in	  group	  c	   (p=0.02).	  A	   cohort	   study	  also	   found	  
that	   HBAbs	   response	   rates	  were	   83%	   and	   91%	   after	   three	   and	   four	   double-­‐doses,	   respectively	   and	  
HBsAb	  levels	  were	  higher	  with	  the	  4-­‐dose	  schedule	  [24].	  	  
	  
The	   ultra-­‐rapid	   vaccination	   course	   (3	   vaccine	   doses	   given	   over	   3	   weeks)	   is	   immunogenic	   and	   can	  
improve	  completion	  rates	  in	  healthy	  adults.	  However,	  a	  randomised	  study	  comparing	  the	  ultra	  rapid-­‐
vaccine	  course	  (0,	  7,	  and	  21	  days)	  with	  the	  typical	  course	  (0,	  1,	  and	  6	  months)	   in	  HIV-­‐positive	  adults	  
found	   that	   the	   former	  had	   reduced	   immunogenicity	   in	  patients	  with	  CD4	  counts	  <500	  cells/μL	   [25].	  
The	  study	  used	  standard-­‐dose	  vaccine;	  there	  are	  no	  data	  for	  using	  high-­‐dose	  vaccine	  in	  an	  ultra-­‐rapid	  
schedule.	  	  
	  
The	   relationship	  between	  HBsAb	   levels	   and	  protection	  has	  been	   investigated	  by	   comparing	   rates	  of	  
HBV	  infection	  among	  vaccine	  recipients	  with	   initial	  HBsAb	  levels	  <10	  IU/ml	  or	  ≥10	  IU/L	  [26].	  Overall,	  
46/409	  (11%)	  vaccine	  recipients	  with	  HBsAb	  <10	  IU/L	  acquired	  HBV	  infection	  compared	  with	  11/217	  
(5%)	  vaccine	  recipients	  with	  HBsAb	  ≥10	   IU/L	   (HR	  0.51;	  95%	  CI	  0.3,	  1.0).	  Furthermore,	   in	  participants	  
with	  initial	  HBsAb	  levels	  <10	  IU/L,	  16/46	  (35%)	  incident	  infections	  became	  chronic,	  whereas	  no	  chronic	  
infections	  were	  detected	  in	  those	  with	  initial	  HBsAb	  levels	  ≥10	  IU/L	  (p=0.02).	  Based	  upon	  these	  data,	  it	  
seems	   desirable	   to	   attempt	   to	   induce	   an	   HBsAb	   response	   in	   patients	   who	   fail	   to	   respond	   to	   the	  
primary	   vaccine	   course,	   as	   determined	   by	  measuring	  HBsAb	   levels	   4-­‐8	  weeks	   after	   the	   last	   vaccine	  
dose.	  As	  longer	  time	  to	  revaccination	  predicts	  nonresponse	  to	  revaccination,	  the	  management	  of	  non-­‐
responders	   should	  be	   timely	   [27].	  Both	  standard-­‐dose	   [27]	  and	  high-­‐dose	   [23,28]	   re-­‐vaccination	  has	  
been	   evaluated	   in	   HIV-­‐positive	   non-­‐responders.	   One	   study	   found	   that	   high-­‐dose	   re-­‐vaccination	  
significantly	  increased	  HBsAb	  response	  rates	  (OR	  4.2;	  CI,	  1.3-­‐13.6;	  p=0.018)	  [28].	  In	  two	  other	  studies,	  
high-­‐dose	  re-­‐vaccination	  was	  effective	  in	  inducing	  HBsAb	  in	  51%	  of	  144	  [23]	  and	  67%	  of	  30	  [29]	  non-­‐
responders	  respectively.	  Emerging	  data	  suggest	  that	  in	  addition	  to	  high-­‐dose	  re-­‐vaccination,	  using	  one	  
[30]	  or	  four	  [31]	  standard	  doses	  of	  the	  adjuvanted	  vaccine	  Fendrix	  may	  improve	  response	  rates	  among	  
people	  who	  do	  not	  make	  a	  HBsAb	  response	  to	  the	  primary	  vaccine	  course.	  In	  one	  cohort	  study,	  18/22	  
(82%)	  HIV-­‐positive	  non-­‐responders	  showed	  HBsAb	  levels	  >100	  IU/L	  following	  a	  4-­‐dose	  schedule,	  with	  
an	  additional	  3	  (14%)	  subjects	  achieving	  titres	  of	  10-­‐100	  IU/L	  [31].	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Duration	  of	  vaccine-­‐induced	  protection	  is	  unknown	  in	  HIV-­‐positive	  persons,	  but	  in	  general	  terms	  post-­‐
vaccination	  HBsAb	  levels	  are	  lower	  and	  disappear	  more	  quickly	  than	  in	  HIV-­‐negative	  persons.	  Among	  
HIV-­‐positive	  responders	  to	  HBV	  vaccination,	  the	  HBsAb	  level	  measured	  4	  weeks	  after	  the	  completion	  
of	  the	  vaccination	  course	  is	  strongly	  predictive	  of	  the	  longevity	  of	  response	  [32,33].	  In	  a	  cohort	  study	  
of	  155	  HIV-­‐positive	  vaccine	  recipients,	  the	  mean	  time	  to	  loss	  of	  detectable	  HBsAb	  was	  2.0,	  3.7	  and	  4.4	  
years	  for	  patients	  with	  HBsAb	  levels	  10-­‐100	  IU/I,	  >100-­‐1000	  IU/I,	  and	  >1000	  IU/I,	  respectively	  [33].	  In	  
addition,	  viral	  load	  suppression	  on	  ART	  during	  vaccination	  and	  at	  follow-­‐up	  predicts	  longer	  persistence	  
of	  HBsAb	  levels	  >10	  IU/L	  [33,33].	  These	  data	  indicate	  that	  it	  is	  desirable	  to	  boost	  the	  HBsAb	  response	  
of	  vaccine	  recipients	  that	  show	  HBsAb	  levels	  >10	  but	  <100	  IU/L	  after	  the	  primary	  vaccine	  course,	  with	  
the	   aim	   improving	   the	   longevity	   of	   the	   response.	   Further	   boosting	   requirements	   for	   patients	   who	  
make	  a	  response	  to	  vaccination	  are	  not	  well	  deﬁned	  in	  immunocompromised	  patients.	  The	  available	  
evidence	   indicates	   that	  while	   it	  may	  be	  practical	   to	  screen	  all	   immunised	  patients	   for	  HBsAb	  yearly,	  
the	   frequency	  of	  HBsAb	  monitoring	  among	  successfully	  vaccinated	  patients	  could	  be	   reduced	  based	  
upon	   the	   strength	   of	   the	   initial	   HBsAb	   response,	   and	   CD4	   count,	   ART	   status,	   and	   viral	   load	   at	  
vaccination	  and	  during	   follow-­‐up.	  Consensus	  opinion	   is	   that	  booster	  doses	   are	   indicated	   in	   subjects	  
whose	  HBsAb	  levels	  decline	  <10	  IU/L	   if	  at	  ongoing	  risk	  of	  exposure.	   Importantly,	  vaccinated	  patients	  
should	  continue	  to	  undergo	  HBV	  surveillance	  as	  they	  remain	  at	  risk	  of	  infection	  [26].	  	  
	  
“Occult”	  HBV	  infection	  and	  vaccination:	  Patients	  who	  test	  HBsAg	  negative,	  HBcAb	  positive	  and	  HBsAb	  
negative	  (isolated	  HBcAb	  positivity)	  have	  traditionally	  posed	  a	  management	  challenge.	  These	  patients	  
may	  belong	  to	  one	  of	  the	  following	  groups:	  (i)	  recent	  resolving	  HBV	  infection	  (HBV	  core	  IgM	  positive);	  
(ii)	   occult	   HBV	   infection	   (low-­‐level	   HBV	   DNA	   persistently	   or	   intermittently	   detectable	   in	   blood	   and	  
detectable	  in	  the	  liver);	  (iii)	  HBsAg	  diagnostic	  escape	  mutants	  (HBV	  DNA	  levels	  usually	  high	  in	  blood	  in	  
untreated	   patients);	   (iv)	   resolved	  HBV	   infection	   (strong	  HBcAb	   reactivity,	   possible	   HBeAb	   positivity,	  
anamnestic	  HBsAb	  response	  >10	  IU/L	  observed	  1-­‐2	  weeks	  after	  a	  single	  HBV	  vaccine	  dose);	  (v)	  false-­‐
positive	  HBcAb	  result	  and	  susceptibility	  to	  infection.	  While	  some	  experts	  recommend	  HBV	  DNA	  testing,	  
HBV	   DNA	   detection	   in	   blood	   may	   be	   intermittent	   in	   those	   with	   occult	   HBV	   infection	   [34].	   HBV	  
vaccination	  can	  elicit	  an	  anamnestic	  HBsAb	  response	  as	  evidence	  of	  past	  infection	  and	  immunity.	  One	  
study	  in	  HIV-­‐negative	  patient	  showed	  anamnestic	  responses	  (HBsAb	  ≥10	  IU/L)	  in	  20/21	  subjects	  with	  
isolated	   HBcAb	   after	   one	   vaccine	   dose	   [35]	   In	   contrast,	   studies	   in	   HIV-­‐positive	   patients	   found	   an	  
anamnestic	  response	  in	  24-­‐33%	  [36,37].	  	  	  
	  
The	  HBV	  vaccine	  is	  safe	  and	  well	  tolerated	  in	  HIV-­‐positive	  individuals.	  Injection	  site	  reactions	  are	  the	  
most	   frequent	   side	   effects.	   HBV	   vaccination	   completion	   rates	   are	   closely	   dependent	   on	   the	   clinical	  
setting	  providing	  HIV	  care	  [16],	  indicating	  that	  compliance	  should	  be	  audited	  regularly.	  	  
	  
6.	   Post-­‐exposure	   prophylaxis:	   After	   a	   recognised	   exposure	   to	   an	   HBsAg-­‐positive	   contact,	   post-­‐
exposure	   prophylaxis	   is	   guided	   by	   the	   vaccination	   history	   of	   the	   patient.	   Hepatitis-­‐B-­‐speciﬁc	  
immunoglobulin	   (HBIg)	   can	   protect	   from	   infection	   or	   attenuate	   disease	   if	   given	   within	   7	   days	   of	  
exposure.	   HBIg	   is	   given	   by	   intramuscular	   injection.	   A	   rapid	   (3	   weekly	   injections	   over	   3	   months)	  
vaccination	   course	   started	  within	   7	   days	   of	   exposure	   appears	   to	   be	   as	   effective	   as	   vaccination	  plus	  
HBIg	   in	   healthy	   persons.	   There	   are	   no	   data	   on	   the	   efﬁcacy	   of	   post-­‐exposure	   prophylaxis	   by	   either	  
strategy	  in	  HIV-­‐positive	  persons.	  	  
	  
7.	  Recommendations	  for	  HIV-­‐positive	  adults	  	  
• We	  recommend	  that	  HIV-­‐positive	  adults	  be	  screened	  for	  evidence	  of	  HBV	  infection	  or	   immunity,	  
and	   that	  non-­‐immune	   individuals	   (HBsAg	  negative,	  HBcAb	  negative,	  HBsAb	  negative)	  be	  offered	  
HBV	  vaccination	  [1A]	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o We	  recommend	  that	  when	  using	  yeast-­‐based	  vaccines,	  high-­‐dose	   (40	  µg)	  vaccination	  be	  
offered	   [1A].	   In	   the	  UK,	  Engerix	  B®	   should	  be	  given	  as	  a	  double-­‐dose	   (total	   40	  µg)	   [1A];	  
with	  HBvaxPRO®	  the	  40µg	  formulation	  should	  be	  used	  [1B]	  
o We	   recommend	   that	   when	   using	   the	   adjuvanted	   vaccine	   Fendrix®	   the	   standard	   20µg	  
formulation	  be	  given	  [1B]	  
o We	  recommend	  that,	  regardless	  of	  vaccine	  type,	  4	  vaccine	  doses	  are	  given	  at	  0,	  1,	  2,	  and	  6	  
months	  [1B]	  
o We	   recommend	   that	   an	  ultra-­‐rapid	   vaccination	   course	   (3	   standard-­‐dose	   administrations	  
given	  over	  3	  weeks)	  be	  considered	  only	  in	  selected	  patients	  with	  CD4	  counts	  >500	  cells/μL	  
where	   there	   is	   an	   imperative	   need	   to	   ensure	   rapid	   completion	   of	   vaccination	   and/or	  
where	  compliance	  with	  a	  full	  course	  is	  doubtful	  [1B].	  We	  recommend	  against	  using	  high-­‐
dose	  vaccination	  in	  an	  ultra-­‐rapid	  schedule	  due	  to	  the	  lack	  of	  safety	  data	  [1D]	  
• We	   recommend	   that	   following	   completion	   of	   the	   primary	   vaccine	   course,	   HBsAb	   levels	   be	  
measured	  4-­‐8	  wks	  after	  the	  last	  vaccine	  dose	  [1A]	  
• We	  recommend	  that	  individuals	  that	  after	  the	  primary	  vaccine	  course	  have	  HBsAb	  levels	  <10	  IU/L	  
receive	  3	  further	  vaccine	  doses	  at	  monthly	  intervals	  [1B]	  
o These	  should	  be	  given	  at	  high	  dose	   (40µg)	  with	  Engerix	  B®	  or	  HBvaxPRO®,	  and	  standard	  
dose	  (20µg)	  with	  Fendrix®	  
o We	  suggest	  that	  re-­‐vaccination	  with	  Fendrix	  may	  be	  preferred	  in	  non-­‐responders	  [2C]	  
o Retesting	  for	  HBsAb	  is	  indicated	  4-­‐8	  weeks	  after	  the	  ﬁnal	  vaccine	  dose	  [GPP]	  
o We	  suggest	  that	  depending	  on	  the	   level	  of	  risk,	  revaccination	  of	  non-­‐responders	  may	  be	  
delayed	  until	   the	  viral	   load	   is	  suppressed	  on	  ART	  and	  the	  CD4	  count	  has	   increased	  >350	  
cells/μL	  [2B]	  
• We	  recommend	  that	  individuals	  that	  after	  the	  primary	  vaccine	  course	  have	  HBsAb	  levels	  ≥10	  but	  
<100	  IU/L	  receive	  one	  booster	  dose	  (see	  above	  for	  dosing)	  [1B]	  
o Retesting	  for	  HBsAb	  is	  indicated	  4-­‐8	  weeks	  after	  the	  ﬁnal	  vaccine	  dose	  [GPP]	  
• We	   recommend	   that	   responders	   to	  HBV	   vaccination	   (HBsAb	   >10	   IU/L	   after	   completion	   of	   a	   full	  
vaccine	  course)	  undergo	  regular	  HBAbs	  testing	  in	  order	  to	  guide	  subsequent	  boosting	  requirement	  
[1B]	  
o We	   recommend	   that	   HBsAb	   screening	   intervals	   be	   guided	   by	   the	   initial	   HBsAb	   level	  
(measured	  after	  completion	  of	  the	  primary	  vaccine	  course),	  risk	  of	  exposure,	  and	  CD4	  cell	  
count,	  ART	  use,	  and	  viral	  load	  at	  the	  time	  of	  vaccination	  and	  during	  follow-­‐up	  [1B].	  Longer	  
intervals	   (i.e.,	   2-­‐4	   years]	   are	   indicated	   for	   subjects	  with	   initial	  HBsAb	   levels	   >100	   IU/ml,	  
CD4	  counts	  >350	  cells/μL,	  and	  viral	   load	  suppression	  on	  ART	  [1C].	  Other	  subjects	  should	  
undergo	  yearly	  HBsAb	  screening	  [1C]	  
o We	  recommend	  that	  subjects	  with	  an	  initial	  HBsAb	  response	  who	  show	  a	  decline	  of	  HBsAb	  
levels	  <10	  IU/ml	  are	  offer	  a	  booster	  dose	  (see	  above	  for	  dosing)	  [1C]	  	  
• We	  recommend	   individuals	  who	  have	  no	  evidence	  of	  protective	  vaccine-­‐induced	   immunity	  have	  
an	  annual	  HBsAg	  test	  or	  more	  frequent	  testing	  if	  there	  are	  known	  and	  ongoing	  risk	  factors	  for	  HBV	  
acquisition	  [1B]	  	  
• We	   recommend	   patients	   with	   isolated	   HBcAb	   positivity	   be	   offered	   one	   HBV	   vaccine	   dose	   (see	  
above	   for	  dosing),	  be	   tested	   for	  HBsAb	  2	  weeks	   later,	  and	  be	  offered	  completion	  of	   the	  vaccine	  
course	  if	  the	  HBsAb	  level	  is	  <10	  IU/L	  [1C]	  	  
• We	  recommend	  that	  compliance	  with	  HBV	  vaccination	  policy	  is	  audited	  regularly	  [1B]	  
• We	  recommend	  that	  following	  a	  high-­‐risk	  exposure	  to	  an	  HBsAg-­‐positive	  source,	  the	  HBV	  status	  of	  
the	  HIV-­‐positive	  contact	  be	  determined	  urgently	  if	  not	  known	  [1C]	  
o No	  prophylaxis	  is	  required	  in	  those	  with	  evidence	  of	  a	  current	  or	  past	  HBV	  infection	  
o Vaccinated	  patients	  with	  initial	  HBsAb	  >10	  IU/L	  should	  be	  offered	  one	  booster	  dose	  and	  if	  
the	  CD4	  count	  is	  <200	  cells/μL	  also	  receive	  HBIg	  [1C]	  
o Non-­‐responders	  to	  previous	  HBV	  vaccination	  (initial	  HBsAb	  <10	  IU/	  L)	  should	  be	  offered	  a	  
booster	  vaccine	  dose	  and	  also	  receive	  HBIg	  regardless	  of	  CD4	  count	  [1C]	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o Patients	  who	  have	  not	  been	  vaccinated	  or	  have	  an	  uncertain	  vaccination	  history	  should	  be	  
offered	  a	  rapid	  vaccine	  course	  (0,	  1,	  2	  months;	  see	  above	  for	  dosing)	  and	  also	  receive	  HBIg	  
regardless	  of	  CD4	  cell	  count	  [1C]	  
o When	  indicated,	  2	  doses	  of	  HBIg	  should	  be	  given	  1	  month	  apart	  
o Post-­‐exposure	   prophylaxis	   should	   be	   given	  within	   7	   days	   of	   exposure	   [1D].	  We	   suggest	  
that	   prophylaxis	   beyond	   7	   days	   (up	   to	   6	   weeks	   after	   exposure)	   may	   be	   considered	   in	  
selected	  cases;	  specialist	  advice	  should	  be	  sought	  [2D]	  
	  
	  








1. Colin	  JF,	  Cazals–Hatem	  D,	  Loriot	  MA	  et	  al.	  Inﬂuence	  of	  human	  immunodeﬁciency	  virus	  infection	  on	  
chronic	  hepatitis	  B	  in	  homosexual	  men.	  Hepatol	  1999;	  29:	  1306–1310.	  	  
2. Martín-­‐Carbonero	  L,	  Poveda	  E.	  Hepatitis	  B	  virus	  and	  HIV	  infection.	  Semin	  Liver	  Dis	  2012;32:114-­‐9.	  
3. Shouval	  D.	  Hepatitis	  B	  vaccines.	  J	  Hepatol	  2003;39	  Suppl	  1:S70-­‐6.	  
4. Shouval	  D,	  Roggendorf	  H,	  Roggendorf	  M.	  Enhanced	   immune	  response	   to	  hepatitis	  B	  vaccination	  
through	  immunization	  with	  a	  Pre-­‐S1/Pre-­‐S2/S	  vaccine.	  Med	  Microbiol	  Immunol.	  2015;204:57-­‐68.	  	  
5. Jack	   AD,	   Hall	   AJ,	   Maine	   N	   et	   al.	   What	   level	   of	   hepatitis	   B	   antibody	   is	   protective?	   J	   Infect	   Dis	  
1999;179:489-­‐92.	  	  
Draft	  BHIVA	  guidelines	  on	  the	  use	  of	  vaccines	  in	  HIV-­‐positive	  adults	  2015	  
 
Consultation	  draft	  	   	   	  
 
28	  
6. Bagheri-­‐Jamebozorgi	  M,	  Keshavarz	   J,	  Nemati	  M,	  et	  al.	   The	  persistence	  of	  anti-­‐HBs	  antibody	  and	  
anamnestic	  response	  20	  years	  after	  primary	  vaccination	  with	  recombinant	  hepatitis	  B	  vaccine	  at	  
infancy.	  Hum	  Vaccin	  Immunother	  2014;10:3731-­‐6.	  
7. Mendy	  M,	  Peterson	   I,	  Hossin	   S,	   et	   al.	  Observational	   study	  of	   vaccine	  efficacy	  24	  years	  after	   the	  
start	   of	   hepatitis	   B	   vaccination	   in	   two	  Gambian	   villages:	   no	   need	   for	   a	   booster	   dose.	   PLoS	  One	  
2013;8:e58029.	  
8. Wainwright	  RB,	  Bulkow	  LR,	  Parkinson	  AJ,	  Zanis	  C,	  McMahon	  BJ.	  Protection	  provided	  by	  hepatitis	  B	  
vaccine	  in	  a	  Yupik	  Eskimo	  population:	  results	  of	  a	  10-­‐year	  study.	  J	  Infect	  Dis	  1997;	  175:	  674–677.	  
9. Yuen	  MF,	  Lim	  WL,	  Cheng	  CC,	  Lam	  SK,	  Lai	  CL.	  Twelve	  year	  follow-­‐up	  of	  a	  prospective	  randomized	  
trial	   of	   recombinant	   DNA	   yeast	   vaccine	   vs.	   plasma-­‐derived	   vaccine	   without	   booster	   doses	   in	  
children.	  Hepatology	  1999;	  29:	  924–927.	  	  
10. European	   Consensus	   Group	   on	   Hepatitis	   B	   Immunity.	   Are	   booster	   immunisations	   needed	   for	  
lifelong	  hepatitis	  B	  immunity?	  Lancet	  2000;	  355:	  561–565.	  	  
11. Kellerman	   SE,	   Hanson	   DL,	   McNaghten	   AD,	   Fleming	   PL.	   Prevalence	   of	   chronic	   hepatitis	   B	   and	  
incidence	   of	   acute	   hepatitis	   B	   infection	   in	   human	   immunodeﬁciency	   virus-­‐infected	   subjects.	   J	  
Infect	  Dis	  2003;188:571-­‐7.	  	  
12. Biggar	   RJ,	   Goedert	   JJ,	   Hoofnagle	   J.	   Accelerated	   loss	   of	   antibody	   to	   hepatitis	   B	   surface	   antigen	  
among	  immunodeﬁcient	  homosexual	  men	  infected	  with	  HIV.	  N	  Engl	  J	  Med	  1987;316:630-­‐1.	  	  
13. Collier	  AC,	  Corey	  L,	  Murphy	  VL,	  Handsﬁeld	  HH.	  Antibody	  to	  human	  immunodeﬁciency	  virus	  (HIV)	  
and	  suboptimal	  response	  to	  hepatitis	  B	  vaccination.	  Ann	  Intern	  Med	  1988;109:101-­‐5.	  	  
14. Tayal	  SC,	  Sankar	  KN.	  Impaired	  response	  to	  recombinant	  hepatitis	  B	  vaccine	  in	  asymptomatic	  HIV-­‐
infected	  individuals.	  AIDS	  1994;8:558-­‐9.	  	  
15. Veiga	  APR,	  Casseb	  J,	  Duarte	  AJS.	  Humoral	  response	  to	  hepatitis	  B	  vaccination	  and	  its	  relationship	  
with	   T	   CD45RA	   (naı¨ve)	   and	   CD45RO	   (memory)	   subsets	   in	   HIV-­‐1-­‐infected	   subjects.	   Vaccine	  
2006;24:7124-­‐8.	  	  
16. Tedaldi	  EM,	  Baker	  RK,	  Moorman	  AC	  et	  al.	  Hepatitis	  A	  and	  B	  vaccination	  practices	  for	  ambulatory	  
patients	  infected	  with	  HIV.	  Clin	  Infect	  Dis	  2004;38:1478-­‐84.	  	  
17. Rey	  D,	  Krantz	  V,	  Partisani	  M	  et	  al.	  Increasing	  the	  number	  of	  hepatitis	  B	  injections	  augments	  anti-­‐
HBs	  response	  rate	  in	  HIV-­‐infected	  patients.	  Effect	  on	  viral	  load.	  Vaccine	  2000;18:1161-­‐5.	  	  
18. Fonseca	  MO,	  Pang	  LW,	  de	  Paula	  Cavalheiro	  N,	  Barone	  AA,	  Heloisa	  Lopes	  M.	  Randomized	  trial	  of	  
recombinant	   hepatitis	   B	   vaccine	   in	   HIV-­‐infected	   adult	   patients	   comparing	   a	   standard	   dose	   to	   a	  
double	  dose.	  Vaccine	  2005;23:2902-­‐8.	  	  
19. Flynn	   PM,	   Cunningham	   CK,	   Rudy	   B,	   et	   al.	   Hepatitis	   B	   vaccination	   in	   HIV-­‐infected	   youth:	   a	  
randomized	  trial	  of	  three	  regimens.	  J	  Acquir	  Immune	  Defic	  Syndr	  2011;56:325-­‐32	  
20. Launay	   O,	   van	   der	   Vliet	   D,	   Rosenberg	   AR,	   et	   al.	   Safety	   and	   immunogenicity	   of	   4	   intramuscular	  
double	  doses	  and	  4	  intradermal	  low	  doses	  vs	  standard	  hepatitis	  B	  vaccine	  regimen	  in	  adults	  with	  
HIV-­‐1:	  a	  randomized	  controlled	  trial.	  JAMA	  2011;305:1432-­‐40.	  
21. Whitaker	  JA,	  Rouphael	  NG,	  Edupuganti	  S,	  Lai	  L,	  Mulligan	  MJ.	  Strategies	  to	  increase	  responsiveness	  
to	  hepatitis	  B	  vaccination	  in	  adults	  with	  HIV-­‐1.	  Lancet	  Infect	  Dis	  2012;12:966-­‐76	  
22. Ni	   JD,	   Xiong	   YZ,	  Wang	   XJ,	   Xiu	   LC.	   Does	   increased	   hepatitis	   B	   vaccination	   dose	   lead	   to	   a	   better	  
immune	  response	   in	  HIV-­‐infected	  patients	  than	  standard	  dose	  vaccination:	  a	  meta-­‐analysis.	   Int	   J	  
STD	  AIDS	  2013	  2013;24:117-­‐22.	  
23. de	  Vries-­‐Sluijs	  TE,	  Hansen	  BE,	  van	  Doornum	  GJ	  et	  al.	  A	  prospective	  open	  study	  of	  the	  efﬁcacy	  of	  
high-­‐dose	   recombinant	   hepatitis	   B	   rechallenge	   vaccination	   in	   HIV-­‐infected	   patients.	   J	   Infect	   Dis	  
2008;197:292-­‐4.	  	  
24. Potsch	  DV,	  Oliveira	  ML,	  Ginuíno	  C,	  et	  al.	  High	  rates	  of	  serological	  response	  to	  a	  modified	  hepatitis	  
B	  vaccination	  schedule	  in	  HIV-­‐infected	  adults	  subjects.	  Vaccine	  2010;28:1447-­‐50.	  
25. de	   Vries-­‐Sluijs	   TE,	   Hansen	   BE,	   van	   Doornum	   GJ,	   et	   al.	   A	   randomized	   controlled	   study	   of	  
accelerated	   versus	   standard	   hepatitis	   B	   vaccination	   in	   HIV-­‐positive	   patients.	   J	   Infect	   Dis	  
2011;203:984-­‐91.	  
26. Landrum	  ML,	  Hullsiek	  KH,	  Ganesan	  A,	  et	  al.	  Hepatitis	  B	  vaccination	  and	  risk	  of	  hepatitis	  B	  infection	  
in	  HIV-­‐infected	  individuals.	  AIDS	  2010;24:545-­‐55.	  
Draft	  BHIVA	  guidelines	  on	  the	  use	  of	  vaccines	  in	  HIV-­‐positive	  adults	  2015	  
 
Consultation	  draft	  	   	   	  
 
29	  
27. Irungu	  E,	  Mugo	  N,	  Ngure	  K,	  et	  al.	  Immune	  response	  to	  hepatitis	  B	  virus	  vaccination	  among	  HIV-­‐1	  
infected	  and	  uninfected	  adults	  in	  Kenya.	  J	  Infect	  Dis	  2013;207:402-­‐10.	  
28. Psevdos	  G,	  Kim	  JH,	  Groce	  V,	  Sharp	  V.	  Efficacy	  of	  double-­‐dose	  hepatitis	  B	  rescue	  vaccination	  in	  HIV-­‐
infected	  patients.	  AIDS	  Patient	  Care	  STDS	  2010;24:403-­‐7.	  
29. Pettit	  NN,	  DePestel	  DD,	  Malani	  PN,	  et	   al.	   Factors	  associated	  with	   seroconversion	  after	   standard	  
dose	   hepatitis	   B	   vaccination	   and	   high-­‐dose	   revaccination	   among	  HIV-­‐infected	   patients.	   HIV	   Clin	  
Trials	  2010;11:332-­‐9.	  
30. Hoebe	  CJ,	  Vermeiren	  AP,	  Dukers-­‐Muijrers	  NH.	  Revaccination	  with	  Fendrix®	  or	  HBVaxPro®	  results	  
in	  better	  response	  rates	  than	  does	  revaccination	  with	  three	  doses	  of	  Engerix-­‐B®	  in	  previous	  non-­‐
responders.	  Vaccine	  2012;30:6734-­‐7.	  	  
31. de	   Silva	   TI,	   Green	   ST,	   Cole	   J,	   Stone	   BJ,	   Dockrell	   DH,	   Vedio	   AB.	   Successful	   use	   of	  Fendrix	  in	   HIV-­‐
infected	  non-­‐responders	  to	  standard	  hepatitis	  B	  vaccines.	  J	  Infect	  2014;68:397-­‐9.	  	  
32. Powis	  JE,	  Raboud	  J,	  Ostrowski	  M,	  Loutfy	  MR,	  Kovacs	  C,	  Walmsley	  SL.	  The	  recombinant	  hepatitis	  B	  
surface	  antigen	  vaccine	  in	  persons	  with	  HIV:	  is	  seroconversion	  sufficient	  for	  long-­‐term	  protection?	  
J	  Infect	  Dis	  2012;205:1534-­‐8.	  
33. Lopes	  VB,	  Hassing	  RJ,	  de	  Vries-­‐Sluijs	  TE,	  et	  al.	  Long-­‐term	  response	  rates	  of	  successful	  hepatitis	  B	  
vaccination	  in	  HIV-­‐infected	  patients.	  Vaccine.	  2013;31:1040-­‐4.	  
34. Nebbia	  G,	  Garcia-­‐Diaz	  A,	  Ayliffe	  U,	  et	  al.	  Predictors	  and	  kinetics	  of	  occult	  hepatitis	  B	  virus	   (HBV)	  
infection	  in	  HIV-­‐infected	  persons.	  J	  Med	  Virol	  2007;79:1464-­‐71.	  	  
35. Su	   FH,	   Bai	   CH,	   Chu	   FY,	   Lin	   YS,	   Su	   CT,	   Yeh	   CC.	   Significance	   and	   anamnestic	   response	   in	   isolated	  
hepatitis	  B	  core	  antibody-­‐positive	  individuals	  18	  years	  after	  neonatal	  hepatitis	  B	  virus	  vaccination	  
in	  Taiwan.	  Vaccine	  2012;30:4034-­‐9.	  
36. Gandhi	  RT,	  Wurcel	  A,	  Lee	  H	  et	  al.	  Response	  to	  hepatitis	  B	  vaccine	  in	  HIV-­‐1-­‐positive	  subjects	  who	  
test	  positive	  for	  isolated	  antibody	  to	  hepatitis	  B	  core	  antigen:	  implications	  for	  hepatitis	  B	  vaccine	  
strategies.	  J	  Infect	  Dis	  2005;191:1435-­‐41.	  	  
37. Chakvetadze	  C,	  Bani-­‐Sadr	  F,	  Le	  Pendeven,	  C,	  et	  al.	  Serologic	  response	  to	  hepatitis	  B	  vaccination	  in	  
HIV-­‐Infected	  patients	  with	  isolated	  positivity	  for	  antibodies	  to	  hepatitis	  B	  core	  antigen.	  Clin	  Infect	  
Dis	  2010;50:1184-­‐6.	  	  
	  
	  
	   	  
Draft	  BHIVA	  guidelines	  on	  the	  use	  of	  vaccines	  in	  HIV-­‐positive	  adults	  2015	  
 
Consultation	  draft	  	   	   	  
 
30	  
HUMAN PAPILLOMA VIRUS  
	  
1.	  Infection	  and	  disease:	  HPV	  establishes	  infection	  in	  the	  skin	  and	  mucous	  membranes.	  Transmission	  
occurs	   through	  direct	  contact,	  when	  microtears	  allow	  the	  virus	   to	   invade	  basal	  epithelial	  cells.	  Most	  
HPV	   infections	   are	   subclinical	   and	   resolve	   spontaneously.	   Persistence	   can	   lead	   to	   disease,	   including	  
premalignant	  and	  malignant	   lesions	   [1].	  Over	  150	  HPV	   types	  have	  been	   identified	  and	  are	  classified	  
according	  to	  the	  oncogenic	  potential.	  HPV-­‐6	  and	  HPV-­‐11	  are	  non-­‐oncogenic	  and	  responsible	  for	  about	  
90%	  of	  genital	  warts	  and	  most	  cases	  of	   recurrent	   respiratory	  papillomatosis.	  Oncogenic	   types	  cause	  
cancers	  of	  the	  cervix,	  vulva,	  and	  vagina	  in	  women,	  penis	  in	  men,	  and	  anus	  and	  oropharynx	  in	  women	  
and	  men	  [1].	  Just	  over	  60%	  of	  HPV-­‐associated	  cancers	  are	  caused	  by	  HPV-­‐16	  or	  HPV-­‐18;	  HPV	  types	  31,	  
33,	  45,	  52,	  and	  58	  account	  for	  ~10%	  of	  cases	  [1-­‐4].	  Co-­‐infection	  with	  multiple	  HPV	  types	  is	  common	  [5].	  	  
	  
2.	  Epidemiology:	  HPV	  is	  the	  most	  prevalent	  sexually	  transmitted	  infection	  in	  industrialised	  countries.	  
Transmission	  between	  sexual	  partners	  is	  common,	  and	  appears	  to	  be	  more	  frequent	  from	  females	  to	  
males	   than	   from	  males	   to	   females.	  Condoms	   reduce	   the	   risk	  of	   infection	   [6],	   although	   they	  are	  not	  
fully	   protective	   (~70%	   efficacy	   with	   consistent	   use).	   In	   women,	   HPV	   acquisition	   increases	   with	   age	  
through	   the	  early	  20s	  and	   then	  decreases,	   although	  acquisition	   continues	   in	  older	  women	   [7].	  Men	  
show	   a	   relatively	   constant	   incidence	   over	   a	   wide	   age	   range.	   HPV	   is	   a	   dominant	   cause	   of	   cancer	  
worldwide.	   Cervical	   cancer	   remains	   a	   major	   health	   burden,	   particularly	   in	   less	   developed	   regions	  
where	   screening	   and	   vaccination	   programmes	   are	   less	   established.	   Other	   HPV-­‐related	   cancers	   are	  
increasing	   in	   incidence	   among	   both	   men	   and	   women	   [1].	   There	   is	   evidence	   indicating	   that	   HIV	  
acquisition	  is	  significantly	  associated	  with	  HPV	  infection	  [8].	  	  
	  
3.	  HPV	  in	  HIV-­‐positive	  adults:	  Men	  and	  women	  with	  HIV	  infection	  show	  an	  increased	  risk	  and	  rate	  of	  
HPV	   acquisition	   and	   persistence,	   frequent	   carriage	   of	  multiple	   HPV	   types,	   and	   an	   increased	   risk	   of	  
HPV-­‐related	  disease	  including	  rapidly	  progressive	  malignancies	  [9-­‐38].	  HPV	  carriage	  rates	  and	  overall	  
disease	   risk	   increase	   at	   low	   CD4	   cell	   counts.	   However,	   despite	   effective	   ART	   HIV-­‐positive	  men	   and	  
women	   remain	   disproportionately	   affected	   by	   HPV-­‐related	   anogenital	   disease	   compared	   with	   HIV-­‐
negative	  people.	  Overall	  prevalence	  of	  HPV-­‐16	  and	  HPV-­‐18	  in	  HIV-­‐positive	  women	  aged	  13-­‐45	  years	  in	  
the	   United	   States,	   Brazil,	   and	   South	   Africa	   is	   32%	   and	   20%	   respectively	   [39].	   Anal	   HPV	   infection	   is	  
highly	  prevalent	  in	  HIV-­‐positive	  men	  who	  have	  sex	  with	  men	  (MSM).	  An	  Australian	  study	  of	  MSM	  aged	  
18-­‐75	   years	   showed	   a	   HPV-­‐16	   seroprevalence	   of	   44%,	   with	   a	   seroincidence	   of	   1.3	   per	   100	  
person/years	  continuing	  in	  the	  mid	  40s	  [19].	  A	  meta-­‐analysis	  of	  34,189	  HIV-­‐positive	  and	  114,260	  HIV-­‐
negative	   individuals	   in	   North	   America	   reported	   that	   between	   1996	   and	   2007	   the	   incidence	   of	   anal	  
cancer	  per	  100,000	  person/years	  was	  131	   in	  HIV-­‐positive	  MSM,	  46	   in	  other	  HIV-­‐positive	  men,	  30	   in	  
HIV-­‐positive	  women,	   2	   in	   HIV-­‐negative	  men,	   and	   zero	   in	   the	   HIV-­‐negative	  women	   surveyed	   in	   this	  
study	  [21].	  The	  analysis	  reported	  that	  incidence	  of	  anal	  cancer	  was	  higher	  in	  ART	  era	  likely	  reflecting	  
improved	  survival	  and	  increased	  awareness	  and	  diagnosis.	  	  
	  
4.	   HPV	   vaccine:	   Three	   virus-­‐like	  particle	   (VLP)	   sub-­‐unit	   vaccines	  based	  on	   the	   L1	   capsid	  protein	   are	  
currently	   in	  use	   for	   the	  prevention	  of	  HPV	  disease	  around	  the	  world	   [2,3].	  They	  comprise	  a	  bivalent	  
product	  (2vHPV;	  Cervarix,	  GlaxoSmithKline;	  HPV	  types	  16	  and	  18)	  and	  a	  quadrivalent	  product	  (4vHPV;	  
Gardasil	  4,	  Merck;	  HPV	  types	  6,	  11,	  16,	  18),	  which	  were	  introduced	  in	  2006	  and	  2007	  respectively,	  and	  
a	  nonavalent	  product	   	   (9vHPV;	  Gardasil	  9,	  Merck;	  HPV	  types	  6,	  11,	  16,	  18,	  31,	  33,	  45,	  52,	  58),	  which	  
was	  licensed	  by	  the	  FDA	  in	  2014.	  Both	  vaccine	  types	  are	  adjuvanted.	  VLPs	  are	  similar	  in	  shape	  and	  size	  
to	  the	  HPV	  virion,	  but	  do	  not	  contain	  viral	  DNA,	  and	  are	  therefore	  non-­‐infectious	  and	  non-­‐oncogenic.	  
The	   vaccines	   are	   given	   by	   parenteral	   administration.	   HPV	   vaccines	   are	   more	   immunogenic	   than	  
natural	  infection,	  and	  highly	  efficacious	  in	  protecting	  susceptible	  women	  against	  cervical	  infection	  and	  
pre-­‐cancer	   related	   to	   HPV-­‐16	   and	   HPV-­‐18.	   Protection	   is	   maintained	   for	   at	   least	   10	   years.	   Ongoing	  
studies	  will	   determine	  whether	   effectiveness	  declines	  with	   time,	   and	   the	   requirement	   for	   boosters.	  
The	  vaccines	  are	  also	  efficacious	  in	  preventing	  HPV-­‐16	  and	  HPV-­‐18	  infections	  at	  other	  anatomical	  sites	  
in	  both	  sexes,	  including	  the	  precursors	  of	  vulvar,	  vaginal	  and	  anal	  cancer	  related	  to	  the	  vaccine	  types	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[2-­‐4,40-­‐42].	  The	  4vHPV	  and	  9vHPV	  vaccines	  also	  reduce	  the	  incidence	  of	  genital	  warts	  associated	  with	  
the	  vaccine	   types.	  Partial	   cross-­‐protection	  against	  non-­‐vaccine	  HPV	  types	  has	  been	  reported,	  but	   its	  
effectiveness	  and	  duration	  is	  unknown.	  HPV	  vaccines	  are	  well	  tolerated	  and	  no	  safety	  concerns	  have	  
emerged	  from	  clinical	  trials	  and	  post-­‐license	  evaluations	  [43].	  Non-­‐inferiority	  of	  immune	  response	  and	  
an	  acceptable	  safety	  profile	  have	  been	  demonstrated	  when	  the	  HPV	  vaccine	   is	  co-­‐administered	  with	  
other	  vaccines	  (assessed	  with	  meningococcal	  conjugate,	  hepatitis	  A,	  hepatitis	  B,	  combined	  hepatitis	  A/	  
B,	  tetanus,	  diphtheria,	  acellular	  pertussis,	  and	  inactivated	  poliovirus	  vaccines)	  [44].	  
	  
General	  indications:	  In	  the	  UK,	  since	  2008,	  HPV	  vaccination	  is	  routinely	  recommended	  for	  all	  girls	  aged	  
12-­‐13,	  along	  with	  a	  catch	  up	  programme	  for	  girls	  13	  to	  under	  18	  years	  of	  age.	  Two	  vaccine	  doses	  are	  
given	  to	  those	  aged	  9-­‐14	  years,	  and	  3	  doses	  to	  those	  aged	  15-­‐18	  years.	  In	  November	  2014,	  the	  Joint	  
Committee	   on	   Vaccination	   and	   Immunisation	   (JCVI)	   issued	   an	   interim	   position	   statement	  
recommending	  HPV	  vaccination	  with	  a	  3	  dose	  series	   (0,	  1-­‐2,	  and	  6	  months)	   for	  MSM	  aged	  up	  to	  40	  
years	  attending	  sexual	  health	  services	  after	  considering	  evidence	  on	  the	  impact	  and	  cost-­‐effectiveness	  
of	   a	   targeted	   vaccination	   programme	   in	   this	   group	   [45].	   The	  price	   of	   the	   vaccine	   and	  HIV	   status	   of	  
MSM	  impacted	  on	  the	  cost	  effectiveness	  of	  this	  recommendation.	  Other	  males	  of	  any	  age	  and	  women	  
>18	   years	   of	   age	   are	   not	   currently	   covered	   by	   the	   UK	   national	   programme,	   although	   this	   is	   under	  
review.	  Gardasil	  (4vHPV	  currently)	  is	  the	  preferred	  vaccine	  in	  the	  UK	  due	  to	  the	  additional	  protection	  
against	  genital	  warts.	  In	  February	  2015,	  the	  US	  Advisory	  Committee	  on	  Immunization	  Practices	  (ACIP)	  
recommended	   9vHPV	   as	   one	   of	   three	   HPV	   vaccines	   that	   can	   be	   used	   for	   routine	   vaccination	   of	  
females,	   whereas	   4vHPV	   or	   9vHPV	   are	   recommended	   for	  males.	   ACIP	   recommends	   vaccination	   for	  
women	  up	  to	  26	  years,	  males	  up	  to	  21	  years,	  MSM	  up	  to	  26	  years,	  and	  immunocompromised	  persons	  
(including	  those	  with	  HIV	  infection)	  up	  to	  26	  years	  [2].	  	  
	  
Cost-­‐effectiveness	   considerations:	   HPV	   vaccination	   has	   been	   shown	   to	   be	   cost-­‐effective	   in	   pre-­‐
adolescent	   females.	   As	   HPV	   vaccines	   protect	   against	   HPV	   types	   not	   already	   acquired,	   cost-­‐
effectiveness	   declines	  with	   increasing	   likelihood	   of	   previous	   exposure.	   For	  women,	   studies	   differ	   in	  
their	   conclusions	  about	   the	  age	  cut-­‐off	  at	  which	   the	  cost-­‐effectiveness	   ratio	  becomes	  unfavourable,	  
ranging	  from	  15	  to	  26	  years	  within	  available	  data.	  The	  cost-­‐effectiveness	  of	  vaccinating	  young	  males	  is	  
generally	  lower	  than	  with	  young	  females,	  firstly	  because	  the	  burden	  of	  disease	  is	  lower	  in	  men	  than	  in	  
women,	   and	   secondly	   because	   men	   derive	   benefits	   from	   female-­‐only	   vaccination	   programmes	   via	  
herd	   immunity,	   particularly	   if	   vaccine	   coverage	   is	   high	   [2-­‐4,41,42,46].	   Population-­‐based	   studies	   in	  
countries	   with	   high	   female	   vaccine	   coverage	   confirm	   a	   beneficial	   impact	   of	   herd	   immunity	   in	  
heterosexual	  males;	  the	  benefit	  however	  is	  not	  extended	  to	  MSM.	  One	  US-­‐based	  study	  addressed	  the	  
cost-­‐effectiveness	   of	   vaccinating	   MSM	   through	   26	   years	   of	   age,	   and	   concluded	   that	   vaccination	   is	  
likely	   to	   be	   a	   cost-­‐effective	   intervention	   for	   the	   prevention	   of	   genital	  warts	   and	   anal	   cancer	   in	   this	  
group	  [46].	  Outcomes	  were	  most	  sensitive	  to	  variations	  in	  anal	  cancer	  incidence,	  duration	  of	  vaccine	  
protection,	   and	   HIV	   prevalence	   in	  MSM.	   A	  more	   recent	   unpublished	   analysis	   reviewed	   by	   the	   JCVI	  
analysed	   the	   cost-­‐effectiveness	   of	   vaccinating	  MSM	  up	   to	   age	  of	   40	   years	   [45].	   In	   this	  model,	   cost-­‐
effectiveness	   was	   higher	   for	   4vHPV	   due	   to	   the	   added	   protection	   against	   genital	   warts.	   Under	   the	  
criteria	  used	  by	  JCVI,	  vaccinating	  HIV-­‐positive	  MSM	  aged	  16	  to	  25	  years	  was	  cost-­‐effective	  at	  the	  list	  
price	  of	  the	  vaccine.	  Vaccinating	  HIV-­‐positive	  MSM	  aged	  16	  to	  40	  years	  was	  also	   incrementally	  cost-­‐
effective	  under	  the	  base	  case	  assumptions.	  Extending	  vaccination	  to	  all	  MSM	  aged	  16	  to	  40	  years	  was	  
not	  incrementally	  cost-­‐effective	  when	  using	  the	  list	  price	  of	  the	  vaccines.	  However,	  vaccination	  of	  all	  
MSM	  aged	  16	   to	   40	   years	  was	   cost-­‐effective	   under	   the	   criteria	   used	  by	   JCVI	   at	   a	   threshold	   vaccine	  
price	  below	  the	  list	  price.	  The	  JCVI	  highlighted	  that	  key	  operational	  and	  delivery	   issues	  remain	  to	  be	  
addressed	  for	  the	  programme	  to	  be	  considered.	  In	  US-­‐based	  models	  assuming	  that	  9vHPV	  would	  cost	  
$13	  more	  per	  dose	  than	  4vHPV,	  introduction	  of	  9vHPV	  was	  cost-­‐effective	  when	  compared	  with	  4vHPV	  
for	  both	  sexes	  [2].	  Because	  the	  additional	  five	  types	  in	  9vHPV	  account	  for	  a	  higher	  proportion	  of	  HPV-­‐
associated	   cancers	   in	   females	   compared	   with	   males	   and	   cause	   cervical	   pre-­‐cancers,	   the	   additional	  
protection	  from	  9vHPV	  is	  expected	  to	  benefit	  mostly	  females.	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Vaccine	  safety:	  For	  eligible	  individuals,	  HPV	  vaccination	  is	  indicated	  regardless	  of	  a	  previous	  history	  of	  
abnormal	   smear	   test	   results,	   pre-­‐cancer	   lesions	   likely	   to	   be	   HPV-­‐associated,	   or	   anogenital	   warts,	  
although	  the	  benefit	  of	  vaccination	  decreases	  with	  increasing	  likelihood	  of	  a	  previous	  exposure	  to	  the	  
vaccine	  types.	  There	  are	  no	  data	  to	  support	  laboratory	  testing	  to	  exclude	  a	  prior	  HPV	  exposure	  before	  
vaccination.	   Whilst	   the	   vaccines	   are	   not	   expected	   to	   have	   therapeutic	   effects,	   vaccination	   of	  
individuals	   pre-­‐exposed	   to	   the	   vaccine	   types	   is	   safe,	   may	   boost	   immunity,	   and	   may	   prevent	   re-­‐
infection	   [47,48].	   For	   those	  with	   incomplete	  vaccination,	   completion	  of	   the	   course	   is	   indicated	  with	  
the	  appropriate	  vaccine	   type,	  although	   there	  are	  no	  strict	  contraindications	   to	  changing	   the	  vaccine	  
mid-­‐course	   [2].	   HPV	   vaccines	   are	   contraindicated	   for	   persons	   with	   a	   history	   of	   immediate	  
hypersensitivity	  to	  any	  vaccine	  component.	  4vHPV	  and	  9vHPV	  are	  contraindicated	  for	  persons	  with	  a	  
history	   of	   immediate	   hypersensitivity	   to	   yeast	   [2].	   HPV	   vaccines	   are	   not	   recommended	   for	   use	   in	  
pregnant	   women,	   as	   pregnant	   women	   were	   not	   included	   in	   the	   vaccine	   clinical	   trials.	   Whilst	  
pregnancy	   testing	   is	   not	   indicated	   before	   vaccination,	   if	   a	   woman	   is	   found	   to	   be	   pregnant	   after	  
initiating	   the	   vaccination	   series,	   the	   remainder	   of	   the	   3-­‐dose	   series	   should	   be	   delayed	   until	   after	  
pregnancy.	   If	   a	   vaccine	  dose	  has	  been	  administered	  during	  pregnancy,	  no	   intervention	   is	  needed.	  A	  
new	  pregnancy	   registry	  has	  been	  established	   for	   9vHPV	  and	  no	   safety	   signal	   has	  been	   identified	   to	  
date.	  Pregnancy	  registries	  for	  2vHPV	  and	  4vHPV	  have	  been	  closed	  [2].	  	  
	  
5.	   HPV	   vaccine	   in	   HIV-­‐positive	   adults:	   In	   studies	   that	   have	   most	   commonly	   employed	   4vHPV,	  
vaccination	   has	   been	   shown	   to	   be	   safe	   and	   immunogenic	   in	   HIV-­‐positive	   children	   [49,50];	   females	  
aged	  16-­‐23	  years	  [51],	  18-­‐25	  years	  [52],	  or	  13-­‐45	  years	  [39];	  males	  aged	  22-­‐61	  years	  [53];	  and	  males	  
and	   females	  aged	  13-­‐27	  years	   [54,55].	  Overall	   seroconversion	   rates	  are	  high	   in	  all	   groups,	  and	  both	  
seroconversion	  rates	  and	  antibody	  titres	  are	  higher	  than	  with	  natural	   infection,	  and	  highest	   in	  those	  
receiving	   ART	   and	   showing	   high	   CD4	   cell	   counts	   and	   a	   suppressed	   viral	   load.	   A	   study	   of	   men	   and	  
women	  aged	  13-­‐27	   years	   compared	   responses	   to	  4vHPV	   in	  46	  HIV-­‐negative	   individuals	   and	  46	  HIV-­‐
positive	  patients	  with	  CD4	  counts	  >200	  cells/μL	  (mean	  715	  cells/μL)	  and	  a	  stably	  suppressed	  viral	  load	  
[54].	   Seroconversion	   rates	   one	  month	   after	   the	   administration	   of	   the	   third	   vaccine	   dose	  were	   91%	  
(HIV-­‐negative)	  and	  85%	  (HIV-­‐positive)	  respectively	  (p=0.52),	  and	  there	  was	  no	  significant	  difference	  in	  
antibody	   titres.	   In	  a	   study	  of	  males	  aged	  22-­‐61	  years,	   the	  proportion	  exhibiting	   seroconversion	  was	  
95%	   or	   greater	   for	   each	   of	   the	   four	   HPV	   types	   included	   in	   4vHPV	   [53].	   Anti-­‐HPV	   16	   antibody	  
concentrations	   were	   lower	   than	   those	   historically	   reported	   in	   HIV-­‐negative	   women	   but	   similar	   to	  
those	   reported	   in	   HIV-­‐negative	  MSM,	   and	   were	   higher	   in	   subjects	   receiving	   ART.	   The	  median	   CD4	  
count	  at	  the	  time	  of	  vaccination	  was	  517	  (IQR	  423-­‐680)	  in	  the	  study	  population,	  and	  92%	  of	  subjects	  
had	  a	  viral	  load	  <10,000	  copies/mL;	  there	  was	  no	  impact	  of	  nadir	  CD4	  count	  on	  immune	  responses.	  In	  
a	   study	   of	   HIV-­‐positive	  women	   aged	   13-­‐45	   years,	   seroconversion	   proportions	   one	  month	   after	   the	  
administration	  of	  the	  third	  dose	  of	  4vHPV	  for	  HPV	  types	  6,	  11,	  16,	  and	  18	  were	  96%,	  98%,	  99%,	  and	  
91%,	  respectively,	  at	  CD4	  count	  >350	  cells/μL;	  100%,	  98%,	  98%,	  and	  85%,	  respectively,	  at	  CD4	  count	  
201-­‐350	  cells/μL,	  and	  84%,	  92%,	  93%,	  and	  75%,	  respectively,	  at	  CD4	  count	  ≤200	  cells/µL	  [53].	  Women	  
with	   viral	   load	   >10,000	   copies/mL	   had	   lower	   rates	   of	   seroconversion.	   In	   one	   study	   of	   HIV-­‐positive	  
adults,	  4vHPV	  was	  reported	  to	  induce	  similar	  antibody	  responses	  in	  males	  and	  females	  [39].	  Following	  
vaccination,	  local	  reactions	  like	  pain,	  swelling	  and	  redness	  occur	  in	  9%	  of	  HIV-­‐negative	  and	  33%	  of	  HIV-­‐
positive	   subjects	   [43],	   but	   are	   usually	   of	   short	   duration.	   Systemic	   adverse	   reactions	   may	   include	  
headache	  (2%	  of	  HIV-­‐negative	  and	  14%	  of	  HIV-­‐positive	  subjects	  [43]),	  and	  occasionally	  fever,	  nausea,	  
dizziness,	   fatigue,	  and	  myalgia,	  but	  these	  are	  also	  short-­‐lived.	  No	  adverse	   impact	  on	  CD4	  cell	  counts	  
and	  viral	  load	  have	  been	  observed	  in	  HIV-­‐positive	  patients.	  
	  
Studies	   are	   ongoing	   to	   demonstrate	   the	   clinical	   efficacy	   of	  HPV	   vaccines	   in	  HIV-­‐positive	   individuals.	  
Meanwhile,	   factors	   that	   inform	   the	   cost-­‐benefit	   evaluation	   include	   a)	   a	   high	   rate	   of	   HPV	   carriage,	  
limiting	   vaccine	   efficacy;	   b)	   uncertainties	   about	   the	   duration	   of	   vaccine-­‐induced	   protection;	   c)	   the	  
consideration	   that	   seropositivity	   for	   all	   vaccine	   types	   is	   uncommon,	   indicating	   that	   at	   least	   partial	  
protection	  can	  be	  achieved;	  d)	  evidence	  that	  HPV	  acquisition	  continues	  in	  adults;	  e)	  the	  high	  burden	  of	  
disease	   in	   spite	   of	   effective	   ART;	   f)	   the	   safety	   of	   HPV	   vaccines,	   including	   safety	   in	   those	   with	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established	  HPV	   infection	  and	  disease;	  g)	   the	  demonstrated	  ability	  of	  HPV	  vaccines	   to	  boost	  natural	  
immunity,	  which	  may	   reduce	   the	   risk	  of	   re-­‐infection;	   h)	   a	  high	   level	   of	  willingness	   to	  be	   vaccinated	  
among	  surveyed	  groups	   [45].	  While	  younger	  HIV-­‐positive	  people	  are	   likely	   to	  benefit	   the	  most	   from	  
vaccination,	  older	  men	  and	  women	  may	  continue	  to	  derive	  at	  least	  partial	  benefit	  from	  vaccination.	  
	  
6.	  Recommendations	  for	  HIV-­‐positive	  adults	  
• We	  recommend	  that	  previously	  unvaccinated	  HIV-­‐positive	  men	  and	  women	  aged	  up	  to	  26	  years	  
be	  offered	  HPV	  vaccination,	  regardless	  of	  CD4	  count,	  ART	  use,	  and	  viral	  load	  [1B]	  	  
• We	  recommend	   that	  previously	  unvaccinated	  HIV-­‐positive	  MSM	  aged	  up	   to	  40	  years	  be	  offered	  
HPV	  vaccination,	  regardless	  of	  CD4	  count,	  ART	  use,	  and	  viral	  load	  [1B]	  
• We	  suggest	  that	  previously	  unvaccinated	  HIV-­‐positive	  women	  aged	  up	  to	  40	  years	  be	  offered	  HPV	  
vaccination,	  regardless	  of	  CD4	  count,	  ART	  use,	  and	  viral	  load	  [2D]	  
• We	  suggest	  that	  in	  ART-­‐naïve	  patients	  with	  CD4	  counts	  <200	  cells/μL	  vaccination	  may	  be	  deferred	  
until	  the	  patient	  is	  established	  on	  ART	  [2B]	  
• We	  recommend	  that	  3	  doses	  of	  the	  quadrivalent	  4vHPV	  vaccine	  be	  administered	  at	  0,	  1-­‐2,	  and	  6	  
months	  [1B].	  We	  recommend	  maintaining	  the	  3-­‐dose	  regimen	  in	  HIV-­‐positive	  patients	  [1A].	  If	  the	  
vaccine	  schedule	  is	  interrupted,	  the	  vaccination	  series	  should	  be	  completed	  rather	  than	  restarted	  
• We	  recommend	  that	  all	  eligible	  HIV-­‐positive	  adults	  who	  have	  received	  <3	  vaccine	  doses	  before	  the	  
age	  of	  18	  years	  complete	  a	  3-­‐dose	  vaccination	  course	  with	  4vHPV	  [1C]	  
• We	  recommend	  that	  9vHPV	  be	  used	  in	  both	  men	  and	  women	  once	  it	  becomes	  available	  in	  place	  
of	  4vHPV	  [1C]	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1.	   Infection	   and	   disease:	   There	   are	   three	   types	   of	   inﬂuenza	   viruses	   –	   A,	   B	   and	   C.	   Inﬂuenza	   A	   and	  
inﬂuenza	  B	  account	  for	  most	  cases	  of	  the	  disease.	   Inﬂuenza	   is	  highly	   infectious.	  Transmission	  occurs	  
through	   respiratory	   droplets	   and	   aerosols.	   Severity	   varies	   from	   asymptomatic	   to	   fatal	   infections.	  
Inﬂuenza	   can	   exacerbate	   underlying	   medical	   conditions	   and	   lead	   to	   serious	   complications.	   The	  
greatest	   morbidity	   and	   risk	   for	   complications,	   hospitalization,	   and	   death	   are	   seen	   in	   very	   young	  
children,	   those	  aged	  ≥65	  years,	  pregnant	  women,	  and	  patients	  with	  underlying	   conditions	   including	  
the	   immunocompromised	   [1,2].	   In	   2012,	   the	  World	   Health	  Organisation	   (WHO)	   identified	   pregnant	  
women	  as	  the	  highest	  priority	  group	  for	  influenza	  vaccination	  [3].	  
	  
2.	   Epidemiology:	   Inﬂuenza	   A	   viruses	   undergo	   changes	   in	   the	   principal	   surface	   antigens,	  
haemagglutinin	  (H)	  and	  neuraminidase	  (N).	  Minor	  changes	  (‘antigenic	  drift’)	  occur	  progressively	  from	  
season	   to	   season.	   Major	   changes	   (‘antigenic	   shift’)	   result	   periodically	   in	   the	   emergence	   of	   new	  
subtypes	  that	  can	  cause	  epidemics	  or	  pandemics.	  Inﬂuenza	  B	  viruses	  are	  also	  subject	  to	  antigenic	  drift	  
but	  with	  less	  frequent	  changes.	  Three	  influenza	  A	  pandemics	  occurred	  in	  the	  last	  century	  (1918,	  1957,	  
1968).	   The	   most	   recent	   pandemic	   occurred	   in	   2009	   with	   a	   novel	   strain	   of	   influenza	   A/H1N1;	   a	  
disproportionately	  high	  mortality	  was	  observed	  among	  children,	  young	  adults,	  and	  pregnant	  women	  
[4].	  Outbreaks	  of	   inﬂuenza	  A	  occur	  most	   years.	   Inﬂuenza	  B	   causes	   less	   extensive	  outbreaks,	   usually	  
between	  outbreaks	  of	   inﬂuenza	  A.	  The	   inﬂuenza	  season	   is	  October-­‐May	   in	  the	  northern	  hemisphere	  
and	  April-­‐September	  in	  the	  southern	  hemisphere.	  In	  the	  tropics,	  inﬂuenza	  may	  occur	  all	  year	  round.	  	  
	  
3.	  Influenza	  in	  HIV-­‐positive	  adults:	  HIV	  infection	  is	  associated	  with	  increased	  severity	  of	  influenza	  and	  
greater	  risk	  of	  complications,	  resulting	  in	  excess	  hospitalisation	  and	  mortality	  during	  inﬂuenza	  seasons	  
[5-­‐14].	  Effective	  ART	   reduces	   the	   rates	  of	  hospitalisations	  and	  mortality,	  although	   the	   risk	  of	   severe	  
outcomes	  remains	  comparable	  to	  that	  of	  other	  high-­‐risk	  groups	  for	  which	  annual	  influenza	  vaccination	  
is	   recommended	   [15,16].	   In	   the	   recent	   2009	   A/H1N1	   pandemic,	   HIV-­‐positive	   adults	   with	   advanced	  
immunosuppression	  or	  comorbid	  conditions	  were	  found	  to	  be	  at	  an	  increased	  risk	  of	  influenza-­‐related	  
complications	  [17].	  
	  
4.	  Inﬂuenza	  vaccine:	  Inﬂuenza	  vaccines	  are	  prepared	  twice	  yearly	  using	  virus	  strains	  considered	  most	  
likely	   to	   be	   circulating	   in	   the	   forthcoming	   winter	   (for	   Northern	   and	   Southern	   Hemisphere),	   as	  
recommended	   by	   WHO	   according	   to	   global	   epidemiological	   surveillance.	   There	   are	   two	   types	   of	  
influenza	  vaccines	  available	  in	  the	  UK	  –	  inactivated	  and	  live-­‐attenuated	  vaccines.	  Inactivated	  vaccines	  
are	  usually	  multivalent.	  Trivalent	   inactivated	  vaccines	   (TIVs)	   typically	  contain	   two	   influenza	  A	  strains	  
and	   one	   influenza	   B	   strain.	   Quadrivalent	   preparations	   contain	   one	   additional	   influenza	   B	   virus.	  
Monovalent	   vaccines	   are	   prepared	   in	   response	   to	   specific	   epidemiological	   circumstances	   such	   as	  
emergence	  of	  a	  shifted	  strain.	  Inactivated	  vaccines	  are	  most	  commonly	  made	  from	  virus	  grown	  in	  hen	  
eggs.	   In	   adults,	   they	   are	   usually	   given	   as	   a	   single	   dose	   by	   intramuscular	   injection	   (or	   deep	  
subcutaneous	  injection	  in	  those	  with	  bleeding	  disorders),	  or	  less	  commonly	  by	  intradermal	  injection.	  A	  
live	   attenuated	   inﬂuenza	   vaccine	   for	   administration	  by	  nasal	   spray	   is	   approved	   for	  use	   in	   the	  UK	   in	  
healthy	   children	   aged	   2	   to	   18	   years.	   	   Studies	   are	   currently	   assessing	   numerous	   vaccine	   candidates	  
including	   inactivated	  egg-­‐grown	  and	  cell-­‐culture	  derived	  subunit	  or	  whole	  virus	  vaccines,	  adjuvanted	  
vaccines,	  and	  live	  attenuated	  vaccines.	  A	  high-­‐dose	  (4-­‐times	  higher	  antigen	  content)	  TIV	  is	  licensed	  in	  
the	  US	  for	  those	  aged	  ≥65	  years	  (Fluzone	  high-­‐dose)	  [18].	  
	  
In	  healthy	  adults,	  TIVs	  provide	  around	  60%	  protection	  against	  virologically-­‐proven	  inﬂuenza	  infection	  
[19].	   Development	   of	   protective	   antibodies	   occurs	   about	   2	   weeks	   after	   vaccination	   and	   protection	  
lasts	  for	  about	  1	  year.	  Although	  responses	  to	  vaccination	  are	  often	  reduced	  in	  the	  elderly	  and	  those	  
with	  underlying	  conditions,	  vaccination	  can	  still	  protect	  against	  severe	  disease,	  complications	  such	  as	  
bronchopneumonia,	  hospital	  admission,	  and	  mortality	  [20-­‐23].	  Inactivated	  influenza	  vaccines	  are	  safe	  
and	  well	  tolerated	  and	  are	  recommended	  for	  use	  in	  pregnant	  and	  breastfeeding	  women	  [24].	  	  
Draft	  BHIVA	  guidelines	  on	  the	  use	  of	  vaccines	  in	  HIV-­‐positive	  adults	  2015	  
 




General	  indications:	  In	  the	  UK,	  annual	  influenza	  vaccination	  is	  recommended	  for	  all	  children	  aged	  2-­‐4	  
years,	  those	  aged	  ≥65	  years,	  adults	  and	  children	  aged	  over	  6	  months	  in	  clinical	  risk	  groups,	  pregnant	  
women,	  and	  health	  care	  workers	   in	  direct	  contact	  with	  patients.	  Clinical	  risk	  groups	   include	  patients	  
with:	  
• Chronic	  respiratory,	  heart,	  renal,	  liver,	  or	  neurological	  disease	  
• Diabetes	  
• Immunocompromise	  (including	  HIV	  infection)	  
• Asplenia	  or	  splenic	  dysfunction	  
• Morbid	  obesity	  	  
	  
5.	   Influenza	   vaccine	   in	  HIV-­‐positive	   adults:	  With	   inactivated	   influenza	  vaccines,	  antibody	   responses	  
have	  been	  found	  to	  be	  lower	  in	  HIV-­‐positive	  patients	  compared	  with	  HIV-­‐negative	  controls,	  and	  to	  be	  
correlated	  with	  CD4	  cell	  counts	  and	  viral	  load	  [25-­‐37].	  Whilst	  ART	  improves	  responses,	  the	  degree	  of	  
immune	  restoration	  remains	  unclear,	  with	  some	  studies	  indicating	  a	  persistent	  defect	  relative	  to	  HIV-­‐
negative	   subjects	   [37-­‐44].	   In	   one	   recent	   study,	   HIV	   infection	   worsened	   age-­‐associated	   defects	   in	  
antibody	   responses	   to	   influenza	   vaccine	   among	  women	  aged	   above	   55	   years	   [44].	  One	  other	   study	  
comparing	  HIV-­‐positive	  and	  HIV-­‐negative	  individuals	  suggested	  merely	  quantitative	  differences	  in	  the	  
vaccine	  responses,	  thus	  offering	  a	  rationale	  for	  boosting	  strategies	  in	  the	  HIV-­‐positive	  population	  [43].	  
In	   HIV-­‐positive	   adults	   however,	   administering	   higher/more	   frequent	   doses	   of	   standard	   non-­‐
adjuvanted	  vaccine	  preparations	  has	  not	  been	  consistently	  associated	  with	  improved	  immunogenicity,	  
whilst	  enhanced	  responses	  have	  been	  observed	  with	  novel	  adjuvanted	  preparations	  [40,45-­‐55].	  Data	  
on	  the	  clinical	  efﬁcacy	  of	  inﬂuenza	  vaccination	  in	  HIV-­‐positive	  adults	  are	  limited.	  A	  previous	  systematic	  
review	  and	  meta-­‐analysis	  concluded	  that	  a	  reasonable	  estimate	  could	  not	  be	  derived	  from	  available	  
data	   [56].	   A	   more	   recent	   systematic	   review	   and	   meta-­‐analysis	   set	   out	   to	   assess	   the	   efficacy	   and	  
effectiveness	  of	   influenza	  vaccination	   in	   respect	   to	   the	  prevention	  of	  all	   clinical	  outcomes,	   including	  
influenza,	  all-­‐cause	  hospitalization,	  pneumonia,	  and	  mortality	  [37].	  Three	  randomized-­‐controlled	  trials	  
and	  three	  cohort	  studies	  were	   identified,	   including	  a	   total	  of	  1562	  HIV-­‐positive	   individuals.	   In	  adults	  
(but	  not	  in	  children),	  TIV	  prevented	  laboratory-­‐confirmed	  influenza	  with	  a	  pooled	  efficacy	  of	  85%	  (95%	  
confidence	   interval	   22-­‐97%;	   evidence	   quality:	   moderate);	   no	   significant	   effects	   on	   other	   clinical	  
outcomes	  were	   demonstrable	   (evidence	   quality:	  moderate	   to	   low;	   high	   risk	   of	   bias	   detected	   in	   the	  
cohort	  studies),	  indicating	  the	  need	  for	  further	  studies.	  A	  recent	  randomized-­‐controlled	  trial	  of	  TIV	  in	  
HIV-­‐positive	  pregnant	  women	  demonstrated	  a	  vaccine	  efficacy	  of	  58%	  (95%CI	  0.2-­‐82%)	  [42].	  
	  
Inactivated	  inﬂuenza	  vaccines	  are	  safe	  and	  well	  tolerated	  in	  HIV-­‐positive	  individuals	  [26-­‐55].	  Injection	  
site	   reactions	   are	   the	  most	   frequent	   side	   effects.	   Systemic	   side	   effects	   are	  uncommon,	   and	   include	  
allergic	  reactions	  most	  likely	  due	  to	  hypersensitivity	  to	  residual	  egg	  protein.	  The	  vaccines	  also	  appear	  
to	  be	  safe	  when	  administered	  to	  HIV-­‐positive	  pregnant	  women	  [42,57].	  	  
	  
6.	   Antiviral	   therapy	   for	   pre-­‐and	   post-­‐exposure	   prophylaxis:	   Antiviral	   therapy	   with	   either	   oral	  
oseltamivir	  or	   inhaled	  zanamivir	  can	  be	  used	  for	  the	  pre-­‐	  and	  post-­‐exposure	  prophylaxis	  of	   inﬂuenza	  
[58].	  The	  efﬁcacy	  in	  HIV-­‐positive	  persons	  is	  unknown.	  	  
	  
7.	  Recommendations	  for	  HIV-­‐positive	  adults	  	  
• We	  recommend	  that	  HIV-­‐positive	  adults	  be	  offered	  annual	  influenza	  vaccination	  with	  a	  parenteral	  
non-­‐replicating	  vaccine,	  and	  this	  includes	  HIV-­‐positive	  pregnant	  women	  [1A]	  	  
o We	  recommend	  the	  vaccine	  be	  given	  between	  Sept	  and	  early	  November	  [1B].	  We	  suggest	  
that	  depending	  on	  the	  epidemiological	  circumstances,	   there	   is	  still	  a	  potential	  beneﬁt	  of	  
vaccination	  until	  March	  [2D]	  
o We	  suggest	  that	  a	  quadrivalent	  vaccine	  may	  be	  preferred	  where	  available	  [1D]	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o We	   recommend	   a	   single	   vaccine	   dose	   be	   given	   [1B].	   There	   is	   insufficient	   evidence	   to	  
recommend	  higher/more	  frequent	  doses	  in	  order	  to	  increase	  immunogenicity	  when	  using	  
the	   inactivated	   influenza	   vaccines	   currently	   available	   in	   the	   UK.	   This	   area	   will	   be	   kept	  
under	  review	  
• We	   recommend	   that	  HIV	   services,	   in	  partnership	  with	  primary	   care,	   devise	   strategies	   to	   ensure	  
prioritized	  patients	  receive	  annual	  vaccination,	  such	  as	  patient	  recall	  and	  notification	  [1C]	  
• We	   recommend	  against	   the	  use	  of	   replicating	   live	   attenuated	   influenza	   vaccines	   in	  HIV-­‐positive	  
adults	  [1D]	  
• We	   recommend	   that	   close	   contacts	   of	   HIV-­‐positive	   persons	   be	   offered	   annual	   influenza	  
vaccination,	   which	   should	   be	   preferably	   with	   inactivated	   rather	   than	   live	   attenuated	   vaccines	  
where	  the	  HIV-­‐positive	  person	  is	  profoundly	  immunocompromised	  [1D]	  
• We	  recommend	  that	  in	  identified	  circumstances	  of	  exposure,	  antiviral	  prophylaxis	  be	  considered	  
for	  patients	  who	  are	  either	  unvaccinated	  or	  unlikely	  to	  benefit	  from	  vaccination	  (CD4	  counts	  <200	  
cells/µL	  or	  poor	  match	  between	  vaccine	  and	  circulating	  inﬂuenza	  strain)	  if	  at	  risk	  of	  complications,	  
particularly	  if	  profoundly	  immunocompromised	  [1D].	  Expert	  advice	  should	  be	  sought	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1.	   Infection	   and	   disease:	   Japanese	   encephalitis	   virus	   (JEV)	   is	   a	   mosquito-­‐borne	   flavivirus	   [1].	  
Approximately	   1:250	   infections	   become	   clinically	   apparent.	   Severity	   ranges	   from	  a	   flu-­‐like	   illness	   to	  
life-­‐threatening	   encephalitis.	   The	   case-­‐fatality	   ratio	   of	   patients	   with	   encephalitis	   is	   20-­‐30%,	   and	  
survivors	   have	   a	   30%	   risk	   of	   permanent	   sequelae.	   Infection	  during	   the	  ﬁrst	   or	   second	   trimesters	   of	  
pregnancy	  can	  cause	  miscarriage.	  No	  antiviral	  therapy	  is	  available.	  	  
	  
3.	   Epidemiology:	   JEV	   is	   a	   leading	   cause	   of	   encephalitis	   in	  Asia,	  mainly	   affecting	   the	   South-­‐East	   and	  
Western	  Pacific	  regions	  [1].	  Infections	  occur	  predominantly	  in	  rice	  growing	  and	  pig	  farming	  rural	  areas,	  
and	  occasionally	  in	  urban	  areas.	  The	  highest	  transmission	  rates	  are	  during	  and	  just	  after	  wet	  seasons,	  
but	  seasonal	  patterns	  vary	  both	  within	  individual	  countries	  and	  from	  year	  to	  year.	  	  
	  
2.	   JEV	   in	  HIV-­‐positive	  adults:	   It	   is	  not	  known	  whether	  the	  natural	  history	  of	  Japanese	  encephalitis	   is	  
modiﬁed	  by	  HIV	  infection.	  
	  
4.	   JEV	  vaccine:	  Several	  JEV	  vaccines	  are	  available	  globally,	   including	  inactivated	  mouse	  brain-­‐derived	  
vaccines	   (no	   longer	   recommended),	   inactivated	  Vero	  cell-­‐derived	  vaccines,	   live	  attenuated	  vaccines,	  
and	  live	  recombinant	  (chimeric)	  vaccines	  [1,2].	  The	  internationally	  licensed	  IXIARO	  vaccine	  is	  Vero	  cell-­‐
derived	  and	  available	  in	  the	  UK.	  The	  IXIARO	  vaccine	  is	  safe	  and	  immunogenic	  in	  healthy	  subjects	  [1,2].	  
The	  vaccine	  is	  given	  by	  parenteral	  administration.	  The	  IXIARO	  vaccine	  is	  given	  to	  adults	  in	  two	  doses	  
24-­‐28	  days	  apart.	  Following	  completion	  of	  the	  primary	  course,	  a	  booster	  is	  recommended	  after	  12-­‐24	  
months	  for	  those	  at	  continued	  risk.	  Responses	  are	  long-­‐lived,	  and	  emerging	  data	  suggest	  that	  further	  
booster	  doses	  may	  be	   scheduled	  10	   years	   following	   the	   first	  booster	   [3].	  A	   randomised	   clinical	   trial	  
evaluated	   short-­‐term	  antibody	   responses	   to	  an	  accelerated	   course	  of	  2	   vaccine	  doses	  1	  week	  apart	  
(and	   co-­‐administered	   with	   rabies	   vaccine)	   in	   healthy	   persons	   aged	   18-­‐65	   years	   [4].	   Short-­‐term	  
immunogenicity	   with	   the	   accelerated	   course	   was	   non-­‐inferior	   to	   that	   measured	   with	   the	   standard	  
schedule.	  	  
	  
General	  indications:	  In	  the	  UK,	  the	  IXIARO	  vaccine	  is	  offered	  to	  travellers	  to	  South	  and	  South-­‐East	  Asia	  
and	   the	   Far	   East	   if	   staying	   for	   a	  month	  or	   longer	   in	   endemic	   areas	   during	   the	   transmission	   season,	  
especially	   if	   travel	   will	   include	   rural	   areas.	   Other	   travellers	   with	   shorter	   exposure	   periods	   are	  
immunised	   if	   the	   risk	   is	   considered	   sufficient.	   The	   vaccine	   is	   also	   recommended	   for	   those	  who	   are	  
going	   to	   reside	   in	   an	   area	  where	   JEV	   is	   endemic	   or	   epidemic,	   and	   for	   those	   at	   risk	   of	   occupational	  
exposure	  (e.g.,	  laboratory	  workers).	  	  
	  
5.	   JEV	   vaccine	   HIV-­‐positive	   adults:	  No	   studies	  have	  been	  published	  on	   the	   safety,	   immunogenicity,	  
and	  clinical	  efficacy	  of	  JEV	  vaccination	  in	  HIV-­‐positive	  adults.	  Studies	  in	  children	  show	  that	  inactivated	  
vaccines	   are	   safe	   and	   immunogenic	   [1].	   Immune	   responses	   are	   reduced	   relative	   to	   HIV-­‐negative	  
children,	   although	   improved	   by	   ART	   [5-­‐7].	   There	   is	   insufﬁcient	   evidence	   for	   modifying	   dosing	   or	  
boosting	  requirements	  relative	  to	  standard	  recommendations.	  	  
	  
6.	  Recommendations	  for	  HIV-­‐positive	  adults	  	  
• We	  recommend	  that	  HIV-­‐positive	  adults	  who	  are	  at	   risk	  of	   JEV	  exposure	   (e.g.,	   through	   travel	  or	  
occupation)	   be	   offered	   an	   inactivated	   Vero	   cell-­‐derived	   JEV	   vaccine	   (typically	   IXIARIO),	   with	   2	  
doses	  given	  24-­‐28	  days	  apart	  [1C]	  	  
o We	  recommend	  against	  the	  use	  of	  an	  abbreviated	  vaccination	  schedule	  (typically	  2	  doses	  
1	  week	  apart),	  unless	  there	  is	  an	  urgent	  need	  to	  complete	  primary	  vaccination	  prior	  to	  a	  
risk	  of	  exposure	  [1C]	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• We	   recommend	   that	   following	   completion	   of	   the	   primary	   course,	   a	   booster	   vaccine	   dose	   is	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MEASLES, MUMPS AND RUBELLA 
	  
1.	   Infection	   and	   disease:	  Measles	   and	  mumps	  are	  paramyxoviruses,	  whereas	   rubella	   is	   a	   togavirus.	  
Measles,	   mumps	   and	   rubella	   are	   transmitted	   by	   the	   respiratory	   route.	   Measles	   is	   highly	  
communicable	  and	  carries	  a	  high	  risk	  of	  complications	  including	  hepatitis	  (60%),	  diarrhoea	  (8%),	  otitis	  
media	  (7%),	  pneumonia	  (1-­‐6%)	  and	  encephalitis	  (0.1%),	  leading	  to	  death	  in	  2:1000	  cases	  in	  developed	  
countries.	  Up	  to	  30%	  of	  mumps	  infections	  are	  asymptomatic	  and	  symptomatic	  infections	  are	  typically	  
in	  the	  form	  of	  parotitis;	  neurological	  complications,	  usually	  mild	  aseptic	  meningitis,	  occur	  in	  up	  to	  15%	  
of	   symptomatic	   cases	   but	   permanent	   neurological	   sequelae	   are	   rare,	   including	   deafness	   (1:20,000	  
cases).	  Other	   complications	  of	  mumps	  are	  orchitis	   (20-­‐50%	  of	  post-­‐pubertal	  males)	  and	  pancreatitis	  
(2-­‐5%);	   the	  mortality	   rate	   is	  1-­‐3:10,000	  cases.	  Rubella	   is	  usually	  a	  mild	   illness;	   in	  up	  to	  70%	  of	  adult	  
women	   it	   is	   complicated	   by	   arthralgia	   or	   arthritis.	   Pregnant	   women	   are	   at	   increased	   risk	   of	   fatal	  
pneumonitis	  and	  miscarriage	  after	  measles	  and	  of	  foetal	  damage	  after	  rubella	  infection.	  
	  
2.	   Epidemiology:	  Measles,	   mumps	   and	   rubella	   remain	   common	   diseases	   in	   many	   countries	   of	   the	  
world.	  Patients	  are	  at	  risk	  of	  exposure	  while	  travelling	  abroad,	  or	  within	  the	  UK	  [1-­‐3].	  There	  has	  been	  a	  
substantial	  increase	  in	  measles	  cases	  reported	  in	  the	  UK	  in	  recent	  years	  due	  to	  a	  reduction	  in	  vaccine	  
coverage	   in	   children,	   with	   ongoing	   risk	   of	   community-­‐wide	   transmission.	   This	   reflects	   poor	   herd	  
immunity	  and	  the	  high	  secondary	  attack	  rate	  of	  measles	  in	  a	  susceptible	  population.	  	  
	  
3.	  Measles,	  Mumps	  and	  Rubella	   in	  HIV-­‐positive	  adults:	  There	  is	  no	  evidence	  to	  suggest	  that	  mumps	  
and	   rubella	  are	  more	   severe	   in	   the	  HIV	   setting.	  However,	  measles	   can	  be	   life-­‐threatening	   in	  people	  
with	  advanced	  HIV	  infection	  [4-­‐6].	  There	  may	  be	  no	  rash,	  and	  complications	  such	  as	  pneumonitis	  and	  
encephalitis	  may	  present	  several	  months	  after	  the	  initial	  infection.	  A	  history	  of	  measles	  immunization	  
is	   not	   a	   reliable	   predictor	   of	  measles	   IgG	   seropositive	   status	   and	   seropositivity	   does	   not	   guarantee	  
protection	  [7,8].	  	  
	  
4.	  MMR	  vaccine:	  The	  MMR	  vaccine	  contains	  replicating	  live	  attenuated	  viruses.	  The	  vaccine	  is	  given	  by	  
parenteral	  administration.	  In	  adults,	  two	  doses	  are	  required	  to	  confer	  protection	  against	  measles,	  with	  
the	  second	  dose	  given	  at	  any	  time	  but	  at	  least	  one	  month	  after	  the	  ﬁrst.	  MMR	  is	  highly	  immunogenic	  
and	   clinically	   efﬁcacious	   in	   preventing	   measles,	   mumps	   and	   rubella	   in	   children	   [9].	   Measles	   IgG	  
develop	   in	   90%	   of	   healthy	   subjects	   after	   one	   dose	   of	  MMR,	   and	   99%	   after	   two	   doses.	   Side	   effects	  
include:	  
• Fever	   and	   rash	   (5-­‐15%	   of	   vaccine	   recipients),	   usually	   starting	   7-­‐12	   days	   after	   vaccination	   and	  
lasting	  1-­‐2	  days	  
• Arthralgia	  and/or	  arthritis	  (up	  to	  25%	  of	  women),	  usually	  mild	  and	  transient	  
• Transient	  lymphadenopathy	  	  
• Parotitis	  and	  deafness	  (rare)	  	  
• Clinically	  apparent	  thrombocytopenia	  (<1	  per	  30,000	  doses)	  
• Neurological	   complications,	   including	   aseptic	   meningitis,	   encephalitis	   and	   encephalopathy	  
(<1:1,000,000	  doses)	  
• Allergic	  reaction;	  severe	  anaphylaxis	  is	  rare	  (<1:1,000,000	  doses)	  
With	   the	   exception	   of	   allergic	   reactions,	   side	   effects	   are	   less	   frequent	   following	   the	   ﬁrst	   dose	   and	  
occur	   primarily	   among	   the	   small	   proportion	   of	   persons	  who	   did	   not	   respond	   to	   the	   ﬁrst	   dose.	   The	  
MMR	  vaccine	   is	   contraindicated	   in	   immunocompromised	  patients	   and	   in	  pregnancy,	   and	  pregnancy	  
should	   be	   avoided	   for	   one	   month	   after	   vaccination.	   The	   vaccine	   is	   not	   contraindicated	   in	   breast-­‐
feeding	  women.	  MMR	  vaccine	  recipients	  do	  not	  act	  as	  a	  potential	  source	  of	  infection	  to	  their	  contacts.	  	  
	  
5.	  MMR	  vaccine	  in	  HIV-­‐positive	  adults:	  Vaccine	  responses	  are	  reduced	  in	  HIV-­‐positive	  patients	  [7,	  10-­‐
12],	   although	   improved	  by	  effective	  ART	   [13-­‐18].	  Revaccination	  of	  previously	   immunised	   individuals	  
following	   immune	  reconstitution	  on	  ART	  provides	  a	  strategy	   for	   improving	  seroconversion	  rates	  and	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magnitude	  and	  longevity	  of	  vaccine-­‐induce	  responses.	  While	  the	  MMR	  vaccine	  is	  also	  contraindicated	  
in	   persons	  who	   are	   severely	   immunocompromised,	   including	  HIV-­‐positive	   patients	  with	   CD4	   counts	  
<200	  cells/μL,	  it	  is	  in	  general	  safe	  in	  HIV-­‐positive	  patients	  with	  less	  profound	  immunocompromise	  [13-­‐
18].	   Prior	   to	  1993,	   it	  was	   advocated	   for	  both	  asymptomatic	   and	   symptomatic	  patients.	  A	   change	   in	  
policy	   was	   prompted	   by	   a	   case	   of	   fatal	   measles-­‐vaccine-­‐associated	   pneumonitis	   in	   a	   severely	  
immunocompromised	   man,	   presenting	   almost	   one	   year	   after	   vaccination	   [19].	   Vaccine-­‐associated	  
pneumonitis	   and	   encephalitis	   have	   also	   been	   described	   in	   severely	   immunocompromised	   patients.	  
Serious	   illnesses	   have	   not	   been	   reported	   in	   HIV-­‐positive	   individuals	   in	   association	   with	   mumps	   or	  
rubella	  vaccine	  administration.	  	  
	  
6.	  Post-­‐exposure	  prophylaxis:	  Following	  a	  contact	  with	  a	  case	  of	  measles,	  passive	  immune	  prophylaxis	  
with	   intramuscular	  Human	  Normal	   Immunoglobulin	   (HNIG)	   is	   indicated	   in	  selected	  groups,	   including	  
immunocompromised	  patients.	  	  In	  most	  cases,	  an	  urgent	  (within	  3	  days	  of	  contact)	  measles	  IgG	  test	  is	  
requested	  to	  decide	  upon	  the	  need	  for	  prophylaxis.	  A	  prophylactic	  dose	  of	  HNIG	  is	  not	  likely	  to	  benefit	  
measles	  IgG-­‐positive	  contacts,	  although	  patients	  with	  profound	  deficits	  of	  cellular	  immunity	  (typically	  
those	  with	  primary	   immunodeficiency)	  may	   still	   benefit.	  HNIG	   is	   given	  as	   soon	  as	  possible	  after	   the	  
contact,	   ideally	  within	   three	  days,	   and	  no	   later	   than	   six	  days	   [20,21].	   In	   selected	   cases,	   intravenous	  
immunoglobulin	   (IVIG)	   may	   be	   considered	   up	   to	   18	   days	   after	   exposure,	   in	   which	   case	   it	   may	  
attenuate	  rather	  than	  prevent	  the	  infection.	  There	  is	  no	  evidence	  to	  support	  the	  use	  of	  HNIG	  following	  
exposure	   to	  mumps	  or	   rubella.	  Because	  of	   the	   rapid	   induction	  of	   the	  measles	  antibody,	   contacts	  of	  
measles	  may	  be	  protected	  by	  MMR	  vaccination	  administered	  within	   three	  days	  of	  exposure.	   This	   is	  
not	   the	   case	   for	   the	  mumps	  and	   rubella	   components.	   There	  are	  no	  data	   regarding	   the	  use	  of	  post-­‐
exposure	   MMR	   vaccination	   following	   measles	   exposure	   in	   individuals	   with	   HIV	   or	   other	  
immunocompromised	  patients.	  
	  
7.	  Recommendations	  for	  HIV-­‐positive	  adults	  	  
• We	   recommend	   that	  HIV-­‐positive	   adults	   be	   screened	   for	  measles	   IgG	   regardless	   of	   a	   history	   of	  
childhood	  vaccination	  [1B]	  
o We	   recommend	   that	  measles	   seronegative	   patients	  with	   CD4	   counts	   >200	   cells/μL	  who	  
are	   clinically	   stable	   are	   offered	   2	   doses	   of	   the	  MMR	  vaccine	   at	   an	   interval	   of	   at	   least	   1	  
month	  [1B]	  
o We	   suggest	   that	   based	  on	   the	   likelihood	  of	   exposure,	   vaccination	  may	  be	  postponed	   in	  
patients	  with	  CD4	  counts	  >200	  cells/μL	  that	  are	  not	  yet	  established	  on	  ART	  [2C]	  
o We	  recommend	  that	  in	  selected	  circumstances	  when	  measles	  seronegative	  patients	  are	  at	  
a	  significant	  risk	  of	  exposure	  but	  cannot	  receive	  the	  MMR	  vaccine	  due	  to	  a	  low	  CD4	  count,	  
patients	  be	  offered	  pre-­‐exposure	  prophylaxis	  with	  HNIG	  [1C].	  Any	  protection	  afforded	  will	  
be	  short-­‐lived	  (~3	  weeks)	  	  
• We	  recommend	  that	  after	  a	  recognised	  exposure	  to	  measles,	  HIV-­‐positive	  adults	  be	  screened	  for	  
measles	   IgG	   within	   3	   days	   of	   exposure	   and	   regardless	   of	   a	   history	   of	   previous	   vaccination	  
(although	  prophylaxis	  should	  not	  be	  delayed	  while	  waiting	   for	   the	  results)	   [1C].	  We	  recommend	  
that	  a	  risk	  assessment	  be	  undertaken	  about	  the	  need	  for	  and	  mode	  of	  post-­‐exposure	  prophylaxis,	  
along	  the	  following	  guidelines:	  
o Measles	   seronegative,	   CD4	   count	   >200	   cells/μL,	   preferably	   with	   stable	   viral	   load	  
suppression	  on	  ART:	  MMR	  vaccine	  within	  3	  days	  of	  contact	  [1D]	  or	  HNIG	  within	  6	  days	  of	  
contact	  [1C]	  
o Other	  measles	  seronegative:	  HNIG	  within	  6	  days	  of	  contact	  [1C]	  or	  IVIG	  up	  to	  18	  days	  after	  
contact	  [1D]	  
o CD4	   count	   <200	   cells/μL	   (regardless	   of	   measles	   IgG	   serostatus):	   HNIG	   within	   6	   days	   of	  
contact	  [1C]	  or	  in	  selected	  high-­‐risk	  cases	  IVIG	  up	  to	  18	  days	  after	  contact	  [1D]	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• We	  recommend	  that	  HIV-­‐positive	  women	  of	  child-­‐bearing	  age	  are	  screened	  for	  rubella	  IgG	  if	  their	  
rubella	  IgG	  status	  is	  unknown,	  and	  that	  rubella	  seronegative	  women	  be	  offered	  MMR	  vaccination	  
provided	  their	  CD4	  count	  is	  >200	  cells/μL	  and	  they	  are	  not	  pregnant	  [1C]	  
o We	  suggest	   that	  either	  one	  MMR	  vaccine	  dose	   followed	  4	  weeks	   later	  by	  repeat	  rubella	  
serology	   and	   revaccination	   if	   required,	   or	   2	   vaccine	   doses	   1	   month	   apart	   may	   be	  
considered	   acceptable	   options	   for	   rubella	   seronegative	   women	   who	   are	   measles	  
seropositive	   [2C].	  Women	  who	   are	   also	  Measles	   seroneagtive	   should	   receive	   2	   vaccine	  
doses	  1	  month	  apart	  [1B]	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1.	   Infection	   and	   disease:	  Neisseria	  meningitidis	   is	   a	   gram-­‐negative	  bacterium.	  There	  are	  at	   least	  12	  
capsular	  groups	  including	  the	  clinically	  important	  A,	  B,	  C,	  Y,	  and	  W135.	  Around	  5-­‐11%	  of	  adults	  carry	  
the	   bacterium	   in	   the	   nasopharynx	   in	   the	   absence	   of	   symptoms.	   Transmission	   occurs	   via	   the	  
respiratory	   route	   during	   close	   contact	   and	   is	   often	   associated	   with	   overcrowded	   conditions.	   N.	  
meningitidis	   is	   a	   common	   cause	  of	  meningitis	   and	   septicaemia	   in	   children	  and	   young	  adults,	  with	   a	  
high	   risk	   of	   mortality	   or	   permanent	   sequelae.	   The	   case	   fatality	   rate	   is	   less	   than	   10%	   overall.	   Less	  
common	   manifestations	   include	   myocarditis,	   endocarditis,	   pericarditis,	   arthritis,	   conjunctivitis,	  
urethritis,	   pharyngitis,	   and	   cervicitis.	   It	   is	   not	   fully	   understood	   why	   the	   disease	   develops	   in	   some	  
individuals	   but	   not	   in	   others.	   Patients	   with	   anatomic	   or	   functional	   asplenia	   and	   those	   with	  
complement	  deﬁciencies	  are	  at	  an	  increased	  risk	  of	  disease.	  	  
	   	  
2.	   Epidemiology:	   Following	   the	  widespread	   use	   of	   group	   C	   conjugate	   vaccines,	   group	   B	   is	   now	   the	  
major	   cause	   of	   bacterial	  meningitis	   and	   septicaemia	   in	   young	   children	   in	   Europe,	   and	   accounts	   for	  
most	   cases	   of	   invasive	  meningococcal	   disease	   (IMD)	   in	   the	  UK.	   In	   June	   2015	   Public	   Health	   England	  
declared	  a	  national	  incident	  related	  to	  the	  rapid	  and	  accelerating	  increase	  in	  cases	  of	  IMD	  caused	  by	  
group	  W	  [1].	   In	   the	  US,	  groups	  C,	  B,	  and	  Y	  account	   for	  35%,	  32%,	  and	  26%	  of	   isolates,	   respectively.	  
Groups	   A	   and	   W135	   are	   common	   epidemic	   strains	   in	   sub-­‐Saharan	   Africa	   and	   the	   Middle	   East,	  
respectively.	  Proof	  of	  vaccination	  within	  the	  past	  three	  years	   is	  required	  for	  visitors	  arriving	   in	  Saudi	  
Arabia	  for	  the	  Hajj	  and	  Umrah	  pilgrimages.	  Outbreaks	  of	  meningococcal	  infection	  have	  been	  observed	  
in	  university	  campuses,	  and	  have	  also	  been	  reported	  among	  men	  who	  have	  sex	  with	  men	  (MSM)	   in	  
Europe	  and	  North	  America.	  In	  2012,	  the	  incidence	  rate	  of	  IMD	  among	  MSM	  aged	  18-­‐64	  years	  in	  New	  
York	  City	  was	  12.6	  per	  100,000	  persons,	  compared	  with	  0.16	  per	  100,000	  persons	  among	  other	  males	  
of	  the	  same	  age	  [2].	  	  
	  
3.	  Meningococcus	   in	   HIV-­‐positive	   adults:	  Recent	   data	   indicate	   that	  HIV-­‐positive	   patients	   remain	   at	  
increased	  risk	  of	  IMD	  in	  the	  ART	  era	  [3-­‐5].	  In	  an	  observational	  study	  from	  New	  York	  City,	  Miller	  et	  al.	  
identified	  263	  (mostly	  unvaccinated)	  patients	  with	  IMD	  of	  whom	  40	  were	  HIV-­‐positive	  [4].	  HIV-­‐positive	  
cases	   differed	   from	  HIV-­‐negative	   patients	  with	   IMD	   in	   being	  more	  often	  male,	   non-­‐white,	   smokers,	  
and	   presenting	   with	   meningococcal	   septicaemia	   rather	   than	   meningitis.	   The	   relative	   risk	   for	   IMD	  
amongst	  HIV	  patients	  was	  overall	  10.0	  (95%	  CI	  7.2-­‐14.1),	  and	  increased	  in	  those	  with	  CD4	  count	  <200	  
cells/μL	  and	  viral	   load	  >400	  copies/mL.	  Similar	  results	  were	  obtained	  from	  an	  observational	  study	   in	  
South	  Africa,	  which	  indicated	  also	  that	  patients	  with	  HIV	  had	  double	  the	  risk	  of	  death	  [5].	  HIV	  infection	  
alone	  is	  not	  currently	  an	  indication	  for	  meningococcal	  vaccination	  [6].	  
	  
4.	  Meningococcus	  vaccine:	  Different	  types	  of	  meningococcal	  vaccine	  are	  currently	  available	  including	  
a	   polysaccharide	   vaccine	   (no	   longer	   recommended	   for	   routine	   use),	   conjugate	   vaccines,	   and	  
multicomponent	  vaccines.	  The	  conjugated	  vaccines	  MenC	  and	  MenACWY	  are	  directed	  against	  group	  C	  
and	   groups	   A,	   C	   W,	   and	   Y,	   respectively.	   The	   multicomponent	   MenB	   vaccines	   are	   directed	   against	  
group	   B.	   The	   choice	   of	   vaccine	   is	   related	   to	   age,	   epidemiological	   circumstances,	   and	   previous	  
vaccination	  history.	  The	  vaccines	  are	  given	  by	  parenteral	  administration.	  Meningococcal	  vaccines	  are	  
highly	  immunogenic	  and	  effective;	  they	  induce	  serogroup-­‐speciﬁc	  protection.	  Fever	  and	  injection	  site	  
reactions	  are	  the	  most	  common	  adverse	  events	  reported.	  More	  serious	  complications	  are	  very	  rare.	  	  
	  
General	  indications:	  Indications	  for	  meningococcal	  vaccination	  are	  evolving	  rapidly	  in	  the	  UK.	  MenC	  is	  
part	  of	  the	  infant	  vaccination	  programme	  and	  is	  also	  indicated	  for	  adults	  aged	  less	  than	  25	  years	  who	  
have	  never	  received	  the	  vaccine,	  received	  the	  last	  MenC	  vaccine	  dose	  before	  10	  years	  of	  age,	  or	  have	  
an	  uncertain	  vaccination	  history.	   In	  March	  2015,	   the	  4CMenB	  vaccine	  was	   included	   in	   the	  UK	   infant	  
vaccination	  programme,	  but	  no	  routine	  use	  has	  yet	  been	  indicated	  for	  those	  over	  11	  years	  of	  age.	  In	  
June	  2015,	  MenACWY	  was	  recommended	  for	  adolescents	  and	  university	  entrants.	  MenC,	  MenACWY,	  
and/or	  MenB	  are	  also	  indicated	  for	  patients	  at	  risk	  of	  disease,	  mainly	  comprising	  those	  with	  asplenia,	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splenic	   dysfunction	   or	   complement	   disorders	   (including	   those	   on	   complement	   inhibitor	   treatment).	  
MenACWY	   is	   indicated	   for	   travellers	   that	   are	   at	   recognised	   risk	  based	  on	   itinerary,	   duration	  of	   stay	  
and	   planned	   activities.	   In	   North	   America,	   targeted	   vaccination	   of	  MSM	   has	   been	   recommended	   in	  
some	   states.	   Vaccination	   is	   also	   used	   during	   outbreaks	   of	   meningococcal	   infection	   with	   vaccine	  
serogroups	  to	  reduce	  the	  number	  of	  secondary	  cases.	  
	  
5.	  Meningococcus	  vaccine	  in	  HIV-­‐positive	  adults:	  Several	  reports	  of	  adequate	  serological	  responses	  to	  
meningococcus	   vaccination	   are	   available,	   generally	   showing	   better	   responses	   in	   those	   with	   less	  
advanced	   disease,	   and	   no	   major	   adverse	   reactions	   [7-­‐11].	   The	   immunogenicity	   and	   safety	   of	  
MenACWY	   in	  HIV-­‐positive	  children	  and	  young	  adults	   (aged	  2-­‐24)	  has	  been	  reported	   from	  the	  P1065	  
study	  in	  the	  USA	  [8-­‐10];	  one	  study	  in	  Brazilian	  children	  reported	  on	  the	  immunogenicity	  and	  safety	  of	  
the	  MenC	  vaccine	  [11].	  In	  the	  P1065	  study,	  response	  rates	  to	  a	  single	  vaccine	  dose	  varied	  from	  55-­‐86%	  
across	  the	  different	  serogroups,	  with	  higher	  response	  rates	  in	  younger	  children	  and	  those	  with	  higher	  
CD4	  cell	  counts	  and	  lower	  viral	   load.	  Response	  rates	  increased	  with	  a	  second	  dose	  of	  vaccine.	  In	  the	  
Brazilian	  study,	  the	  response	  rate	  to	  a	  single	  dose	  of	  MenC	  vaccine	  was	  72%,	  increasing	  to	  81%	  when	  
non-­‐responders	   received	   a	   second	   dose.	   In	   both	   of	   these	   studies	   adverse	   events	   were	   rare	   and	  
compatible	  with	  studies	  in	  HIV-­‐negative	  subjects.	  	  
	  
6.	   Post-­‐exposure	   prophylaxis:	   Close	   contacts	   of	   conﬁrmed	   cases	   of	   meningococcal	   infection	   are	  
offered	  antibiotic	  prophylaxis	  (e.g.,	  ciprofloxacin)	  and	  appropriate	  vaccination.	  	  
	  
7.	  Recommendations	  for	  HIV-­‐positive	  adults	  
• We	   recommend	   that	   HIV-­‐positive	   adults	   follow	   the	   general	   indications	   for	   meningococcal	  
vaccination	   and	  be	  offered	   vaccination	  where	   indicated	   [1B].	   The	   categories	   and	   recommended	  
vaccine	  currently	  comprise:	  	  
o Those	   aged	   <25	   years	   of	   age	  who	   have	   not	   been	   previously	   vaccinated,	   have	   uncertain	  
vaccination	  history,	  or	  received	  the	  last	  MenC	  vaccine	  below	  the	  age	  of	  10	  years	  –	  MenC	  
[1B]	  and	  MenACWY	  [1B],	  and	  possibly	  MenB	  [1C],	  according	  to	  national	  guidance	  
o Have	   functional	  or	  anatomic	  asplenia	  or	  persistent	  complement	  component	  deficiency	  –	  
MenC,	  MenB,	  and/or	  MenACWY,	  according	  to	  vaccination	  history	  [1B]	  
o Are	  at	  risk	  of	  exposure	  through	  travel	  –	  MenACWY	  [1B]	  
o Are	  at	  risk	  of	  exposure	  through	  an	  outbreak	  –	  MenC	  [1B],	  MenB	  [1C],	  or	  MenACWY	  [1B],	  
according	   to	   the	   epidemiological	   scenario,	   and	   including	  MSM	  who	  may	   be	   exposed	   to	  
outbreaks	  due	  to	  residence,	  travel,	  or	  social	  interactions	  	  
• We	  recommend	  that	  HIV-­‐positive	  patients	  are	  offered	  2	  vaccine	  doses	  at	  the	  interval	  of	  2	  months	  
in	  order	  to	  increase	  immunogenicity	  [1C]	  
• We	  recommend	  that	  patients	  receiving	  MenACWY	  are	  offered	  a	  booster	  dose	  every	  5	  years	   if	  at	  
ongoing	  risk	  through	  travel	  or	  due	  to	  underlying	  conditions	  [2C]	  
• This	  guidance	  should	  be	   interpreted	   in	   the	  context	  of	  national	  epidemiological	  data	  and	  applied	  
according	  to	  the	  evolving	  national	  vaccination	  programme	  [GPP]	  
• We	   recommend	   that	   HIV-­‐positive	   adults	   who	   are	   close	   contacts	   of	   meningococcal	   disease	   be	  
offered	  antibiotic	  prophylaxis	  and	  appropriate	  vaccination	  [1C]	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PERTUSSIS (WHOOPING COUGH) 
	  
1.	   Infection	   and	   disease:	  Whooping	   cough	   is	   a	   highly	   contagious	   disease	   of	   the	   respiratory	   tract	  
usually	   caused	   by	   the	   bacterium	   Bordetella	   pertussis.	   A	   similar	   illness	   can	   be	   caused	   by	   B.	  
parapertussis	  but	  this	  is	  not	  preventable	  with	  available	  vaccines.	  The	  infection	  is	  transmitted	  through	  
direct	   close	   contact	   with	   a	   case,	   and	   vaccination	   provides	   the	   most	   effective	   prevention	   strategy.	  
Protection	  afforded	  by	  vaccination	  or	   from	  past	   infection	   is	  not	   life-­‐long	  [1].	  Disease	  severity	  ranges	  
from	  mild	  to	  life-­‐threatening,	  and	  infants	  and	  young	  children	  are	  most	  at	  risk	  of	  complications.	  Older	  
children	  and	  adults	  who	  have	  previously	  had	  disease	  or	  been	  vaccinated	  may	  still	  become	  infected	  but	  
usually	  have	  mild	  disease.	  	  
	  
2.	  Epidemiology:	  In	  the	  UK	  the	  introduction	  of	  routine	  vaccination	  against	  pertussis	  in	  1957	  resulted	  in	  
a	  marked	   reduction	   in	  pertussis	  notifications	  and	  deaths,	  and	  pertussis	   control	  has	  been	  good	  since	  
the	   1990s	   during	   a	   sustained	   period	   of	   high	   coverage	   [2].	   Pertussis	   activity	   increased	   considerably	  
from	   late	   2011	   leading	   to	   a	   national	   outbreak	   being	   declared	   in	   April	   2012.	   Most	   cases	   were	   in	  
previously	   vaccinated	   adolescents	   and	   young	   adults	   but	   the	   highest	   incidence	   of	   morbidity	   and	  
mortality	   occurred	   in	   unvaccinated	   infants.	   Public	   health	   action	   has	   identified	   two	   target	   groups:	  
those	  who	   are	   vulnerable	   to	   suffering	   severe	   disease	   (young	   infants)	   and	   those	  who	   are	   at	   risk	   of	  
transmitting	  the	  infection	  to	  vulnerable	  individuals	  [1].	  In	  October	  2012	  a	  temporary	  programme	  was	  
introduced	   to	   offer	   pertussis	   vaccination	   to	   pregnant	   women,	   ideally	   between	   28-­‐32	   weeks	   of	  
pregnancy,	  with	  the	  aim	  of	  protecting	  infants	  through	  intrauterine	  transfer	  of	  maternal	  antibodies.	  In	  
June	  2014	  the	   Joint	  Committee	  on	  Vaccination	  and	   Immunisation	   (JCVI)	  advised	  that	   this	   temporary	  
programme	   should	   continue	   for	   at	   least	   a	   further	   five	   years	   as	   pertussis	   continues	   to	   circulate	   at	  
heightened	  levels.	  
	  
3.	  Pertussis	   in	  HIV-­‐positive	  adults:	  Pertussis	  has	  been	  diagnosed	  in	  HIV-­‐positive	  children	  and	  adults,	  
and	   should	   be	   considered	   as	   a	   cause	   of	   respiratory	   disease	   in	   persons	   with	   HIV	   [3-­‐7].	   However,	  
pertussis	   is	   not	   generally	   considered	   an	   opportunistic	   infection	   amongst	   immunocompromised	  
individuals	  [1]	  and	  current	  evidence	  does	  not	  suggest	  that	  pertussis	   is	  common	  among	  persons	  with	  
HIV	  or	  that	  they	  are	  more	  likely	  to	  be	  a	  reservoir	  for	  B.	  pertussis	  in	  the	  community.	  
	  
4.	  Pertussis	  vaccine:	  Pertussis	  vaccines	  licensed	  in	  the	  UK	  are	  inactivated	  acellular	  vaccines	  made	  from	  
highly	  puriﬁed	  components	  of	  B.	  pertussis,	  and	  are	  only	  available	  as	  part	  of	  combined	  products:	  
1)	  diphtheria/tetanus/acellular	  pertussis/inactivated	  polio	  vaccine/	  
Haemophilus	  influenzae	  type	  b	  (DTaP/IPV/Hib)	  -­‐	  for	  primary	  immunisation	  in	  children	  
2)	  diphtheria/tetanus/acellular	  pertussis/inactivated	  polio	  vaccine/	  (DTaP/	  
IPV	  or	  dTaP/IPV)	  -­‐	  for	  pre-­‐school	  boosters	  
3)	  diphtheria/tetanus/acellular	  pertussis/inactivated	  polio	  vaccine	  (dTaP/	  
IPV)	  -­‐	  for	  adults	  requiring	  vaccination,	  including	  pregnant	  women	  
	  
The	  vaccines	  are	  given	  by	  parenteral	  administration.	  Pertussis	  vaccines	  are	  safe	  and	  immunogenic	   in	  
immunocompetent	  adults.	  Vaccination	  does	  not	   induce	   lifelong	   immunity,	  and	  the	  possible	  need	  for	  
boosters	   in	   adolescence	   is	   under	   review.	   Vaccination	   is	   generally	   well	   tolerated	   [7].	   Injection	   site	  
reactions	  are	  common	  and	  may	  occur	  more	  frequently	  following	  subsequent	  doses.	  
	  
General	   indications:	   Pertussis	   vaccination	   in	   not	   available	   for	   individuals	   aged	   ≥10	   years,	   except	   in	  
pregnancy	  or	  as	  part	  of	  outbreak	  control.	  For	  adults,	  including	  pregnant	  women,	  a	  vaccine	  containing	  
low	   dose	   diphtheria	   and	   tetanus	   is	   preferred.	   Since	   2014,	   Boostrix®-­‐IPV	   (dTaP/IPV)	   is	   the	   vaccine	  
offered	   for	   the	   prenatal	   programme.	   Repevax®	   (dTaP/IPV)	   may	   be	   a	   suitable	   alternative,	   whereas	  
Infanrix®-­‐IPV	   is	   used	   only	   in	   exceptional	   circumstances	   when	   neither	   Boostrix®-­‐IPV	   nor	   Repevax®	  
(dTaP/IPV)	   is	  available.	  Pregnant	  women	  are	  offered	  a	  single	  vaccine	  dose	  not	  earlier	  than	  28	  weeks	  
and	  ideally	  between	  week	  28	  and	  week	  32	  of	  pregnancy.	  The	  vaccine	  will	  act	  as	  a	  reinforcing	  dose	  and	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is	   offered	   in	   every	   pregnancy	   regardless	   of	   prior	   vaccination	   status.	   Vaccination	   after	   week	   38	   is	  
unlikely	   to	   provide	   passive	   protection	   to	   the	   infant	   but	  would	   potentially	   protect	   the	  mother	   from	  
pertussis	  infection	  and	  thereby	  reduce	  the	  risk	  of	  exposure	  to	  her	  infant.	  	  
	  
5.	  Pertussis	  vaccine	  in	  HIV-­‐positive	  adults:	  After	  vaccination,	  antibody	  titres	  are	  lower	  in	  HIV-­‐positive	  
children	  compared	  to	  HIV-­‐negative	  children,	  and	  correlate	  with	  the	  CD4	  cell	  count	  [6].	  No	  data	  on	  the	  
efﬁcacy	  of	  the	  pertussis	  vaccine	  in	  HIV-­‐positive	  adults	  are	  available.	  There	  is	  no	  evidence	  of	  increased	  
risk	  of	  side	  effects	  or	  adverse	  reactions	  to	  vaccination	  in	  individuals	  with	  HIV	  infection.	  
	  
6.	   Post-­‐exposure	  prophylaxis:	  Antibiotic	  prophylaxis	   (usually	  with	  macrolides)	   -­‐	   to	  be	  started	  within	  
21	  days	  of	  onset	  of	  cough	  in	  the	  index	  patient	  -­‐	  is	  indicated	  for	  all	  asymptomatic	  household	  contacts	  
of	  a	  suspected,	  epidemiologically	  linked,	  or	  confirmed	  pertussis	  case.	  Secondary	  attack	  rates	  are	  high,	  
even	   when	   household	   contacts	   are	   current	   with	   vaccinations.	   Antibiotic	   prophylaxis	   may	   also	   be	  
indicated	   for	  contacts	  who	  are	  at	  high	   risk	  of	   severe	  disease	  or	  are	   likely	   to	  come	   in	  contact	  with	  a	  
person	  at	  high	  risk	  (e.g.,	  pregnant	  women	  in	  the	  third	  trimester).	  Vaccination	  may	  also	  be	  considered	  
for	  those	  who	  have	  been	  offered	  antibiotic	  prophylaxis.	  
	  
7.	  Recommendations	  for	  HIV-­‐positive	  adults	  	  
• We	  recommended	  that	  HIV-­‐positive	  adults	  who	  meet	  general	  indications	  for	  pertussis	  vaccination	  
and	   including	   HIV-­‐positive	   pregnant	   women	   be	   offered	   one	   dose	   of	   the	   dTaP/IPV	   vaccine	  
regardless	  of	  CD4	  count,	  ART	  use,	  and	  viral	  load	  [1C]	  
• We	   recommended	   that	   HIV-­‐positive	   adults	   who	   are	   in	   contact	   with	   case	   of	   pertussis	   are	  
considered	  for	  antibiotic	  prophylaxis	  and	  vaccination	  in	  line	  with	  standard	  recommendations	  [1C]	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1.	  Infection	  and	  disease:	  Streptococcus	  pneumoniae,	  or	  pneumococcus,	  is	  a	  Gram-­‐positive	  bacterium.	  
There	  are	  over	  90	  serotypes	  and	  although	  all	  can	  cause	  infections,	  a	  few	  serotypes	  account	  for	  most	  
cases	   of	   disease	   [1].	   Infection	   is	   acquired	   through	   direct	   person-­‐to-­‐person	   contact	   via	   respiratory	  
droplets	   and	   by	   autoinoculation	   in	   persons	   carrying	   the	   bacteria	   in	   their	   upper	   respiratory	   tract.	  
Pneumococci	  may	  be	  isolated	  from	  the	  nasopharynx	  of	  healthy	  persons	  in	  the	  absence	  of	  disease.	  The	  
rate	   of	   asymptomatic	   carriage	   varies	   with	   age,	   environmental	   factors,	   and	   the	   presence	   of	   other	  
infections	  of	  the	  respiratory	  tract.	  HIV-­‐positive	  adults	  and	  children	  tend	  to	  have	  higher	  carriage	  rates.	  
The	   mechanisms	   that	   control	   the	   healthy	   carrier	   state	   vs.	   invasive	   disease	   are	   poorly	   understood.	  
Pneumococci	   can	   cause:	   (i)	   upper	   respiratory	   tract	   infections	   (e.g.	   otitis	   media	   and	   sinusitis)	   (ii)	  
pneumonia	  and	  other	  lower	  respiratory	  tract	  infections,	  and	  (iii)	  invasive	  pneumococcal	  disease	  (IPD),	  
including	  bacteraemia	  and	  meningitis;	   the	   latter	   is	   frequently	  complicated	  by	  neurological	   sequelae.	  
Pneumococcal	  case	  fatality	  is	  high,	  up	  to	  15%	  in	  pneumonia	  and	  30%	  in	  meningitis.	  
	  
2.	  Epidemiology:	  Pneumococcal	  disease	  occurs	  throughout	  the	  world,	  although	  geographically	  there	  is	  
wide	  variation	  in	  the	  incidence	  of	  IPD.	  The	  greatest	  burden	  of	  disease	  is	  in	  developing	  countries.	  In	  the	  
UK	  infections	  are	  more	  common	  during	  the	  winter	  and	  in	  early	  spring.	  The	  pneumococcus	  is	  the	  most	  
frequent	  bacterial	  co-­‐infection	  associated	  with	  influenza.	  Rates	  of	  antibiotic	  resistance	  are	  increasing	  
in	  many	  parts	  of	  the	  world	  and	  susceptibility	  to	  penicillin,	  cephalosporin	  and	  macrolides	  can	  no	  longer	  
be	  assumed.	  Penicillin	  resistance	  is	  present	  in	  5%	  of	  UK	  isolates	  with	  a	  similar	  proportion	  of	  macrolide	  
resistant	  isolates.	  This	  has	  little	  impact	  on	  management	  of	  respiratory	  infections,	  but	  penicillin	  cannot	  
be	   used	   to	   manage	   meningitis	   when	   resistance	   is	   present.	   Pneumococcal	   infection	   is	   a	   major	  
contributor	  to	  mortality	  among	  young	  children	  in	  developing	  countries.	  Pneumococcal	  disease	  is	  also	  
common	  in	  children	   in	  developed	  countries,	  but	   in	  these	  settings	  mortality	   is	  seen	  predominantly	   in	  
those	  aged	  ≥65	  years	  and	  adults	  with	  underlying	  conditions	  [2],	  including:	  	  
• alcoholism	  
• cancer	  (particularly	  haematological	  malignancy)	  
• chronic	  cardiovascular	  disease	  
• chronic	  pulmonary	  disease	  (e.g.	  chronic	  obstructive	  pulmonary	  disease	  or	  emphysema,	  but	  
not	  asthma)	  
• chronic	  liver	  disease	  (cirrhosis)	  
• chronic	  renal	  disease	  
• diabetes	  mellitus	  
• absent	  or	  non-­‐functioning	  spleen	  (e.g.	  sickle	  cell	  disease)	  
• hypogammaglobulinaemia	  
• malnutrition	  
• immunocompromise,	  including	  HIV	  infection	  
	  
3.	  Pneumococcus	  in	  HIV-­‐positive	  adults:	  Pneumococcus	  infection	  is	  a	  significant	  cause	  of	  pneumonia	  
and	  IPD	  in	  HIV-­‐positive	  persons	  [3,4].	  Disease	  can	  occur	  early	  in	  the	  course	  of	  HIV	  infection	  and	  may	  
recur.	  Paediatric	  serotypes	  are	  frequently	  involved	  and	  close	  contact	  with	  children	  is	  a	  recognized	  risk	  
factor	  for	  infection.	  Risk	  factors	  for	  severe	  disease	  include	  low	  CD4	  cell	  counts,	  African	  race,	  injecting	  
drug	  use,	  smoking,	  a	  previous	  AIDS-­‐defining	  diagnosis,	  previous	  pneumonia,	  chronic	   illness	  (i.e.	   lung,	  
heart,	   liver,	   or	   kidney	   disease),	   and	   alcoholism	   [5-­‐8].	   The	   annual	   attack	   rate	   of	   pneumococcal	  
bacteraemia	  was	  as	  high	  as	  1%	  among	  persons	  with	  AIDS	  [9].	  The	  incidence	  of	  IPD	  has	  declined	  with	  
effective	   ART	   [10,11]	   but	   HIV-­‐positive	   adults	   remain	   at	   an	   approximately	   40	   times	   higher	   risk	   of	  
disease	   compared	   with	   age-­‐matched	   HIV-­‐negative	   adults.	   Major	   risk	   factors	   for	   IPD	   are	   similar	   to	  
those	   reported	   in	  HIV-­‐negative	   individuals	  and	   include	  associated	  co-­‐morbidity,	  prior	  hospitalization	  
with	   alcoholism,	   and	   current	   smoking	   as	   prominent	   [12].	   Compared	  with	   HIV-­‐negative	   adults,	   HIV-­‐
positive	   persons	   show	   an	   increased	   risk	   of	   mortality	   after	   controlling	   for	   age	   and	   severity	   of	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presentation,	  and	  the	  risk	  is	  related	  to	  the	  CD4	  cell	  count.	  With	  an	  increasing	  proportion	  of	  associated	  
co-­‐morbidities	   in	   ageing	   HIV-­‐positive	   populations	   (e.g.	   cirrhosis,	   chronic	   pulmonary	   disease)	   case-­‐
fatality	  has	  tended	  to	  increase	  in	  recent	  years.	  
	  
Universal	   vaccination	   with	   pneumococcal	   conjugate	   vaccine	   	   (PCV)	   was	   introduced	   into	   the	   UK	  
paediatric	  vaccine	  schedule	  in	  2006;	  PCV-­‐7	  initially	  including	  serotypes	  4,	  6B,	  9V,	  14,	  18C,	  19F	  &	  23F;	  
in	  2011	  PCV-­‐13	  added	  the	  serotypes	  1,	  3,	  5,	  6A,	  7F,	  19A.	  These	  vaccines	  have	  had	  a	  dramatic	  impact	  
on	  the	  epidemiology	  of	  pneumococcal	  disease.	  Not	  only	  have	  they	  been	  highly	  effective	  at	  presenting	  
disease	  from	  the	  vaccine	  serotypes	  in	  the	  vaccinated	  children,	  but	  also	  there	  has	  been	  a	  reduction	  in	  
disease	  caused	  by	  vaccine	  serotypes	   in	  all	  age	  groups	  as	  a	  consequence	  of	  herd	  protection.	  This	  has	  
however	   been	   offset	   by	   an	   increase	   in	   disease	   caused	   by	   non-­‐PCV	   serotypes.	   In	   the	   US,	   a	   net	  
reduction	  in	  IPD	  in	  HIV-­‐positive	  adults	  of	  around	  25%	  was	  attributed	  to	  paediatric	  PCV	  use	  with	  only	  
about	  8%	  of	  IPD	  disease	  caused	  by	  PCV-­‐7	  serotypes	  five	  years	  after	  introduction	  [13].	  The	  pattern	  has	  
been	  similar	  in	  the	  UK	  with	  PCV-­‐7	  serotypes	  dramatically	  reducing	  as	  a	  cause	  of	  disease	  [8].	  Recent	  UK	  
surveillance	  among	  adults	  with	  IPD	  has	  also	  shown	  a	  fall	  in	  the	  6	  additional	  serotypes	  included	  in	  PCV-­‐
13.	  At	  the	  present	  time,	  the	  proportion	  of	  IPD	  cases	  caused	  by	  PCV-­‐13	  serotypes	  in	  HIV-­‐positive	  adults	  
is	  unclear,	  although	  it	  is	  likely	  to	  be	  falling.	  The	  burden	  of	  non-­‐bacteraemic	  pneumococcal	  pneumonia	  
is	  believed	  to	  be	  5-­‐10	  times	  greater	  than	  the	  IPD	  burden.	  The	  contribution	  of	  PCV-­‐13	  serotypes	  to	  this	  
syndrome	  is	  less	  clear	  due	  to	  difficulties	  of	  measurement,	  but	  is	  also	  likely	  to	  be	  falling	  as	  a	  result	  of	  
reduced	  community	  transmission.	  
	  	  
4.	   Pneumococcal	   vaccine:	   Two	   different	   vaccines	   have	   been	   developed:	   the	   pneumococcal	  
polysaccharide	  vaccine	   (PPV)	  and	   the	  pneumococcal	  protein-­‐conjugated	  vaccine	   (PCV).	  Both	  vaccine	  
types	  have	  a	  license	  in	  the	  UK	  for	  use	  in	  adults	  and	  are	  given	  by	  parenteral	  administration.	  
• PPV-­‐23	   is	   composed	   of	   purified	   preparations	   of	   pneumococcal	   capsular	   polysaccharide	   from	  23	  
different	  serotypes,	  which	  has	  traditionally	  accounted	  for	  around	  90%	  of	  cases	  of	  IPD.	  PPV-­‐23	  has	  
been	  available	  in	  the	  UK	  for	  much	  of	  the	  last	  30	  years.	  It	  is	  given	  as	  a	  single	  dose	  by	  subcutaneous	  
or	  intramuscular	  injection.	  
• PCV	  vaccines	  were	  specifically	  designed	  for	  use	   in	   infant	  populations	  where	  pure	  polysaccharide	  
vaccines	   fail	   to	   induce	   protective	   immune	   responses.	   Immunogenicity	   is	   improved	   by	   attaching	  
the	   pneumococcal	   polysaccharide	   to	   a	   “carrier”	   protein.	   Two	   preparations	   are	   available:	   a	   13-­‐
valent	  preparation	  (PCV-­‐13)	  and	  a	  10-­‐valent	  preparation	  (PCV-­‐10).	  PCV-­‐13	  has	  been	  evaluated	  in	  
adult	  populations.	  No	  adult	  studies	  have	  been	  reported	  with	  PCV-­‐10.	  
	  
No	   serious	   safety	   concerns	   have	   been	   identified	   with	   either	   PPV-­‐23	   or	   the	   PCVs.	   Injection	   site	  
reactions	   occur	   in	   30-­‐50%	   of	   PPV-­‐23	   vaccine	   recipients	   but	   usually	   resolve	   within	   48	   hours.	   Local	  
reactions	  are	  reported	  more	   frequently	   following	  a	  second	  dose	  of	  PPV-­‐23	  than	  after	   the	   first	  dose,	  
especially	  if	  fewer	  than	  three	  years	  have	  elapsed	  since	  the	  first	  injection.	  Systemic	  reactions	  with	  fever	  
and	  myalgia	  occur	  uncommonly	  (<1%)	  and	  more	  serious	  adverse	  events	  are	  very	  rare.	  Reactions	  to	  the	  
PCVs	   may	   be	   more	   common	   than	   with	   PPV-­‐23	   but	   the	   serious	   adverse	   event	   profile	   is	   similar.	  
Contraindications	  to	  vaccination	  include:	  
•	   PPV-­‐23:	  Vaccination	  given	  within	  the	  previous	  three	  years	  
•	   PCV:	  Previous	  serious	  adverse	  reaction	  to	  PCV	  
	  
5.	  Vaccine	  efficacy:	  The	  efficacy	  of	  pneumococcal	  vaccines	  has	  been	  the	  subject	  of	  significant	  debate.	  
In	  the	  case	  of	  PPV	  there	  have	  been	  a	  limited	  number	  of	  randomised	  controlled	  trials	  (RCT)	  and	  large	  
number	  of	  observational	  studies	  with	  significant	  variation	   in	  reports	  of	  efficacy,	  particularly	   in	  those	  
reported	   from	  outside	   the	  US.	   In	   the	   case	   of	   PCV,	   there	   is	   a	  much	   smaller	   literature,	   although	   this	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Immunogenicity:	   More	   than	   80%	   of	   healthy	   young	   adults	   who	   receive	   PPV-­‐23	   develop	   antibodies	  
against	  the	  serotypes	  contained	  in	  the	  vaccine,	  usually	  within	  2-­‐3	  weeks.	  In	  older	  adults	  and	  persons	  
with	   underlying	   conditions,	   responses	   are	   often	   reduced	   or	   absent.	   HIV-­‐positive	   adults	   produce	  
significantly	   lower	   peak	   levels	   and	   durability	   of	   response	   compared	   to	   HIV-­‐negative	   adults.	   The	  
functional	  quality	  of	  antibodies	  produced	  in	  HIV-­‐positive	  adults	  in	  response	  to	  PPV	  is	  also	  significantly	  
impaired	  in	  comparison	  to	  HIV-­‐negative	  adults.	  ART	  use	  has	  not	  been	  shown	  to	  convincingly	  improve	  
response	  to	  PPV-­‐23	  [14-­‐19].	  The	  degree	  of	  immunodeficiency	  as	  measured	  by	  CD4	  cell	  count	  may	  also	  
affect	  immunogenicity	  [15,20].	  HIV-­‐positive	  patients	  with	  CD4	  counts	  <500	  cells/μL	  have	  shown	  lower	  
responses	  than	  patients	  with	  higher	  CD4	  cell	  counts	  [21],	  although	  this	  effect	  is	  not	  consistent	  across	  
reports	   [22-­‐24].	   Routine	   boosting	   is	   not	   recommended	   in	   immunocompetent	   individuals	   previously	  
vaccinated	  with	  the	  PPV-­‐23	  vaccine.	  However	  revaccination	  after	  5-­‐10	  years	  of	  the	  first	  dose	  is	  part	  of	  
general	   guidance	   for	   the	   use	   of	   PPV-­‐23	   in	   specific	   risk	   groups.	   Repeat	   doses	   of	   PPV	   in	  HIV-­‐positive	  
adults	  however	  produce	  attenuated	  antibody	  responses	  [25].	  Recent	  studies	  in	  thalassaemic	  patients	  
have	  suggested	  a	  dose	  dependent	  attenuation	  in	  pneumococcal	  memory	  responses	  with	  repeat	  doses	  
of	   PPV	   [26].	   Importantly,	   the	   relationship	   between	   antibody	   levels	   and	   protection	   from	   IPD	   is	   not	  
certain	  in	  adult	  populations.	  	  
	  
Clinical	  efficacy:	  Overall,	  PPV-­‐23	   is	  estimated	  to	  be	  approximately	  60%	  effective	   in	  preventing	   IPD	   in	  
otherwise	  healthy	  older	  adults,	  but	  is	  less	  or	  ineffective	  in	  those	  groups	  that	  also	  have	  the	  greatest	  risk	  
of	   disease.	   PPV-­‐23	   efficacy	   against	   non-­‐bacteraemic	   pneumonia	   has	   not	   been	   demonstrated	  
unequivocally.	   Several	   meta-­‐analyses	   have	   shown	   that	   vaccination	   reduced	   bacteraemic	  
pneumococcal	   pneumonia	   in	   low-­‐risk	   adults,	   but	   did	   not	   show	   efficacy	   against	   non-­‐bacteraemic	  
pneumonia	   and	   in	   high-­‐risk	   groups	   [27-­‐30].	   	   Studies	   on	   the	   clinical	   efficacy	   of	   pneumococcal	  
vaccination	   in	  HIV-­‐positive	  adults	  have	  reported	   inconsistent	   findings.	  Most	  have	  been	  conducted	   in	  
persons	   not	   receiving	  ART	  or	   receiving	   suboptimal	  mono	   and	  dual	   therapy.	   In	   the	   only	   randomized	  
controlled	  trial,	  the	  vaccine	  showed	  no	  efficacy	   in	  reducing	  the	  risk	  of	  pneumococcal	  disease	  among	  
Ugandan	   HIV-­‐positive	   persons	   not	   taking	   ART	   [31].	   Surprisingly,	   there	   was	   a	   borderline	   increase	   in	  
pneumonia	  of	  any	  cause	   in	  vaccine	  recipients	  (HR	  1.89,	  95%	  CI	  1.1-­‐3.2).	  Follow-­‐up	  reports	  showed	  a	  
persistent	  excess	  of	  ‘all-­‐cause’	  pneumonia	  in	  vaccine	  recipients	  –	  although	  a	  small	  survival	  advantage	  
was	  also	  observed	  in	  this	  extremely	  high	  mortality	  study	  [32].	  	  	  
	  
Ten	  observational	  studies	  of	  varying	  size	  and	  quality	  have	  been	  reported	  evaluating	  PPV-­‐23	  in	  routine	  
use	  against	  a	  pneumococcal	  disease	  end-­‐point,	  six	  from	  the	  USA	  [5,6,33-­‐36],	  two	  from	  Spain	  [37,38],	  
one	   from	  Brazil	   [39],	  and	  one	   from	  Taiwan	   [15].	   Six	   studies	   reported	  varying	  effectiveness	   (20-­‐79%)	  
against	   IPD;	   two	   studies	   reported	   20-­‐35%	   effectiveness	   against	   pneumonia.	   Within	   these	   studies	  
effectiveness	   was	   associated	   with	   higher	   CD4	   cell	   counts	   (>200	   or	   >500	   cells/μL)	   [5,33,36],	   non	  
African-­‐American	  race	  [6],	  and	  viral	   load	  <100,000	  copies/mL	  [36].	  In	  the	  six	  studies	  able	  to	  evaluate	  
ART	   use,	   five	   confirmed	   this	   as	   independently	   protective	   against	   pneumococcal	   disease	   (50-­‐77%	  
effective)	   with	   only	   one	   study	   showing	   no	   independent	   protective	   effect	   [36].	   None	   of	   the	   studies	  
were	   able	   to	   demonstrate	   an	   impact	   of	   ART	   use	   on	   PPV-­‐23	   efficacy.	   The	   underlying	   confounding	  
associated	   with	   vaccine	   receipt	   and	   risk	   of	   pneumococcal	   disease	   remains	   problematic	   when	  
interpreting	  these	  observational	  studies.	  There	  are	  no	  studies	  reporting	  clinical	  end-­‐point	  efficacy	  with	  
repeat	  PPV-­‐23	  use	  in	  HIV-­‐positive	  adults.	  	  
	  
PCV	  
PCV	  is	  a	  highly	  effective	  paediatric	  vaccine,	  which	  is	  now	  in	  use	  in	  most	  developed	  countries	  following	  
a	   series	   of	   successful	   RCTs.	   As	   noted	   above	   the	   introduction	   of	   these	   vaccines	   has	   led	   to	   dramatic	  
changes	  in	  pneumococcal	  disease	  epidemiology	  through	  herd	  protection	  effects.	  A	  large-­‐scale	  trial	  of	  
PCV-­‐13	   in	   approximately	   85,000	   over	   65	   year-­‐old	   HIV-­‐negative	   Dutch	   residents	   was	   recently	  
completed	  [40].	  In	  this	  study	  a	  single	  dose	  of	  PCV-­‐13	  reduced	  vaccine	  serotype	  IPD	  by	  75%.	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Immunogenicity:	   Serological	   studies	   of	   PCV	   confirm	   its	   immunogenicity	   in	   HIV-­‐positive	   adults.	  
However	   responses	   are	   reduced	   when	   compared	   to	   HIV-­‐negative	   adults	   [41,42]	   and	   demonstrable	  
superiority	  of	  PCV	  response	  over	  PPV	  response	  may	  be	  limited	  to	  certain	  serotypes	  [43-­‐49].	  Durability	  
of	  serological	  response	  appears	  to	  be	  enhanced	  by	  ART	  usage	  [50,51]	  and	  repeat	  dosing	  elicits	  a	  better	  
response	  than	  with	  repeat	  doses	  of	  PPV	  [52].	  
	  
Clinical	  efficacy:	  The	  vaccine	  is	  effective	  in	  HIV-­‐positive	  children,	  reducing	  the	  risk	  of	  vaccine	  serotype	  
IPD	   by	   60-­‐65%	   and	   the	   risk	   of	   clinical	   lower	   respiratory	   tract	   disease	   by	   15%	   [53].	   A	   randomised	  
placebo-­‐controlled	   trial	   of	   PCV-­‐7	   in	   HIV-­‐positive	   Malawian	   adults	   who	   had	   recovered	   from	   IPD,	  
reduced	  vaccine	  serotype	   IPD	  by	  74%	  [54].	   In	  this	  study	  efficacy	  was	  unequivocally	  demonstrated	  at	  
CD4	  counts	  <200	  cells/μL.	  The	  study	  was	  not	  powered	  to	  assess	  the	  interaction	  with	  ART	  or	  duration	  
of	   response.	   Most	   participants	   received	   vaccine	   prior	   to	   commencing	   ART	   and	   efficacy	   was	   not	  
measurable	  12	  months	  after	  vaccination.	  The	  study	  used	  a	  two-­‐dose	  schedule	  with	  vaccinations	  given	  
one	  month	  apart.	  Serological	  assessments	  suggest	  that	  the	  second	  dose	  of	  vaccine	  may	  provide	  little	  if	  
any	  benefit	  over	  a	  single	  dose.	  	  
	  
PCV	  +	  PPV	  
Only	  serological	  studies	  are	  available	  to	  inform	  this	  approach	  to	  vaccination.	  Serological	  responses	  to	  
PCV	  serotypes	  are	  increased	  by	  boosting	  with	  either	  PCV	  or	  PPV	  in	  the	  majority	  of	  published	  studies	  
[42,43,45,47,48].	  There	  are	  no	  studies	  to	  support	  the	  effectiveness	  of	  this	  approach	  to	  prevent	  disease	  
end-­‐points.	  
	  
5.	   Pneumococcal	   vaccine	   in	   HIV-­‐positive	   adults:	   The	   most	   robust	   evidence	   for	   the	   use	   of	  
pneumococcal	   vaccines	   in	   HIV-­‐positive	   adults	   relates	   to	   PCV	   use.	   The	   conjugated	   vaccines	   are	  
immunogenic	   and	   have	   proven	   to	   be	   clinically	   effective	   in	   RCTs	   including	   one	   undertaken	   in	   HIV-­‐
positive	  adults	  with	  low	  CD4	  counts.	  A	  strong	  recommendation	  based	  on	  these	  data	  would	  be	  justified	  
for	  vaccine	  to	  be	  given	  at	  all	  CD4	  counts	  with	  or	  without	  ART,	  and	  with	  or	  without	  co-­‐morbidities	  that	  
would	  increase	  pneumococcal	  disease	  risk.	  However,	  with	  the	  routine	  use	  of	  PCV	  in	  the	  infant	  vaccine	  
programme,	   the	   burden	   of	   pneumococcal	   disease	   attributable	   to	   PCV-­‐13	   serotypes	   is	   now	   falling.	  
With	   a	   large	   herd	   protection,	   the	   clinical	   effectiveness	   of	   this	   approach	   may	   become	   increasingly	  
limited	  as	  disease	  burden	  falls.	  There	  is	  a	  clear	  research	  need	  to	  determine	  the	  burden	  of	  IPD	  and	  non	  
bactaeramic	   pneumonia	   caused	   by	   PCV-­‐13,	   PPV-­‐23,	   and	   non-­‐vaccine	   serotypes	   among	   HIV-­‐positive	  
populations	  in	  the	  UK,	  in	  order	  to	  inform	  vaccination	  practices.	  	  
	  
6.	  Recommendations	  for	  HIV-­‐positive	  adults	  
• We	  recommend	  that	  HIV-­‐positive	  adults	   receive	  a	  single	  dose	  of	  PCV-­‐13	   irrespective	  of	  CD4	  cell	  
count,	  ART	  use,	  and	  viral	  load	  [1B].	  This	  recommendation	  will	  be	  reviewed	  in	  light	  of	  the	  evolving	  
epidemiology	  of	  PCV-­‐13	  type	  pneumococcal	  disease	  in	  the	  UK.	  	  
o PCV-­‐13	  should	  be	  given	  at	  least	  3	  months	  after	  any	  use	  of	  PPV-­‐23	  
• We	  suggest	   that	  HIV-­‐positive	  adults	   that	  meet	   the	   indications	   for	  PPV-­‐23	  vaccination	  within	   the	  
national	  programme	  (typically	  aged	  >65	  years	  or	  with	  co-­‐morbidity	  other	  than	  HIV)	  follow	  general	  
guidance	  and	  receive	  a	  single	  dose	  of	  PPV-­‐23	  	  [2C]	  	  
o PPV-­‐23	  should	  be	  given	  at	  least	  3	  months	  after	  any	  PCV-­‐13	  
• We	  recommend	  against	  repeat	  PPV-­‐23	  or	  repeat	  PCV-­‐13	  dosing	  [1C]	  
	  
References	  
1. Hausdorff	  WP,	  Bryant	  J,	  Paradiso	  PR,	  Siber	  GR.	  Which	  pneumococcal	  serogroups	  cause	  the	  most	  
invasive	   disease:	   implications	   for	   conjugate	   vaccine	   formulation	   and	   use,	   part	   I.	   Clin	   Infect	   Dis	  
2000;30:100-­‐21.	  
Draft	  BHIVA	  guidelines	  on	  the	  use	  of	  vaccines	  in	  HIV-­‐positive	  adults	  2015	  
 
Consultation	  draft	  	   	   	  
 
58	  
2. van	  Hoek	  AJ,	  Andrews	  N,	  Waight	  PA,	  Stowe	  J,	  Gates	  P,	  George	  R,	  Miller	  E.	  The	  effect	  of	  underlying	  
clinical	   conditions	   on	   the	   risk	   of	   developing	   invasive	   pneumococcal	   disease	   in	   England.	   J	   Infect	  
2012;65:17-­‐24.	  
3. Miller	  RF,	  Foley	  NM,	  Kessel	  D,	  Jeffrey	  AA.	  Community	  acquired	  lobar	  pneumonia	  in	  patients	  with	  
HIV	  infection	  and	  AIDS.	  Thorax	  1994;49:367-­‐8.	  
4. Rimland	  D,	  Navin	  TR,	  Lennox	  JL,	  et	  al.	  Prospective	  study	  of	  etiologic	  agents	  of	  community-­‐acquired	  
pneumonia	  in	  patients	  with	  HIV	  infection.	  AIDS	  2002;16:85-­‐95.	  
5. Dworkin	   MS,	   Ward	   JW,	   Hanson	   DL,	   Jones	   JL,	   Kaplan	   JE.	   Pneumococcal	   disease	   among	   human	  
immunodeficiency	  virus-­‐infected	  persons:	   incidence,	   risk	   factors,	   and	   impact	  of	   vaccination.	  Clin	  
Infect	  Dis	  2001;32:794-­‐800.	  
6. Breiman	   RF,	   Keller	   DW,	   Phelan	   MA,	   et	   al.	   Evaluation	   of	   effectiveness	   of	   the	   23-­‐valent	  
pneumococcal	   capsular	   polysaccharide	   vaccine	   for	   HIV-­‐infected	   patients.	   Arch	   Intern	   Med	  
2000;160:2633-­‐8.	  
7. Gilks	  CF,	  Ojoo	  SA,	  Ojoo	  JC,	  et	  al.	  Invasive	  pneumococcal	  disease	  in	  a	  cohort	  of	  predominantly	  HIV-­‐
1	  infected	  female	  sex-­‐workers	  in	  Nairobi,	  Kenya.	  Lancet	  1996;347:718-­‐23.	  
8. Yin	   Z,	   Rice	   BD,	  Waight	   P,	   et	   al.	   Invasive	   pneumococcal	   disease	   among	   HIV-­‐positive	   individuals,	  
2000-­‐2009.	  AIDS	  2012;26:87-­‐94.	  
9. Redd	   SC,	   Rutherford	   GW,	   Sande	  MA,	   Lifson	   AR,	   Hadley	  WK,	   Facklam	   RR,	   Spika	   JS.	   The	   role	   of	  
human	  immunodeficiency	  virus	  infection	  in	  pneumococcal	  bacteremia	  in	  San	  Francisco	  residents.	  J	  
Infect	  Dis	  1990;162:1012-­‐7.	  
10. Heffernan	   RT,	   Barrett	   NL,	   Gallagher	   KM,	   et	   al.	   Declining	   incidence	   of	   invasive	   Streptococcus	  
pneumoniae	  infections	  among	  persons	  with	  AIDS	  in	  an	  era	  of	  highly	  active	  antiretroviral	  therapy,	  
1995-­‐2000.	  J	  Infect	  Dis	  2005;191:2038-­‐45.	  
11. Grau	   I,	  Pallares	  R,	  Tubau	  F,	  et	  al.	  Epidemiologic	  changes	   in	  bacteremic	  pneumococcal	  disease	   in	  
patients	   with	   human	   immunodeficiency	   virus	   in	   the	   era	   of	   highly	   active	   antiretroviral	   therapy.	  
Arch	  Intern	  Med	  2005;165:1533-­‐40.	  
12. Grau	   I,	   Ardanuy	   C,	   Linares	   J,	   Podzamczer	   D,	   Schulze	   MH,	   Pallares	   R.	   Trends	   in	   mortality	   and	  
antibiotic	   resistance	  among	  HIV-­‐infected	  patients	  with	   invasive	  pneumococcal	  disease.	  HIV	  Med	  
2009;10:488-­‐95.	  
13. Cohen	  AL,	  Harrison	  LH,	  Farley	  MM,	  et	  al.	  Prevention	  of	  invasive	  pneumococcal	  disease	  among	  HIV-­‐
infected	  adults	  in	  the	  era	  of	  childhood	  pneumococcal	  immunization.	  AIDS	  2010;24:2253-­‐62.	  
14. Rodriguez-­‐Barradas	   MC,	   Alexandraki	   I,	   Nazir	   T,	   Foltzer	   M,	   Musher	   DM,	   Brown	   S,	   Thornby	   J.	  
Response	  of	  human	  immunodeficiency	  virus-­‐infected	  patients	  receiving	  highly	  active	  antiretroviral	  
therapy	   to	   vaccination	   with	   23-­‐valent	   pneumococcal	   polysaccharide	   vaccine.	   Clin	   Infect	   Dis	  
2003;37:438-­‐47.	  
15. Hung	  CC,	  Chen	  MY,	  Hsieh	  SM,	  Hsiao	  CF,	  Sheng	  WH,	  Chang	  SC.	  Clinical	  experience	  of	  the	  23-­‐valent	  
capsular	   polysaccharide	   pneumococcal	   vaccination	   in	   HIV-­‐1-­‐infected	   patients	   receiving	   highly	  
active	  antiretroviral	  therapy:	  a	  prospective	  observational	  study.	  Vaccine	  2004;22:2006-­‐12.	  
16. Subramaniam	   KS,	   Segal	   R,	   Lyles	   RH,	   Rodriguez-­‐Barradas	   MC,	   Pirofski	   LA.	   Qualitative	   change	   in	  
antibody	   responses	   of	   human	   immunodeficiency	   virus-­‐infected	   individuals	   to	   pneumococcal	  
capsular	   polysaccharide	   vaccination	   associated	  with	   highly	   active	   antiretroviral	   therapy.	   J	   Infect	  
Dis	  2003;187:758-­‐68.	  
17. Iyer	  AS,	  Leggat	  DJ,	  Ohtola	  JA,	  et	  al.	  Response	  to	  pneumococcal	  polysaccharide	  vaccination	  in	  HIV-­‐
positive	  individuals	  on	  long	  term	  highly	  active	  antiretroviral	  therapy.	  J	  AIDS	  Clin	  Res	  2015;6:421.	  	  
18. Leggat	   DJ,	   Iyer	   AS,	   Ohtola	   JA,	   et	   al.	   Response	   to	   pneumococcal	   polysaccharide	   vaccination	   in	  
newly	  diagnosed	  HIV-­‐positive	  individuals.	  J	  AIDS	  Clin	  Res	  2015;6:419.	  	  
19. Rodriguez-­‐Barradas	   MC,	   Serpa	   JA,	   Munjal	   I,	   Mendoza	   D,	   Rueda	   AM,	   Mushtaq	   M,	   Pirofski	   LA.	  
Quantitative	   and	   qualitative	   antibody	   responses	   to	   immunization	   with	   the	   pneumococcal	  
polysaccharide	  vaccine	  in	  HIV-­‐Infected	  patients	  after	  initiation	  of	  antiretroviral	  treatment:	  results	  
from	  a	  randomized	  clinical	  trial.	  J	  Infect	  Dis	  	  2015;211:1703-­‐11.	  
Draft	  BHIVA	  guidelines	  on	  the	  use	  of	  vaccines	  in	  HIV-­‐positive	  adults	  2015	  
 
Consultation	  draft	  	   	   	  
 
59	  
20. Loeliger	   AE,	   Rijkers	  GT,	   Aerts	   P,	   Been-­‐Tiktak	   A,	   Hoepelman	  AI,	   van	  Dijk	  H,	   Borleffs	   JC.	   Deficient	  
antipneumococcal	   polysaccharide	   responses	   in	   HIV-­‐seropositive	   patients.	   FEMS	   Immunol	   Med	  
Microbiol	  1995;12:33-­‐41.	  
21. Rodriguez-­‐Barradas	   MC,	   Musher	   DM,	   Lahart	   C,	   et	   al.	   Antibody	   to	   capsular	   polysaccharides	   of	  
Streptococcus	  pneumoniae	  after	  vaccination	  of	  human	   immunodeficiency	  virus-­‐infected	  subjects	  
with	  23-­‐valent	  pneumococcal	  vaccine.	  J	  Infect	  Dis	  1992;165:553-­‐6.	  
22. Vandenbruaene	   M,	   Colebunders	   R,	   Mascart-­‐Lemone	   F,	   et	   al.	   Equal	   IgG	   antibody	   response	   to	  
pneumococcal	   vaccination	   in	   all	   stages	   of	   human	   immunodeficiency	   virus	   disease.	   J	   Infect	   Dis	  
1995;172:551-­‐3.	  
23. French	  N,	  Gilks	  CF,	  Mujugira	  A,	  Fasching	  C,	  O'Brien	  J,	  Janoff	  EN.	  Pneumococcal	  vaccination	  in	  HIV-­‐
1-­‐infected	  adults	  in	  Uganda:	  humoral	  response	  and	  two	  vaccine	  failures.	  AIDS	  1998;12:1683-­‐9.	  
24. Amendola	   A,	   Tanzi	   E,	   Zappa	   A,	   Colzani	   D,	   Boschini	   A,	   Musher	   DM,	   Zanetti	   AR.	   Safety	   and	  
immunogenicity	  of	  23-­‐valent	  pneumococcal	  polysaccharide	  vaccine	  in	  HIV-­‐1	  infected	  former	  drug	  
users.	  Vaccine	  2002;20:3720-­‐4.	  
25. Tasker	  SA,	  Wallace	  MR,	  Rubins	  JB,	  Paxton	  WB,	  O'Brien	  J,	  Janoff	  EN.	  Reimmunization	  with	  23-­‐valent	  
pneumococcal	  vaccine	   for	  patients	   infected	  with	  human	   immunodeficiency	  virus	   type	  1:	  clinical,	  
immunologic,	  and	  virologic	  responses.	  Clin	  Infect	  Dis	  2002;34:	  813-­‐21.	  
26. Papadatou	   I,	  Piperi	  C,	  Alexandraki	  K,	  Kattamis	  A,	  Theodoridou	  M,	  Spoulou	  V.	  Antigen-­‐Specific	  B-­‐
Cell	   Response	   to	   13-­‐valent	   pneumococcal	   conjugate	   vaccine	   in	   asplenic	   individuals	   with	   beta-­‐
thalassemia	   previously	   immunized	   with	   23-­‐valent	   pneumococcal	   polysaccharide	   vaccine.	   Clin	  
Infect	  Dis	  2014;59:862-­‐5.	  	  
27. 	  Huss	  A,	  Scott	  P,	  Stuck	  AE,	  Trotter	  C,	  Egger	  M.	  Efficacy	  of	  pneumococcal	  vaccination	   in	  adults:	  a	  
meta-­‐analysis.	  CMAJ	  2009;180:48-­‐58.	  
28. Cornu	   C,	   Yzebe	   D,	   Leophonte	   P,	   Gaillat	   J,	   Boissel	   JP,	   Cucherat	   M.	   Efficacy	   of	   pneumococcal	  
polysaccharide	  vaccine	  in	  immunocompetent	  adults:	  a	  meta-­‐analysis	  of	  randomized	  trials.	  Vaccine	  
2001;19:4780-­‐90.	  
29. Moore	  RA,	  Wiffen	  PJ,	  Lipsky	  BA.	  Are	  the	  pneumococcal	  polysaccharide	  vaccines	  effective?	  Meta-­‐
analysis	  of	  the	  prospective	  trials.	  BMC	  Fam	  Pract	  2000;1:1.	  
30. Fine	   MJ,	   Smith	   MA,	   Carson	   CA,	   et	   al.	   Efficacy	   of	   pneumococcal	   vaccination	   in	   adults.	   A	   meta-­‐
analysis	  of	  randomized	  controlled	  trials.	  Arch	  Intern	  Med	  1994;154:2666-­‐77.	  
31. French	  N,	  Nakiyingi	  J,	  Carpenter	  LM,	  et	  al.	  23-­‐valent	  pneumococcal	  polysaccharide	  vaccine	  in	  HIV-­‐
1-­‐infected	   Ugandan	   adults:	   double-­‐blind,	   randomised	   and	   placebo	   controlled	   trial.	   Lancet	  
2000;355:2106-­‐11.	  
32. Watera	   C,	   Nakiyingi	   J,	   Miiro	   G,	   Muwonge	   R,	   Whitworth	   JA,	   Gilks	   CF,	   French	   N.	   23-­‐Valent	  
pneumococcal	   polysaccharide	   vaccine	   in	   HIV-­‐infected	   Ugandan	   adults:	   6-­‐year	   follow-­‐up	   of	   a	  
clinical	  trial	  cohort.	  AIDS	  2004;18:1210-­‐3.	  
33. Gebo	   KA,	   Moore	   RD,	   Keruly	   JC,	   Chaisson	   RE.	   Risk	   factors	   for	   pneumococcal	   disease	   in	   human	  
immunodeficiency	  virus-­‐infected	  patients.	  J	  Infect	  Dis	  1996;173:857-­‐62.	  
34. Guerrero	  M,	  Kruger	  S,	  Saitoh	  A,	  Sorvillo	  F,	  Cheng	  KJ,	  French	  C,	  Beall	  G.	  Pneumonia	  in	  HIV-­‐infected	  
patients:	  a	  case-­‐control	  survey	  of	  factors	  involved	  in	  risk	  and	  prevention.	  AIDS	  1999;13:1971-­‐5.	  
35. Rodriguez-­‐Barradas	  MC,	   Goulet	   J,	   Brown	   S,	   Get	   al.	   Impact	   of	   pneumococcal	   vaccination	   on	   the	  
incidence	   of	   pneumonia	   by	   HIV	   infection	   status	   among	   patients	   enrolled	   in	   the	   Veterans	   Aging	  
Cohort	  5-­‐Site	  Study.	  Clin	  Infect	  Dis	  2008;46:1093-­‐1100.	  
36. Teshale	  EH,	  Hanson	  D,	  Flannery	  B,	  Phares	  C,	  Wolfe	  M,	  Schuchat	  A,	  Sullivan	  P.	  Effectiveness	  of	  23-­‐
valent	  polysaccharide	  pneumococcal	   vaccine	  on	  pneumonia	   in	  HIV-­‐infected	  adults	   in	   the	  United	  
States,	  1998-­‐-­‐2003.	  Vaccine	  2008;26:5830-­‐4.	  
37. Lopez-­‐Palomo	  C,	  Martin-­‐Zamorano	  M,	  Benitez	   E,	   Fernandez-­‐Gutierrez	   C,	  Guerrero	   F,	   Rodriguez-­‐
Iglesias	  M,	  Giron-­‐Gonzalez	   JA.	   Pneumonia	   in	  HIV-­‐infected	  patients	   in	   the	  HAART	   era:	   incidence,	  
risk,	  and	  impact	  of	  the	  pneumococcal	  vaccination.	  J	  Med	  Virol	  2004;72:517-­‐24.	  
38. Penaranda	  M,	  Falco	  V,	  Payeras	  A,	  et	  al.	  Effectiveness	  of	  polysaccharide	  pneumococcal	  vaccine	  in	  
HIV-­‐infected	  patients:	  a	  case-­‐control	  study.	  Clin	  Infect	  Dis	  2007;45:e82-­‐7.	  
Draft	  BHIVA	  guidelines	  on	  the	  use	  of	  vaccines	  in	  HIV-­‐positive	  adults	  2015	  
 
Consultation	  draft	  	   	   	  
 
60	  
39. Veras	   MA,	   Enanoria	   WT,	   Castilho	   EA,	   Reingold	   AL.	   Effectiveness	   of	   the	   polysaccharide	  
pneumococcal	  vaccine	  among	  HIV-­‐infected	  persons	  in	  Brazil:	  a	  case	  control	  study.	  BMC	  Infect	  Dis	  
2007;7:119.	  
40. Bonten	  M,	  Bolkenbaas	  M,	  Huijts	  S,	  Webber	  C,	  Gault	  S,	  Gruber	  W,	  Grobbee	  D.	  Community	  acquired	  
pneumonia	  immunisation	  trial	  in	  adults	  (CAPITA).	  Pneumonia	  2004;3:1.	  
41. Gordon	   SB,	   Kayhty	   H,	  Molyneux	  ME,	   et	   al.	   Pneumococcal	   conjugate	   vaccine	   is	   immunogenic	   in	  
lung	  fluid	  of	  HIV-­‐infected	  and	  immunocompetent	  adults.	  J	  Allergy	  Clin	  Immunol	  2007;120:208-­‐10.	  
42. Chen	   M,	   Ssali	   F,	   Mulungi	   M,	   et	   al.	   Induction	   of	   opsonophagocytic	   killing	   activity	   with	  
pneumococcal	   conjugate	   vaccine	   in	   human	   immunodeficiency	   virus-­‐infected	   Ugandan	   adults.	  
Vaccine	  2008;26:4962-­‐8.	  
43. Feikin	  DR,	  Elie	  CM,	  Goetz	  MB,	  et	  al.	  Randomized	  trial	  of	  the	  quantitative	  and	  functional	  antibody	  
responses	  to	  a	  7-­‐valent	  pneumococcal	  conjugate	  vaccine	  and/or	  23-­‐valent	  polysaccharide	  vaccine	  
among	  HIV-­‐infected	  adults.	  Vaccine	  2001;20:545-­‐53.	  
44. Kroon	  FP,	  van	  Dissel	  JT,	  Ravensbergen	  E,	  Nibbering	  PH,	  van	  Furth	  R.	  Enhanced	  antibody	  response	  
to	  pneumococcal	  polysaccharide	  vaccine	  after	  prior	   immunization	  with	  conjugate	  pneumococcal	  
vaccine	  in	  HIV-­‐infected	  adults.	  Vaccine	  2000;19:886-­‐94.	  
45. Lesprit	   P,	   Pedrono	   G,	  Molina	   JM,	   et	   al.	   Immunological	   efficacy	   of	   a	   prime-­‐boost	   pneumococcal	  
vaccination	  in	  HIV-­‐infected	  adults.	  AIDS	  2007;21:2425-­‐34.	  
46. Crum-­‐Cianflone	  NF,	  Huppler	  Hullsiek	  K,	  Roediger	  M,	   et	   al.	  A	   randomized	   clinical	   trial	   comparing	  
revaccination	   with	   pneumococcal	   conjugate	   vaccine	   to	   polysaccharide	   vaccine	   among	   HIV-­‐
infected	  adults.	  J	  Infect	  Dis	  2010;202:1114-­‐25.	  
47. Penaranda	  M,	  Payeras	  A,	  Cambra	  A,	  Mila	  J,	  Riera	  M.	  Conjugate	  and	  polysaccharide	  pneumococcal	  
vaccines	  do	  not	  improve	  initial	  response	  of	  the	  polysaccharide	  vaccine	  in	  HIV-­‐infected	  adults.	  AIDS	  
2010;24:1226-­‐8.	  
48. Ho	   YL,	   Brandao	   AP,	   de	   Cunto	   Brandileone	   MC,	   Lopes	   MH.	   Immunogenicity	   and	   safety	   of	  
pneumococcal	   conjugate	   polysaccharide	   and	   free	   polysaccharide	   vaccines	   alone	  or	   combined	   in	  
HIV-­‐infected	  adults	  in	  Brazil.	  Vaccine	  2013;31:4047-­‐53.	  
49. Lu	   CL,	   Hung	   CC,	   Chuang	   YC,	   et	   al.	   Serologic	   response	   to	   primary	   vaccination	   with	   7-­‐valent	  
pneumococcal	   conjugate	   vaccine	   is	   better	   than	   with	   23-­‐valent	   pneumococcal	   polysaccharide	  
vaccine	   in	   HIV-­‐infected	   patients	   in	   the	   era	   of	   combination	   antiretroviral	   therapy.	   Hum	   Vaccin	  
Immunother	  2013;9:398-­‐404.	  
50. Sogaard	   OS,	   Schonheyder	   HC,	   Bukh	   AR,	   Harboe	   ZB,	   Rasmussen	   TA,	   Ostergaard	   L,	   Lohse	   N.	  
Pneumococcal	  conjugate	  vaccination	  in	  persons	  with	  HIV:	  the	  effect	  of	  highly	  active	  antiretroviral	  
therapy.	  AIDS	  2010;24:1315-­‐22.	  
51. Slayter	  KL,	  Singer	  J,	  Lee	  TC,	  Kayhty	  H,	  Schlech	  WF.	  Immunization	  against	  pneumococcal	  disease	  in	  
HIV-­‐infected	   patients:	   conjugate	   versus	   polysaccharide	   vaccine	   before	   or	   after	   reconstitution	   of	  
the	  immune	  system	  (CTN-­‐147).	  Int	  J	  STD	  AIDS	  2013;24:227-­‐31.	  
52. Lu	  CL,	  Chang	  SY,	  Chuang	  YC,	  et	  al.	  Revaccination	  with	  7-­‐valent	  pneumococcal	   conjugate	  vaccine	  
elicits	   better	   serologic	   response	   than	   23-­‐valent	   pneumococcal	   polysaccharide	   vaccine	   in	   HIV-­‐
infected	   adult	   patients	   who	   have	   undergone	   primary	   vaccination	   with	   23-­‐valent	   pneumococcal	  
polysaccharide	  vaccine	  in	  the	  era	  of	  combination	  antiretroviral	  therapy.	  Vaccine	  2014;32:1031-­‐5.	  
53. Klugman	   KP,	   Madhi	   SA,	   Huebner	   RE,	   Kohberger	   R,	   Mbelle	   N,	   Pierce	   N.	   A	   trial	   of	   a	   9-­‐valent	  
pneumococcal	  conjugate	  vaccine	   in	  children	  with	  and	  those	  without	  HIV	   infection.	  N	  Engl	   J	  Med	  
2003;349:1341-­‐8.	  
54. French	  N,	  Gordon	  SB,	  Mwalukomo	  T,	  et	  al.	  A	  trial	  of	  a	  7-­‐valent	  pneumococcal	  conjugate	  vaccine	  in	  
HIV-­‐infected	  adults.	  N	  Engl	  J	  Med	  2010;362:812-­‐22.	  
	  
	  
	   	  
Draft	  BHIVA	  guidelines	  on	  the	  use	  of	  vaccines	  in	  HIV-­‐positive	  adults	  2015	  
 





1.	   Infection	   and	  disease:	  Poliomyelitis	   is	   caused	  by	  poliovirus	   serotypes	  1,	  2	  and	  3.	  Polioviruses	  are	  
neuroinvasive	  enteroviruses	  that	  are	  spread	  by	  the	  faecal-­‐oral	  and	  respiratory	  routes.	  Most	  infections	  
are	   sub-­‐clinical,	   but	   a	  minority	   give	   rise	   to	   neurological	  manifestations	   including	   aseptic	  meningitis,	  
encephalomyelitis,	   and	   the	   poliomyelitis	   syndrome,	   characterized	   by	   the	   acute	   onset	   of	   ﬂaccid	  
paralysis.	   The	   live	   attenuated	  oral	   poliovirus	   vaccine	   (OPV)	   is	   shed	   asymptomatically	   in	   the	   stool	   of	  
vaccine	   recipients	   for	   several	   days;	   shedding	   may	   be	   prolonged	   in	   immunocompromised	   persons,	  
which	  may	  allow	   reversion	   to	   virulence	  and	  give	   rise	   to	   vaccine-­‐associated	  paralytic	  polio	   (VAPP)	   in	  
vaccine	  recipients	  or	  their	  contacts.	  	  
	  
2.	  Epidemiology:	  Poliomyelitis	  continues	  to	  occur	  in	  only	  a	  few	  countries	  and	  is	  now	  exceedingly	  rare	  
in	  the	  UK.	  The	  last	  indigenous	  case	  of	  wild-­‐type	  infection	  was	  in	  1984,	  with	  the	  last	  imported	  case	  in	  
1993.	  Travellers	  going	  to	  certain	  parts	  of	  Africa	  and	  Asia	  may	  be	  at	  risk	  for	  polio.	  
	  
3.	   Poliomyelitis	   in	   HIV-­‐positive	   people:	  No	   speciﬁc	   data	   are	   available	   on	  wild-­‐type	   poliomyelitis	   in	  
HIV-­‐positive	   persons.	   HIV-­‐positive	   children	   -­‐	   including	   those	   who	   are	   mildly	   to	   moderately	  
symptomatic	  -­‐	  retain	  the	  ability	  to	  clear	  enteroviruses,	  including	  vaccine-­‐related	  poliovirus,	  and	  do	  not	  
appear	  to	  be	  at	  increased	  risk	  of	  prolonged	  OPV	  shedding	  relative	  to	  HIV-­‐negative	  children	  [1,2].	  	  
	  
4.	  Polio	  vaccine:	  Replicating	  live	  attenuated	  OPV	  is	  no	  longer	  available	  in	  the	  UK,	  having	  been	  replaced	  
in	  2004	  with	  the	  trivalent	  (serotypes	  1-­‐3)	  enhanced	  inactivated	  poliovirus	  vaccine	  (IPV)	   in	  all	  routine	  
vaccine	   schedules.	  The	  vaccine	   is	  given	   to	  adults	   in	   combination	  with	   tetanus	  and	  diphtheria	   toxoid	  
(Td/IPV).	  The	  vaccine	  is	  given	  by	  parenteral	  administration.	  IPV	  is	  highly	  immunogenic.	  Antibodies	  to	  
all	  three	  poliovirus	  serotypes	  develop	  in	  >90%	  of	  healthy	  recipients	  after	  2	  doses	  and	  in	  >99%	  after	  3	  
doses.	  The	  duration	  of	   immunity	  conferred	  by	   IPV	   is	  not	  known.	  A	  total	  of	   five	  vaccine	  doses	  at	   the	  
appropriate	   intervals	   (as	   per	   the	   UK	   childhood	   vaccination	   schedule)	   are	   considered	   to	   give	   lasting	  
immunity,	  with	  reinforcing	  doses	   recommended	  every	  10	  years	   for	   those	  at	   risk.	  The	  vaccine	   is	  well	  
tolerated.	  Injection	  site	  reactions	  are	  common	  but	  usually	  self-­‐limited	  and	  may	  occur	  more	  frequently	  
following	   subsequent	   doses.	   Fever	   and	   other	   systemic	   reactions	   are	   uncommon.	   Severe	   systemic	  
reactions	  are	  rare.	  	  
	  
General	  indications:	  The	  aim	  of	  the	  UK	  national	  vaccination	  programme	  is	  to	  ensure	  that	  all	  individuals	  
receive	   at	   least	   5	   vaccine	   doses.	   Td/IPV	   is	   recommended	   for	   vaccination	   of	   those	   aged	   ≥10	   years.	  
Adults	  who	  are	  either	  unvaccinated	  or	  have	  an	  uncertain	   vaccination	  history	   are	   advised	   to	   receive	  
primary	  immunization	  with	  three	  vaccine	  doses	  at	  either	  monthly	  intervals	  or	  at	  0,	  1-­‐2	  months,	  and	  6-­‐
12	  months	  [3].	  Two	  further	  doses	  are	  scheduled	  5	  and	  10	  years	  after	  the	  last	  dose.	  Adults	  who	  have	  
received	  partial	  vaccination	  are	  advised	  to	  receive	  the	  remaining	  doses,	  regardless	  of	  the	  interval	  since	  
the	  last	  dose	  and	  type	  of	  vaccine	  previously	  received.	  It	  is	  also	  recommended	  that	  travellers	  to	  areas	  
that	  pose	  a	  risk	  of	  exposure	  should	  ensure	  they	  are	  fully	  vaccinated.	  
	  
5.	  Polio	  vaccine	  in	  HIV-­‐positive	  adults:	  Both	  OPV	  and	  IPV	  can	  elicit	  neutralizing	  antibody	  responses	  in	  
HIV-­‐positive	   children	   and	   adults,	   and	   in	   patients	   with	   CD4	   counts	   <300	   cells/μL	   [4-­‐9].	   The	  
seroprevalence	   of	   poliovirus-­‐neutralizing	   antibodies	   varies	   among	   HIV-­‐positive	   adults.	   HIV-­‐positive	  
patients	  born	  and	   resident	   in	   the	  UK	  since	  1962	  have	  generally	   received	  a	   complete	  5-­‐dose	  vaccine	  
course	   as	   part	   of	   routine	   childhood	   immunization.	   High	   prevalence	   rates,	   comparable	   to	   those	   in	  
normal	   controls,	   have	   been	   reported	   in	   some	   cohorts.	   However,	   in	   a	   seroepidemiological	   study	   of	  
Italian	  drug	  users,	  those	  with	  HIV	  infection	  were	  more	  likely	  to	  lack	  protection,	  with	  34%	  seronegative	  
for	   poliovirus	   type	   3	   and	   11%	   lacking	   neutralizing	   antibodies	   to	   all	   three	   virus	   types	   [10].	   OPV	   is	  
contraindicated	   in	   patients	   with	   HIV	   and	   their	   contacts.	   IPV	   can	   be	   administered	   safely	   to	  
immunocompromised	  adults.	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6.	   Post-­‐exposure	   prophylaxis:	   Following	   inadvertent	   administration	   of	   OPV,	   exposure	   to	   a	   close	  
contact	   given	   OPV,	   or	   exposure	   to	   wild-­‐type	   poliovirus,	   immunocompromised	   patients	   can	   receive	  
post-­‐exposure	  prophylaxis	  with	  intramuscular	  human	  normal	  immunoglobulin	  (HNIG).	  A	  serum	  should	  
be	  collected	  for	  baseline	  serology	  testing,	  but	  prophylaxis	  should	  not	  be	  delayed	  pending	  the	  results.	  
HNIG	  is	  not	  indicated	  if	  the	  patient	  is	  known	  to	  be	  antibody-­‐positive	  to	  all	  three	  poliovirus	  types.	  Stool	  
samples	  are	  collected	  one	  week	  apart	  for	  analysis.	  If	  poliovirus	  is	  detected,	  administration	  of	  HNIG	  is	  
repeated	   at	   3-­‐weekly	   intervals	   until	   two	   consecutive	   stool	   samples	   test	   negative.	   Intravenous	  
immunoglobulin	  may	  be	  considered	  if	  intramuscular	  injections	  are	  contraindicated.	  
7.	  Recommendations	  for	  HIV-­‐positive	  adults	  	  
• We	   recommend	   that	  HIV-­‐positive	   adults	   that	   require	   vaccination	   against	   diphtheria,	   tetanus,	   or	  
polio	  be	  given	   the	  Td/IPV	  vaccine	   in	  accordance	  with	  general	   indications,	  and	   regardless	  of	  CD4	  
cell	  count,	  ART	  use,	  and	  viral	  load	  [1B]	  
o We	   recommend	   that	   individuals	   who	   are	   either	   unvaccinated	   or	   have	   an	   uncertain	  
vaccination	   history	   receive	   3	   vaccine	   doses	   at	   monthly	   interval	   (or	   at	   0,	   1-­‐2,	   and	   6-­‐12	  
months)	  followed	  by	  2	  reinforcing	  doses	  after	  5	  and	  10	  years,	  whereas	  partially	  vaccinated	  
individuals	  should	  complete	  the	  5-­‐dose	  vaccine	  course	  [1B]	  
o We	  recommend	  that	  fully	  vaccinated	  individuals	  (5	  doses)	  receive	  a	  booster	  dose	  every	  10	  
years	  if	  at	  risk	  of	  exposure,	  typically	  through	  travel	  [1C]	  	  
• We	  recommend	  that	  individuals	  who	  may	  be	  occupationally	  exposed	  to	  poliovirus	  (e.g.	  laboratory	  
workers)	   be	   tested	   for	   specific	   antibodies	   3	   months	   after	   vaccination	   to	   confirm	   protective	  
immunity	  and	  revaccinated	  if	  required	  [1C]	  
• We	   recommend	   that	   HIV-­‐positive	   patients	   who	   are	   exposed	   to	   OPV	   or	   wild-­‐type	   polio	   are	  
considered	   for	   post-­‐exposure	   prophylaxis	   with	   HNIG,	   based	   on	   considerations	   of	   vaccination	  
history,	  CD4	  cell	  counts,	  viral	  load,	  ART	  status,	  and	  poliovirus	  serology	  [1C]	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1.	   Infection	   and	   disease:	   Rabies	   is	   caused	   by	   viruses	   of	   the	   lyssavirus	   genus,	   including	   the	   classic	  
rabies	  virus	  genotype	  1	  and	  other	  related	  viruses	  [e.g.	  European	  Bat	  lyssaviruses	  (EBLV)	  and	  Australian	  
bat	  lyssavirus	  (ABLV)].	  Rabies	  is	  transmitted	  by	  contact	  with	  a	  rabid	  animal,	  generally	  as	  the	  result	  of	  a	  
bite	   or	   scratch	   [1-­‐3].	   Transmission	   may	   also	   occur	   when	   infectious	   material,	   such	   as	   saliva	   or	  
aerosolized	   secretions	   from	   an	   infected	   animal,	   comes	   into	   contact	   with	   mucous	   membranes	   or	  
abraded	   skin,	   or	   on	   rare	   occasions	   through	   inhalation	   of	   virus-­‐containing	   aerosol.	   Virus	   may	   be	  
present	  in	  the	  saliva	  of	  patients	  with	  rabies,	  but	  person-­‐to-­‐person	  spread	  of	  the	  disease	  has	  not	  been	  
documented,	   with	   the	   exception	   of	   a	   few	   cases	   of	   transplant-­‐associated	   transmission	   from	   donors	  
unsuspected	  of	   having	   rabies	   [4].	   Rabies	   classically	   presents	   as	   an	   acute	   encephalomyelitis	   and	   less	  
commonly	  with	  an	  ascending	  ﬂaccid	  paralysis.	  In	  both	  forms,	  coma	  and	  death	  follow	  almost	  invariably	  
although	  a	  few	  cases	  of	  survival	  have	  been	  described	  [5].	  	  
	  
2.	   Epidemiology:	   Human	   rabies	   is	   common	   in	   most	   developing	   countries,	   where	   it	   occurs	   in	   both	  
urban	   and	   rural	   areas	   [1-­‐3].	   In	   the	  majority	   of	   industrialised	   countries	   human	   rabies	   is	   rare,	  mainly	  
because	   of	   oral	   vaccination	   of	  wildlife	   and	  mandatory	   vaccination	   of	   domestic	   animals.	   No	   case	   of	  
indigenous	   human	   rabies	   from	   terrestrial	   animals	   has	   been	   reported	   in	   the	   UK	   since	   1902.	   An	  
indigenous	  case	  of	  EBLV	  infection	  occurred	  in	  2002	  in	  a	  bat	  handler	  who	  was	  bitten	  by	  a	  bat	  and	  did	  
not	   receive	  pre-­‐or	  post-­‐exposure	   rabies	  prophylaxis.	  Animal	   rabies	   is	  widespread	   in	  every	   continent	  
except	  Antarctica.	  In	  Asia,	  Africa,	  and	  parts	  of	  Latin	  America	  both	  stray	  and	  domestic	  dogs	  remain	  the	  
principal	   vector	   and	   transmitter	   of	   rabies	   to	   humans.	   Canine	   rabies	   is	   endemic	   throughout	  most	   of	  
these	  regions,	  and	  90%	  of	  human	  cases	  with	  a	  deﬁned	  source	  are	  caused	  by	  exposure	  to	  dogs,	  usually	  
in	   the	   form	  of	  bites.	  Rabies	   reservoir	   species	   include	  wild	  mammals	   such	  as	   racoons,	   skunks,	   foxes,	  
and	   insectivorous	   bats	   in	   North	   America;	   vampire	   bats	   and	  mongooses	   in	   Central	   America;	   jackals,	  
hyenas	   and	  mongooses	   in	   Africa;	  wolves,	   foxes,	   and	   insectivorous	   bats	   in	   Europe;	   and	   fruit	   bats	   in	  
Australia.	   In	   some	  parts	  of	   the	  world,	  other	  domestic	  and	  wild	  mammals	   such	  as	   cats	  and	  monkeys	  
may	   transmit	   infection.	   In	   the	  UK,	  EBLVs	  have	  been	  detected	   in	  Daubenton’s	  bats	   [6].	  Public	  Health	  
England	  (PHE)	  provides	  indications	  of	  rabies	  risk	  by	  country	  [7].	  Prevention	  through	  vaccination	  prior	  
to	  exposure	  is	  available	  but	  underused,	  and	  disease	  prevention	  mostly	  relies	  on	  rabies	  post-­‐exposure	  
prophylaxis	  (rabies-­‐PEP)	  [8].	  The	  number	  of	  people	  requiring	  rabies-­‐PEP	  has	  increased	  in	  recent	  years	  
in	   the	   UK,	   and	   is	   almost	   900	   per	   year	   in	   England	   and	   Wales,	   of	   which	   10%	   in	   people	   potentially	  
exposed	  to	  bats	  in	  the	  UK	  and	  90%	  potentially	  exposed	  overseas.	  
	  
3.	   Rabies	   in	   HIV-­‐positive	   adults:	   It	   is	   not	   known	   if	   the	   natural	   history	   of	   rabies	   is	  modified	   by	  HIV	  
infection.	  	  
	  
4.	   Rabies	   vaccine:	  Human	   rabies	   vaccines	   are	   inactivated.	   Vaccines	   commonly	   available	   in	   Europe,	  
North	  America,	  Australia,	  and	  New	  Zealand	  are	  cell	  culture-­‐based	  and	  include	  the	  human	  diploid	  cell	  
vaccine	   (HDCV),	   the	   puriﬁed	   chick	   embryo	   cell	   vaccine	   (PCECV),	   and	   the	   purified	   Vero	   cell	   rabies	  
vaccine	  (PVRV)	  [9].	  HDCV	  and	  PCECV	  are	  available	  in	  the	  UK.	  Vaccines	  of	  nerve	  tissue	  origin	  are	  still	  in	  
use	  in	  some	  developing	  countries,	  but	  are	  reactogenic	  and	  some	  are	  of	  low	  immunogenicity;	  these	  are	  
not	   generally	   recommended,	   although	   they	   are	   still	   preferable	   to	   no	   vaccine.	   Rabies	   vaccines	   are	  
administered	  intramuscularly	  (or	  subcutaneously	  if	  bleeding	  disorders);	  the	  standard	  schedule	  is	  with	  
three	  vaccine	  doses	  given	  at	  0,	  7,	  and	  28	  (or	  21)	  days.	   Intradermal	  administration	  of	  smaller	  vaccine	  
doses	  is	  used	  in	  some	  developing	  countries,	  but	  is	  generally	  not	  recommended.	  In	  pre-­‐exposure	  rabies	  
prophylaxis,	   cell	   culture-­‐based	   vaccines	   administered	   through	   the	   intramuscular	   route	   induce	   a	  
satisfactory	   antibody	   response	   in	   approximately	   95%	   of	   healthy	   recipients,	   with	   rare	   failures;	  
responses	  are	  usually	  maintained	   for	  at	   least	  10	  years.	  Although	  associated	  with	  mild	  and	   transient	  
reactions,	  cell	  culture-­‐derived	  rabies	  vaccines	  are	  considered	  safe	  [10].	  Injection	  site	  reactions	  occur	  in	  
30-­‐74%	  of	  vaccine	  recipients,	  whereas	  mild	  systemic	  reactions	  are	  reported	  in	  5-­‐40%.	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Serology	   testing:	   A	   rabies-­‐neutralizing	   antibody	   level	   ≥0.5	   IU/ml,	   as	   per	  World	   Health	   Organization	  
(WHO)	   guidelines,	   is	   considered	   the	   minimal	   adequate	   response	   indicating	   unequivocal	  
seroconversion	  [11].	  There	  are	  strict	   indications	  for	  serological	  testing	   in	  order	  to	  guide	  vaccine	  use,	  
and	  those	  eligible	  in	  the	  UK	  include	  vaccine	  candidates	  who	  have	  had	  a	  severe	  reaction	  to	  a	  previous	  
vaccine	   dose,	   people	   with	   regular	   and	   continuous	   exposure	   to	   rabies,	   and	   those	   in	   whom	   vaccine	  
immunogenicity	   may	   be	   reduced	   including	   HIV-­‐positive	   individuals.	   Rabies	   serology	   is	   available	   at	  
selected	  UK	  laboratories	  and	  advice	  can	  be	  obtained	  through	  the	  PHE	  Rabies	  clerk	  on	  +44	  (0)	  20	  8327	  
6204	  or	  through	  the	  Animal	  and	  Plant	  Health	  Agency	  (APHA)	  Rabies	  Help	  Line	  (+44	  (0)	  1932	  357345	  or	  
(0)	  1932	  341111).	  
	  
General	   indications	   for	   pre-­‐exposure	   rabies	   prophylaxis	   in	   healthy	   individuals:	   Pre-­‐exposure	   rabies	  
vaccination	  is	  offered	  in	  the	  UK	  to	  the	  following	  categories:	  
• At	   continuous	   risk	   of	   exposure	   -­‐	   Laboratory	  workers	   (3	   vaccine	   doses,	   serology	   testing	   after	   the	  
primary	  course	  and	  every	  6	  months	   thereafter,	  booster	  vaccine	  dose	   if	  antibody	   titre	   falls	  below	  
0.5	  IU/ml)	  
• At	  frequent	  risk	  of	  exposure	  -­‐	  Bat	  handlers,	  persons	  who	  regularly	  handle	  imported	  animals,	  animal	  
control	  and	  wildlife	  workers,	  veterinary	  staff	  or	   zoologists	  who	   travel	   regularly	   in	   rabies	  enzootic	  
areas,	  health	  workers	  in	  rabies	  enzootic	  areas	  who	  will	  be	  at	  risk	  of	  direct	  exposure	  to	  body	  fluids	  
or	  tissue	  from	  a	  patient	  with	  confirmed	  or	  probable	  rabies	  (3	  vaccine	  doses,	  booster	  vaccine	  dose	  
at	   1	   year,	   then	   a	   booster	   vaccine	   dose	   every	   3-­‐5	   years,	   or	   based	   on	   serology	   results	   where	  
available)	  
• At	   occasional	   risk	   of	   exposure	   -­‐	   Travellers	   to	   rabies	   enzootic	   areas,	   especially	   if	   post-­‐exposure	  
medical	   care	   and	   rabies	   biologics	   at	   the	   destination	   are	   lacking	   or	   in	   short	   supply,	   or	   they	   are	  
undertaking	  higher	  risk	  activities	  such	  as	  cycling	  or	  running,	  or	  they	  are	   living	  or	  staying	  for	  more	  
than	  one	  month	  (3	  vaccine	  doses,	  booster	  dose	  considered	  at	  10	  years	  post-­‐primary	  course	  if	  the	  
risk	  recurs;	  serology	  not	  generally	  offered).	  It	  should	  be	  noted	  that	  an	  Australian	  study	  called	  into	  
question	  such	  selection	  criteria,	  based	  on	  a	  case	  series	  indicating	  that	  most	  injuries	  occurred	  within	  
30	   days	   of	   arrival	   in	   a	   rabies-­‐endemic	   region,	  most	  were	   injured	  whilst	   participating	   in	   common	  
tourist	   activities,	  more	   than	  a	   third	  did	  not	   initiate	   contact	  with	   animals,	   and	   the	  most	   common	  
injury	  sites	  were	  hands	  and	  fingers	  –	  high	  risk	  sites	  for	  rabies	  transmission	  due	  to	  rich	  nerve	  supply	  
[12].	  
	  
5.	   Post-­‐exposure	   prophylaxis:	  Management	   consists	   of	   wound	   treatment	   and	   risk	   assessment	   for	  
appropriate	   rabies-­‐PEP,	   taking	   into	   account	   the	   circumstances	   of	   the	   exposure,	   including	   the	   local	  
incidence	  of	   rabies	   in	   the	   species	   involved	  and	   the	   immune	  status	  of	   the	  person.	  Detailed	  guidance	  
has	  been	  published	  by	  PHE	  [9].	  Contact	  details	   for	  specialist	  advice	   in	  England,	  Wales,	  Scotland,	  and	  
Northern	   Ireland	   are	   listed	   in	   the	   Green	   Book	  
[www.gov.uk/government/uploads/system/uploads/attachment_data/file/85762/Green-­‐Book-­‐
Chapter-­‐27-­‐v3_0.pdf].	  For	  head	  and	  neck	  bites,	  treatment	  should	  ideally	  be	  started	  within	  12	  hours	  of	  
reporting;	   for	   other	   exposures	   treatment	   should	   be	   started	   ideally	   within	   24	   hours.	   Because	   the	  
incubation	  period	  for	  rabies	  can	  be	  prolonged,	  treatment	  should	  be	  considered	  whatever	  the	  interval	  
from	  exposure.	  Rabies-­‐PEP	  initiated	  at	  an	  early	  stage	  is	  nearly	  100%	  effective	  in	  preventing	  rabies,	  but	  
delayed	  or	  incomplete	  treatment	  results	  in	  human	  deaths,	  often	  associated	  with	  severe	  lesions	  on	  or	  
near	  the	  head	  or	  hand.	  	  
	  
Rabies	  vaccine	  is	  the	  mainstay	  of	  rabies-­‐PEP,	  and	  the	  aim	  is	  to	  achieve	  an	  antibody	  titre	  of	  ≥0.5	  IU/mL,	  
as	   per	  WHO	  guidelines	   [11],	   as	   quickly	   as	   possible.	   Individuals	  with	   no	   prior	   vaccination	   or	  with	   an	  
incomplete	  or	  uncertain	  vaccination	  history	  are	  offered	  five	  vaccine	  doses	  at	  0,	  1,	  3,	  7,	  14,	  and	  30	  days.	  
Individuals	   that	   have	   received	   a	   full	   primary	   course	   of	   a	   cell	   culture-­‐based	   vaccine	   are	   offered	   two	  
vaccine	  doses	  at	  0	  and	  3-­‐7	  days.	  Human	  rabies	  immunoglobulin	  (HRIG)	  is	  employed	  in	  selected	  cases,	  
and	  is	  usually	  given	  within	  7	  days	  post-­‐initiation	  of	  rabies	  vaccination	  in	  individuals	  who	  were	  not	  fully	  
vaccinated	  pre-­‐exposure.	  The	  entire	  HRIG	  dose	  (20	  IU/kg)	  is	  inﬁltrated,	  if	  anatomically	  possible,	  in	  and	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around	   the	   site	   of	   exposure,	   with	   any	   remaining	   solution	   administered	   intramuscularly	   at	   a	   site	  
different	  from	  that	  used	  for	  the	  vaccine.	  Reactions	  with	  HRIG	  include	  local	  pain	  and	  low-­‐grade	  fever,	  
but	   no	   serious	   adverse	   reactions	   have	   been	   reported.	   In	   developing	   countries,	   equine	   rabies	  
immunoglobulin	   (ERIG)	   is	  sometimes	  used,	  which	  has	  a	  higher	   incidence	  of	  adverse	  effects	  and	  may	  
vary	  in	  quality.	  	  
	  
In	  the	  US	  and	  Australia	  the	  full	  vaccine	  course	  for	  rabies-­‐PEP	  consists	  of	  four	  vaccine	  doses	  (at	  0,	  3,	  7,	  
and	   14	   days),	   with	   a	   fifth	   dose	   offered	   (day	   28)	   only	   in	   the	   case	   of	   immune	   impairment	   (through	  
disease	  or	  treatment)	  [12].	  
	  
6.	   Rabies	   vaccine	   in	  HIV-­‐positive	   adults:	  There	  are	   limited	  data	  on	   the	   immunogenicity	  and	  clinical	  
efﬁcacy	   of	   rabies	   vaccines	   for	   pre-­‐	   or	   post-­‐exposure	   prophylaxis	   in	   HIV-­‐positive	   patients.	   Available	  
evidence	  indicates	  that	  vaccine	  immunogenicity	  is	  influenced	  by	  the	  CD4	  cell	  count	  and	  viral	  load,	  with	  
low	  or	  absent	  antibody	  responses	  reported	  in	  some	  patients	  with	  CD4	  counts	  <200-­‐250	  cells/µL	  [13-­‐
17]	   or	   even	   with	   CD4	   counts	   >500	   cells/µL	   [9].	   Effective	   ART	   has	   been	   shown	   to	   restore	   antibody	  
responses	   to	   vaccination	   [18].	   Approximately	   88%	   of	   subjects	   with	   CD4	   counts	   >450	   cells/µL	  while	  
receiving	  stably	  suppressive	  ART	  (6	  months)	  develop	  a	  protective	  antibody	  response	  to	  three	  doses	  of	  
a	   cell	   culture-­‐based	   vaccine	   [19].	   The	   duration	   of	   responses	   is	   reduced	   relative	   to	   HIV-­‐negative	  
persons,	  and	   is	  affected	  by	  ART	  discontinuation	   [18,19].	  Higher	   (double)	  and	  more	   frequent	  vaccine	  
doses,	   and	   combined	   intradermal	   and	   subcutaneous	   vaccine	   administration	  have	  been	  proposed	   as	  
management	   options	   for	  HIV-­‐positive	   patients	  who	   fail	   to	  mount	   an	   acceptable	   antibody	   response,	  
but	   data	   are	   limited	   [12].	   Whether	   the	   intradermal	   route	   may	   be	   more	   effective	   at	   producing	   an	  
immune	   response	   in	  HIV-­‐positive	  patients	   than	   intramuscular	   vaccine	   remains	  unclear	   [20].	   Current	  
opinion	   is	   that	  caution	   is	  needed	   in	  assessing	  HIV-­‐positive	  patients	  after	  a	  potential	   rabies	  exposure	  
even	  when	   immunocompromise	   is	   thought	   to	   be	  mild	   [12].	   In	   the	   few	   studies	   reported,	   rabies	   cell	  
culture-­‐based	  vaccines	  were	  well	   tolerated	   in	  HIV-­‐positive	  persons	   [12-­‐17],	   including	  when	  vaccines	  
were	  used	  at	  double	  the	  standard	  dose	  [12].	  	  
	  
7.	  Recommendations	  for	  HIV-­‐positive	  adults	  	  
	  
Pre-­‐exposure	  prophylaxis	  for	  travellers	  
• We	   recommend	   that	   HIV-­‐positive	   adults	  who	   are	   at	   risk	   of	   rabies	   exposure	   through	   travel	   be	  
counselled	   about	   pre-­‐exposure	   prophylaxis	   and	   offered	   vaccination	  with	   a	   cell	   culture-­‐derived	  
vaccine	  as	  indicated	  [1B]	  
o We	  recommend	  3	  vaccine	  doses	  be	  given	  intramuscularly	  on	  days	  0,	  7,	  and	  28.	  Advancing	  the	  
third	  dose	  to	  day	  21	  is	  not	  recommended	  because	  it	  may	  curtail	  the	  immune	  response	  [1B]	  
o We	  recommend	  that	  patients	  be	  counselled	  about	  the	  risk	  of	  poor	  vaccine	  immunogenicity,	  
which	  is	  reduced	  although	  not	  abolished	  in	  patients	  with	  CD4	  cell	  counts	  >500	  cells/µL	  who	  
are	  receiving	  stably	  suppressive	  ART	  [1B]	  
o We	  recommend	  that	  patients	  at	  increased	  risk	  of	  vaccine	  failure	  (based	  upon	  CD4	  count,	  ART	  
use,	  and	  viral	  load)	  undergo	  rabies	  serology	  testing	  2-­‐4	  weeks	  after	  the	  last	  vaccine	  dose,	  and	  
if	  the	  antibody	  response	  is	  <0.5	  IU/mL	  be	  offered	  a	  booster	  vaccine	  dose,	  followed	  by	  repeat	  
serology	  testing	  [1C].	  We	  suggest	  that	  the	  booster	  may	  be	  given	  at	  double	  the	  standard	  dose	  
to	  increase	  immunogenicity	  [2C]	  
• We	  recommend	  that	  if	  the	  risk	  of	  travel-­‐related	  exposure	  recurs,	  a	  ﬁrst	  booster	  be	  offered	  1	  year	  
after	   completion	   of	   the	   primary	   vaccine	   course,	   and	   subsequent	   boosters	   be	   given	   every	   3-­‐5	  
years	  or	  based	  on	  the	  results	  of	  serology	  testing	  where	  indicated	  [1C]	  
• We	  recommend	   travellers	  be	  advised	   that	   vaccination	  does	  not	  eliminate	   the	  need	   for	  wound	  
management	  and	  post-­‐exposure	  vaccination	  [GPP]	  
	  
Pre-­‐exposure	  prophylaxis	  for	  those	  at	  continuous	  or	  frequent	  exposure	  in	  the	  occupational	  setting	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• We	   recommend	   that	   HIV-­‐positive	   adults	   with	   CD4	   counts	   >200	   cells/µL	   and	   stable	   viral	   load	  
suppression	  on	  ART	  be	   offered	  pre-­‐exposure	   rabies	   vaccination	  with	   3	   doses	   of	   a	   cell	   culture-­‐
derived	   vaccine	   given	   intramuscularly	   at	   0,	   7,	   and	   28	   days	   [1C].	   We	   recommend	   that	   such	  
patients	   undergo	   rabies	   serology	   testing	   2-­‐4	   weeks	   after	   the	   last	   vaccine	   dose,	   and	   if	   the	  
antibody	  response	  is	  <0.5	  IU/mL	  be	  offered	  a	  booster	  vaccine	  dose,	  followed	  by	  repeat	  serology	  
testing	  [1B].	  We	  suggest	  that	  the	  booster	  may	  be	  given	  at	  double	  the	  standard	  dose	  to	  increase	  
immunogenicity	   [2C].	   Exposure	   must	   be	   avoided	   in	   those	   who	   fail	   to	   mount	   an	   acceptable	  
antibody	  response	  after	  the	  booster	  dose	  [GPP]	  	  
• We	  recommend	  that	   in	  patients	  at	  continuous	  risk	  of	  exposure	  who	  have	  an	  initial	  response	  to	  
vaccination,	  subsequent	  booster	  doses	  are	  guided	  by	  serology	  testing	  performed	  every	  6	  months	  
as	  per	  national	  guidance	  [1C]	  
• We	   recommend	   that	   in	   patients	   at	   frequent	   risk	   exposure	   who	   have	   an	   initial	   response	   to	  
vaccination,	   subsequent	   booster	   doses	   be	   guided	   by	   serology	   testing	   performed	   at	   regular	  
intervals	  [1C].	  We	  recommend	  that	   in	  such	  patients	  the	  frequency	  of	  serology	  testing	  may	  vary	  
between	  1	  and	  3	  years,	  and	  be	  guided	  by	  the	  CD4	  cell	  count,	  ART	  use,	  and	  viral	  load	  at	  the	  time	  
of	  vaccination	  and	  during	  follow-­‐up	  [1C]	  
• We	   recommend	   that	   patients	   with	   CD4	   counts	   <200	   cells/µL	   avoid	   continuous	   or	   frequent	  
exposure	  to	  rabies	  [1C]	  
	  
Post-­‐exposure	  prophylaxis	  	  
• We	  recommend	  that	  each	  case	  be	  assessed	  individually	  following	  expert	  advice,	  because	  responses	  
to	  rabies	  vaccination	  may	  be	  reduced	  even	  in	  patients	  with	  mild	  immunodeficiency	  [1B]	  
• We	  recommend	  that	  the	  following	  patients	  are	  regarded	  as	  non-­‐immune	  and	  offered	  5	  doses	  of	  a	  
cell	  culture-­‐derived	  vaccine	  given	  intramuscularly	  at	  0,	  1,	  3,	  7,	  14,	  and	  30	  days,	  together	  with	  HRIG	  
[1C]:	  	  
o Previously	  unvaccinated	  	  
o Previously	  given	  partial	  vaccination	  (<3	  doses)	  
o Previously	  given	  complete	  vaccination	  (3	  doses)	  not	  followed	  by	  serological	  evidence	  
of	  an	  adequate	  antibody	  response	  
o Uncertain	  vaccination	  history	  
o CD4	  count	  <500	  cells/µL	  and	  not	  receiving	  stably	  suppressive	  ART	  	  
• We	  suggest	  that	  patients	  who	  previously	  received	  a	  complete	  vaccine	  course	  (3	  doses)	  followed	  by	  
serological	   evidence	   of	   an	   adequate	   antibody	   response,	   and	  with	   a	   CD4	   count	   >500	   cells/µL	   and	  
stable	  viral	  load	  suppression	  (>6	  months)	  on	  ART	  at	  the	  time	  of	  vaccination	  and	  during	  subsequent	  
follow-­‐up	  may	  be	  managed	  with	  2	  intramuscular	  vaccine	  doses	  given	  at	  0	  and	  3-­‐7	  days	  and	  without	  
HRIG	  [2D]	  
• We	   recommend	   that	   all	   patients	  undergo	   serology	   testing	  2	  weeks	   after	   the	   last	   vaccine	  dose	   to	  
determine	  responses	  to	  vaccination	  and	  that	  non-­‐responders	  are	  offered	  double-­‐dose	  and/or	  more	  
frequent	   vaccine	   doses	   accordingly	   [1C],	   and	   are	   considered	   for	   combined	   intradermal	   and	  
subcutaneous	  double-­‐dose	  vaccine	  administration	  [1D]	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1.	  Infection	  and	  disease:	  Variola	  virus,	  a	  member	  of	  the	  orthopoxviridae	  family,	  causes	  smallpox.	  The	  
infection	   is	   spread	   through	   droplets	   and	   aerosol	   and	   the	   most	   common	   mode	   of	   transmission	   is	  
through	   face-­‐to-­‐face	   contact	  with	   an	   infectious	   individual	   [1].	   The	   fatality	   rate	   is	   ~25%	  overall,	   and	  
severe	   complications	   such	   as	   blindness	   can	   occur.	   Following	   a	   worldwide	   vaccination	   campaign,	  
smallpox	  was	  declared	  eradicated	  from	  the	  world	   in	  1980	  and	  routine	  vaccination	  was	  stopped.	  The	  
last	   naturally	   occurring	   case	   in	   the	   world	   was	   in	   Somalia	   in	   1977.	   Vaccine	   programmes	   were	   later	  
restarted	   in	   several	   countries	   (e.g.,	   in	   the	   military	   or	   health	   care	   workers)	   in	   response	   to	   a	  
hypothetical	  threat	  from	  bioterrorism	  [1-­‐3].	  In	  the	  UK,	  people	  who	  were	  vaccinated	  against	  smallpox	  
prior	  to	  national	  programmes	  being	  discontinued	  (i.e.,	  most	  people	  born	  before	  1971)	  will	  have	  some	  
level	  of	  protection	   [4,5];	   the	  vaccine	   is	  currently	  available	   for	  selected	   individuals	  who	  may	  come	   in	  
contact	  with	  orthopox	  viruses	  through	  their	  occupation	  (e.g.,	  laboratory	  workers).	  Some	  governments	  
have	  stockpiled	  smallpox	  vaccines	  for	  deployment	  in	  case	  of	  intentional	  or	  accidental	  release	  [2,3].	  
	  
2.	  Smallpox	  vaccine:	  Replicating	  smallpox	  vaccines	  such	  as	  ACAM2000	  are	  prepared	  with	  live	  vaccinia	  
virus,	  which	  is	  closely	  related	  to	  the	  smallpox	  virus,	  and	  administered	  percutaneously	  via	  scarification	  
in	  the	  skin	  of	  the	  upper	  arm	  [2,3].	  Virus	  replication	  at	  the	  injection	  site	  produces	  a	  major	  cutaneous	  
reaction	  or	  "take",	  which	  indicates	  a	  successful	  immune	  response.	  Primary	  vaccination	  is	  administered	  
in	   a	   single	   dose;	   a	   booster	   dose	   is	   recommended	   after	   three	   years.	   People	  who	  have	   received	   two	  
doses	   are	   likely	   to	   be	   protected	   for	   at	   least	   10	   years.	   A	   non-­‐replicating	   vaccine	   based	   on	  Modified	  
Vaccinia	  Ankara	  (Imvanex)	  was	  approved	  in	  2013	  for	  use	  in	  adults,	  including	  HIV-­‐positive	  patients	  [6].	  
The	  approval	  was	   granted	  under	   'exceptional	   circumstances'	   due	   to	   lack	  of	   clinical	   data.	   Imvanex	   is	  
derived	   from	  a	  vaccinia	  virus	   strain	   that	  was	  attenuated	   through	  multiple	  passages	   in	   tissue	  culture	  
and	   lost	   the	  ability	   to	   replicate	   in	  mammalian	  cells.	   The	  primary	  course	   for	  previously	  unvaccinated	  
individuals	  consists	  of	  two	  doses	  given	  by	  subcutaneous	  administration	  at	  least	  one	  month	  apart.	  Two	  
doses	  are	  also	  recommended	  for	  previously	  vaccinated	  patients	  who	  are	  immunocompromised.	  There	  
are	   inadequate	   data	   to	   determine	   the	   need	   for	   and	   appropriate	   timing	   of	   further	   booster	   doses.	  
Imvanex	  does	  not	  produce	  a	  visible	  cutaneous	  reaction	  following	  administration.	   In	  healthy	  persons,	  
smallpox	  vaccines	  are	  highly	  effective	  in	  inducing	  protective	  immunity	  [2,3,6].	  The	  protective	  efficacy	  
of	  Imvanex	  against	  smallpox	  has	  not	  been	  studied	  [6].	  	  
	  
3.	  Vaccine	  safety:	  Replicating	  smallpox	  vaccines	  have	  been	  associated	  with	  side	  effects	  ranging	  from	  
frequent	   benign	   events	   to	   rare	   but	   life-­‐threatening	   complications.	   Among	   vaccine	   recipients,	   36%	  
become	  sufficiently	  ill	  to	  miss	  work,	  school,	  or	  recreational	  activities	  or	  to	  have	  trouble	  sleeping	  [2].	  In	  
a	  smallpox	  vaccination	  campaign	  conducted	   in	  health	  care	  workers	   in	  Arkansas	   in	  2003,	  there	  was	  a	  
2%	  adverse	  event	  rate	  and	  a	  0.5%	  hospitalization	  rate	  [7].	  Myopericarditis	  is	  a	  recognised	  complication	  
[8].	   It	   is	   reported	   to	   occur	   in	   5.7	   of	   1000	   primary	   vaccine	   recipients;	  most	   cases	   are	  mild	   and	   self-­‐
limited	   with	   few	   documented	   reports	   of	   dilated	   cardiomyopathy	   [3].	   Other	   serious	   adverse	   events	  
include	   encephalitis,	   encephalomyelitis,	   encephalopathy,	   progressive	   vaccinia,	   generalized	   vaccinia,	  
severe	   vaccinial	   skin	   infections,	   erythema	  multiforme	  major	   (including	   Stevens-­‐Johnson	   syndrome),	  
and	  eczema	  vaccinatum	  (severe	  and	  destructive	  infection	  of	  skin	  affected	  by	  eczema	  or	  other	  chronic	  
skin	  disorder	  caused	  by	  spread	  of	  vaccinia	  virus).	  Permanent	  sequelae	  or	  death,	  ocular	  complications,	  
blindness,	  and	  foetal	  death	  have	  occurred	  following	  either	  primary	  vaccination	  or	  revaccination	  with	  
replicating	   smallpox	   vaccines	   [3].	   Inadvertent	   transfer	   from	   the	   site	   of	   inoculation	   causes	   swelling,	  
tenderness	  and	  rash	  at	  the	  site	  of	  transfer,	  and	  may	  result	  in	  vaccinia	  keratitis	  and	  subsequent	  corneal	  
scarring.	  Progressive	  vaccinia	   is	  characterized	  by	  a	  slow	  and	  uncontrolled	  growth	  of	  vaccinia	  virus	  at	  
the	  site	  of	  inoculation,	  frequently	  complicated	  by	  viraemia	  and	  generalized	  infection	  involving	  skin	  and	  
multiple	  organs,	  with	  a	  40-­‐80%	  risk	  of	  mortality;	  it	  usually	  occurs	  in	  the	  presence	  of	  immunodeficiency.	  
Death	  is	  most	  often	  the	  result	  of	  encephalitis	  or	  progressive	  vaccinia.	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A	  vaccinated	  person	  can	  transmit	  the	  vaccine	  virus	  directly	  through	  contact	  with	  the	  injection	  site	  and	  
indirectly	   through	  objects	   that	   come	   in	   contact	  with	   the	  area	  around	   the	  vaccination	   site,	   including	  
clothes,	  bedding,	  bandages	  and	  furniture.	  Infectivity	  lasts	  until	  the	  vaccination	  wound	  has	  healed	  and	  
the	  scab	  has	  fallen	  off,	  usually	  within	  14-­‐21	  days.	  	  
	  
Contraindications	  to	  replicating	  smallpox	  vaccines	  include:	  	  
• Pregnancy	   and	   breast-­‐feeding.	   The	   overall	   risk	   associated	   with	   maternal	  smallpox	  vaccination	  
appears	  low.	  Foetal	  vaccinia	  is	  a	  rare	  consequence	  but	  is	  associated	  with	  a	  high	  rate	  of	  foetal	  loss	  
[9]	  
• Current	  or	  past	  eczema	  and	  atopic	  dermatitis,	  or	  a	  current	  signiﬁcant	  skin	  condition	  
• Heart	  disease,	  or	  ≥3	  known	  major	  cardiac	  risk	  factors	  
• Immunodeﬁciency	  caused	  by	  disease	  or	  treatment	  (including	  HIV	  infection)	  
• The	  vaccines	  are	  generally	  not	  recommended	  for	  those	  >65	  years	  of	  age	  
	  
Imvanex	   appears	   to	   be	   safe	   and	  well	   tolerated	   and	   does	   not	   increase	   the	   risk	   for	   development	   of	  
myopericarditis	   [3,10].	  The	  most	  common	  adverse	  reactions	  observed	   in	  clinical	  trials	  were	   injection	  
site	   reactions	   and	   mild	   to	   moderate	   systemic	   reactions	   that	   resolved	   without	   intervention	   within	  
seven	   days	   following	   vaccination.	   Imvanex	   is	   preferable	   for	   individuals	   at	   increased	   risk	   of	   adverse	  
events	  with	  replicating	  smallpox	  vaccines	  in	  circumstances	  when	  the	  risk	  for	  smallpox	  is	  minimal	  and	  a	  
delay	  in	  the	  onset	  of	  immunity	  (relative	  to	  using	  the	  replicating	  vaccine)	  would	  not	  increase	  this	  risk	  to	  
an	   unacceptable	   level	   [3].	   As	   a	   precautionary	   measure,	   use	   is	   avoided	   during	   pregnancy	   and	  
breastfeeding	  unless	  it	  is	  considered	  that	  the	  possible	  benefit	  in	  terms	  of	  preventing	  smallpox	  would	  
outweigh	  the	  potential	  risk.	  	  
	  
4.	  Smallpox	  vaccine	  in	  HIV-­‐positive	  adults:	  Although	  the	  safety	  of	  the	  replicating	  vaccine	  ACAM2000	  
has	  not	  been	  studied	  in	  persons	  with	  HIV	  infection,	  HIV-­‐positive	  persons	  with	  low	  CD4	  cell	  counts	  are	  
at	  risk	  of	  progressive	  vaccinia	  when	  vaccinated	  with	  replicating	  smallpox	  vaccines	  [11-­‐13].	  In	  a	  study	  of	  
10	  military	  recruits	  with	  a	  mean	  CD4	  count	  of	  483	  cells/µL	  (range	  286-­‐751)	  the	  replicating	  vaccine	  was	  
well	   tolerated	  and	   immunogenic	   [13];	  however,	   there	   is	  one	  case	  report	  of	  progressive	  vaccinia	   in	  a	  
HIV-­‐positive	  military	  recruit	  who	  received	  smallpox	  vaccination	  in	  1984	  with	  a	  CD4	  count	  <25	  cells/µL	  
[12].	   The	   non-­‐replicating	   vaccine	   Imvanex	   was	   well	   tolerated	   and	   highly	   immunogenic	   in	   91	   HIV-­‐
positive	  patients	  with	  CD4	  counts	  ≥350	  cells/µL	  and	  viral	  load	  <400	  copies/mL,	  with	  no	  vaccine-­‐related	  
serious	  adverse	  events	  and	  an	  overall	   safety	  profile	   comparable	   to	   that	  of	  uninfected	   subjects	   [14].	  
LC16m8,	  a	  replicating	  smallpox	  vaccine	   licensed	   in	   Japan,	  shows	  reduced	  virulence	   in	  animal	  studies	  
and	   has	   been	   proposed	   as	   a	   potential	   option	   for	   immunocompromised	   patients	   [15].	   This	   remains	  
controversial	   however	   as	   clinical	   data	   are	   lacking	   [16].	   In	   2014,	   the	   World	   Health	   Organisation	  
specifically	   indicated	   that	   Imvanex	   should	  be	  considered	   for	  use,	  where	  approved,	   in	   individuals	   for	  
whom	  replicating	  smallpox	  vaccines	  are	  contraindicated	  due	  to	  immunocompromise	  [17].	  	  
	  
In	   the	   past,	   high	   doses	   of	   intravenous	   vaccinia	   immunoglobulin	   (VIGIV)	   derived	   from	   immunized	  
individuals	   appeared	   to	   be	   effective	   in	   halting	   a	   proportion	   of	   cases	   of	   progressive	   vaccinia.	   The	  
experience	  with	  VIGIV	  for	  the	  treatment	  of	  progressive	  vaccinia	  in	  persons	  with	  AIDS	  is	  limited	  to	  one	  
reported	   case	   [12].	   Antiviral	   drugs	   such	   as	   cidofovir	   (or	   others	   in	   advanced	   stages	   of	   development	  
such	   as	   liposomal	   cidofovir,	   tecovirimat	   or	   brincidofovir)	   are	   recommended	   for	   the	   treatment	   of	  
complications	  [3],	  although	  clinical	  data	  are	  scarce.	  	  
	  
5.	   Post-­‐exposure	  prophylaxis:	  Persons	  exposed	  to	  smallpox	  are	  at	  high	  risk	   for	  developing	  smallpox	  
and	  transmitting	  the	  virus	  to	  others.	  Vaccination	  with	  replicating	  smallpox	  vaccines	  given	  within	  three	  
days	   of	   exposure	   prevents	   disease	   or	   reduces	   its	   severity;	   partial	   protection	   is	   observed	   if	   post-­‐
exposure	  prophylaxis	  is	  started	  after	  4-­‐7	  days	  of	  exposure.	  There	  are	  no	  absolute	  contraindications	  to	  
the	   use	   of	   replicating	   smallpox	   vaccines	   in	   this	   setting	   [3].	   Whilst	   persons	   with	   atopic	   dermatitis	  
(eczema),	  HIV	   infection	  with	  CD4	  counts	  of	  50-­‐199	   cells/µL,	  other	   immunocompromised	   states,	   and	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persons	  with	  vaccine	  or	  vaccine-­‐component	  allergies	  are	  at	  higher	  risk	  for	  adverse	  events,	  replicating	  
vaccines	   still	   are	   recommended	   in	   these	   groups	   as	   the	   risk	   of	   severe	   smallpox	   is	   considered	   higher	  
than	  the	  risk	  of	  vaccine-­‐related	  adverse	  events	  [3].	  Although	  persons	  vaccinated	  with	  Imvanex	  have	  a	  
lower	   risk	   for	  serious	  adverse	  events,	  protection	   is	   less	  certain	  also	  considering	   the	  requirement	   for	  
two	   doses	   given	   at	   least	   one	   month	   apart.	   Persons	   with	   severe	   immunodeficiency,	   including	   HIV-­‐
positive	  patients	  with	  CD4	  cell	  counts	  <50	  cells/µL,	  are	  not	  expected	  to	  benefit	  from	  vaccination	  and	  
can	  be	  managed	  with	  appropriate	  antivirals,	  or	  Imvanex	  when	  antivirals	  are	  not	  immediately	  available	  
[3].	  	  
	  
6.	  Recommendations	  for	  HIV-­‐positive	  adults	  	  
• We	   recommend	   that	   all	   vaccine	   candidates	   are	   informed	   that	   smallpox	   vaccines	  might	   pose	   a	  
serious	  risk	  to	  people	  with	  HIV	   infection,	  and	  that	  HIV	  testing	   is	  offered	  prior	  to	  vaccination	  to	  
those	  who	  wish	  to	  be	  tested	  [1B]	  
• We	  recommend	  that	  for	  vaccine	  candidates	  that	  are	  HIV-­‐positive,	  an	  assessment	  is	  made	  of	  the	  
risk	  of	  contracting	  smallpox	  vs.	  the	  risk	  of	  vaccine-­‐related	  side	  effects,	  using	  the	  CD4	  cell	  count	  as	  
a	  guide	  to	  inform	  vaccine	  use	  [1B]	  
• We	  recommend	  that	  in	  cases	  where	  vaccination	  is	  indicated	  but	  there	  is	  no	  urgency	  to	  induce	  a	  
rapid	   immune	  response	  (e.g.,	  most	  occupational	  settings)	  HIV-­‐positive	  adults	  regardless	  of	  CD4	  
cells	   counts	   receive	   the	   non-­‐replicating	   smallpox	   vaccine	   Imvanex,	   with	   2	   doses	   given	  
subcutaneously	  at	  least	  1	  month	  apart	  [1B]	  
• We	  recommended	  that	   in	  selected	  scenarios	  where	  there	   is	  urgency	  to	   induce	  a	  rapid	   immune	  
response,	  patients	  with	  CD4	  counts	  ≥200	  cells/µL	  may	  be	  offered	  a	  replicating	  smallpox	  vaccine	  
followed	  by	  close	  monitoring	  for	  adverse	  events	  [1C]	  
• We	   recommend	   that	   following	   exposure,	   patients	   with	   CD4	   counts	   >50	   cells/µL	   are	   offered	  
vaccination	  with	  a	  replicating	  smallpox	  vaccine	  given	  preferably	  within	  3	  days	  and	  up	  to	  10	  days	  
after	  the	  exposure	  [1C].	  We	  suggest	  that	  in	  similar	  circumstances	  patients	  with	  CD4	  counts	  <50	  
cells/µL	  are	  unlikely	  to	  respond	  to	  vaccination	  and	  should	  be	  managed	  by	  appropriate	  antiviral	  
therapy,	   although	   there	   is	   no	   absolute	   contraindication	   to	   Imvanex	   vaccination	   [2C].	   Expert	  
opinion	  should	  be	  sought	  
• We	  recommended	  that	  vaccine	  recipients	  who	  experience	  vaccine	  complications	  should	  receive	  
VIGIV	  and/or	  appropriate	  antiviral	   therapy	  according	   to	  availability	   [1C].	  Expert	  opinion	   should	  
be	  sought	  
• We	   recommend	   that	   HIV-­‐positive	   persons	   avoid	   close	   contact	   with	   recipients	   of	   replicating	  
smallpox	  vaccines	  as	   they	  may	  spread	  the	  vaccine	  virus	   through	  direct	  or	   indirect	  contact	  with	  
the	  vaccine	  reaction	  site	  [1C]	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1.	  Infection	  and	  disease:	  Tetanus	  is	  caused	  by	  the	  action	  of	  a	  neurotoxin	  (tetanospasmin)	  released	  by	  
the	   gram-­‐positive,	   anaerobic	   bacterium	   Clostridium	   tetani	   [1,2].	   The	   bacterium	   and	   its	   spores	   are	  
found	   primarily	   in	   the	   soil	   and	   intestinal	   tracts	   of	   animals	   and	   humans.	   Transmission	   occurs	   when	  
spores	  are	  introduced	  into	  the	  body,	  typically	  through	  puncture	  wounds,	  burns	  and	  scratches,	  but	  also	  
through	   trivial,	   unnoticed	   wounds,	   injecting	   drug	   use	   and	   occasionally	   abdominal	   surgery.	   Tetanus	  
spores	  are	  widely	  distributed	  in	  soil	  or	  manure	  and	  may	  be	  introduced	  to	  a	  wound	  easily	  following	  an	  
injury.	   The	   spores	   can	   also	   be	   found	   on	   skin	   surfaces	   and	   in	   contaminated	   heroin	   and	   drug	  
paraphernalia.	   In	   the	   presence	   of	   anaerobic	   conditions,	   the	   spores	   germinate	   and	   the	   toxins	   are	  
produced	  and	  released	  systemically.	  Tetanus	  is	  not	  contagious	  from	  person	  to	  person.	  Tetanus-­‐prone	  
wounds	  or	  burns	  include	  those	  that	  require	  surgical	  intervention	  and	  when	  that	  treatment	  is	  delayed	  
for	   more	   than	   6	   hours;	   show	   a	   significant	   degree	   of	   devitalized	   tissue;	   are	   puncture-­‐type	   injury	  
particularly	  in	  contact	  with	  soil	  or	  manure;	  contain	  foreign	  bodies;	  are	  compound	  fractures;	  or	  occur	  in	  
patients	   who	   have	   systemic	   sepsis.	   In	   its	   most	   common	  manifestation,	   tetanus	   is	   characterized	   by	  
generalized	  rigidity	  and	  spasms	  of	  skeletal	  muscles	  and	  can	  lead	  to	  respiratory	  and	  cardiac	  failure.	  The	  
case	  fatality	  ratio	  is	  29%	  overall,	  but	  ranges	  from	  8%	  to	  90%.	  Recovery	  from	  tetanus	  may	  not	  result	  in	  
immunity,	  and	  vaccination	  following	  tetanus	  is	  indicated.	  
	  
2.	  Epidemiology:	  Tetanus	  occurs	  worldwide	  but	  is	  most	  common	  in	  densely	  populated	  regions	  in	  hot,	  
damp	  climates	  with	  soil	  rich	  in	  organic	  matter.	  Tetanus	  has	  occurred	  only	  rarely	  among	  persons	  who	  
had	  previously	  received	  a	  primary	  vaccine	  course.	  The	  proportions	  of	  persons	  lacking	  protective	  levels	  
of	  circulating	  antitoxins	  against	  tetanus	  increase	  with	  age;	  at	  least	  40%	  of	  those	  aged	  >60	  years	  may	  
lack	   protection.	   Between	   2001	   and	   2012,	   88	   cases	   of	   tetanus	   were	   reported	   in	   the	   UK,	   mostly	   in	  
individuals	  aged	  ≥45	  years	  who	  had	  not	  been	  appropriately	  immunised	  [2].	  In	  2003-­‐2004	  a	  first	  cluster	  
of	   cases	   of	   tetanus	   occurring	   in	   young	   injecting	   drug	   users	   (IDUs)	  was	   identified	   (case	   fatality	   8%).	  
Following	  this	  cluster,	  only	  sporadic	  cases	  of	  tetanus	  were	  reported	  in	  IDUs	  in	  England	  to	  the	  end	  of	  
2014	  [2,3].	  	  
	  
3.	  Tetanus	  in	  HIV-­‐positive	  adults:	  In	  a	  US	  cohort	  of	  HIV-­‐positive	  patients,	  94%	  of	  those	  born	  in	  the	  US	  
had	   evidence	   of	   tetanus	   immunity	   at	   the	   time	   of	   HIV	   diagnosis,	   whereas	   only	   55%	   of	   those	   born	  
outside	  of	  the	  US	  had	  a	  positive	  tetanus	  antibody	  test	  [4].	  It	  is	  not	  known	  whether	  the	  natural	  history	  
of	  tetanus	  is	  modified	  by	  HIV	  infection.	  
	  
4.	   Tetanus	   vaccine:	   The	   tetanus	   vaccine	   is	  non-­‐replicating	  and	   is	  made	   from	  cell-­‐free	  purified	   toxin	  
extracted	   from	   C.	   tetani	   and	   converted	   into	   tetanus	   toxoid.	   The	   vaccine	   is	   given	   to	   adults	   in	  
combination	   with	   diphtheria	   toxoid	   and	   inactivated	   polio	   vaccine	   (Td/IPV).	   The	   vaccine	   is	   given	   by	  
parenteral	   administration.	   The	   tetanus	   vaccine	   is	   highly	   immunogenic	   and	   effective.	   Although	  
antitoxin	   levels	   decrease	   with	   age,	   the	   majority	   of	   vaccinated	   adults	   maintain	   protective	   antitoxin	  
levels	   for	   many	   years.	   A	   total	   of	   five	   vaccine	   doses	   at	   the	   appropriate	   intervals	   (as	   per	   the	   UK	  
childhood	   vaccination	   schedule)	   are	   considered	   to	   give	   lifelong	   immunity,	   with	   reinforcing	   doses	  
recommended	  every	  10	  years	   for	   those	  at	  risk.	  The	  vaccine	   is	  well	   tolerated.	   Injection	  site	  reactions	  
are	   common	   but	   usually	   self-­‐limited	   and	   may	   occur	   more	   frequently	   following	   subsequent	   doses.	  
Fever	  and	  other	  systemic	  reactions	  are	  uncommon.	  Severe	  systemic	  reactions	  are	  rare.	  	  
	  
General	  indications:	  The	  aim	  of	  the	  UK	  national	  vaccination	  programme	  is	  to	  ensure	  that	  all	  individuals	  
receive	   at	   least	   5	   vaccine	   doses.	   Td/IPV	   is	   recommended	   for	   vaccination	   of	   those	   aged	   ≥10	   years.	  
Adults	  who	  are	  either	  unvaccinated	  or	  have	  an	  uncertain	   vaccination	  history	  are	   advised	   to	   receive	  
primary	  immunization	  with	  3	  vaccine	  doses	  at	  either	  monthly	  intervals	  or	  at	  0,	  1-­‐2	  months,	  and	  6-­‐12	  
months.	  Two	  further	  doses	  are	  scheduled	  5	  and	  10	  years	  after	  the	  last	  dose.	  Adults	  who	  have	  received	  
partial	  vaccination	  are	  advised	  to	  receive	  the	  remaining	  doses,	  regardless	  of	  the	  interval	  since	  the	  last	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dose	   and	   type	   of	   vaccine	   previously	   received.	   It	   is	   also	   recommended	   that	   travels	   to	   areas	   where	  
access	  to	  post-­‐exposure	  prophylaxis	  may	  be	  limited	  ensure	  they	  are	  fully	  vaccinated.	  	  
	  
5.	  Tetanus	  vaccine	  in	  HIV-­‐positive	  adults:	  The	  vaccine	  has	  been	  shown	  to	  be	  immunogenic	  in	  a	  variety	  
of	   immunocompromised	   hosts	   including	   HIV-­‐positive	   adults,	   although	   less	   so	   than	   in	   HIV-­‐negative	  
persons	   [5-­‐10].	   In	   HIV-­‐positive	   children,	   serological	   response	   rates	   are	   60-­‐100%	   after	   primary	  
vaccination	   and	   75-­‐90%	   after	   booster	   vaccination	   [10].	   Children	   show	   lower	   serum	   antitoxin	   levels	  
compared	  to	  controls,	  and	  antibody	  levels	  deteriorate	  such	  that	  non-­‐immune	  levels	  may	  be	  reached	  in	  
less	  than	  five	  years	   [11].	  Adults	  who	  received	  full	  primary	  vaccination	  before	  acquiring	  HIV	   infection	  
may	  have	  sufficient	  humoral	  immunity	  for	  several	  years	  and	  are	  likely	  to	  develop	  protective	  levels	  of	  
antitoxin	   following	   a	   booster	   dose.	  However,	   this	   response	   is	   lower	   in	   patients	   aged	  >50	   years	   and	  
those	  with	  a	  history	  of	  AIDS	  [12].	  As	  a	  general	  rule,	  responses	  are	  inversely	  correlated	  to	  the	  CD4	  cell	  
count	   and	   immunity	   improves	   after	   successful	  ART	   [13].	   There	   is	   no	   reported	   increased	   risk	  of	   side	  
effects	  or	  adverse	  reactions	  in	  individuals	  with	  HIV	  infection.	  
	  
6.	  Post-­‐exposure	  prophylaxis:	  Tetanus	  vaccine	  and	  human	  tetanus	  Immunoglobulin	  (TIG)	  are	  used	  for	  
post-­‐exposure	   prophylaxis	   in	   cases	   of	   potential	   exposure,	   and	   used	   according	   to	   the	   vaccination	  
history	   and	   type	   of	   wound.	   Use	   of	   TIG	   is	   guided	   by	   recommendations	   set	   out	   in	   the	   Green	   Book	  
[www.gov.uk/government/uploads/system/uploads/attachment_data/file/148506/Green-­‐Book-­‐
Chapter-­‐30-­‐dh_103982.pdf].	  Efficacy	  in	  HIV-­‐positive	  persons	  has	  not	  been	  established.	  
	  
7.	  Recommendations	  for	  HIV-­‐positive	  adults	  
• We	   recommend	   that	  HIV-­‐positive	   adults	   that	   require	   vaccination	   against	   diphtheria,	   tetanus,	   or	  
polio	  be	  given	   the	  Td/IPV	  vaccine	   in	  accordance	  with	  general	   indications,	  and	   regardless	  of	  CD4	  
cell	  count,	  ART	  use,	  and	  viral	  load	  [1B]	  
o We	   recommend	   that	   individuals	   who	   are	   either	   unvaccinated	   or	   have	   an	   uncertain	  
vaccination	  history	  receive	  3	  vaccine	  doses	  at	  1	  month	  interval,	  followed	  by	  2	  reinforcing	  
doses	  after	  5	  and	  10	  years,	  whereas	  partially	  vaccinated	  individuals	  should	  complete	  the	  
5-­‐dose	  vaccine	  course	  [1B]	  
o We	  recommend	  that	  fully	  vaccinated	  individuals	  (5	  doses)	  receive	  a	  booster	  dose	  every	  10	  
years	  if	  at	  risk	  of	  exposure,	  typically	  if	  they	  are	  due	  to	  travel	  to	  areas	  where	  they	  may	  not	  
be	  able	  to	  receive	  post-­‐exposure	  prophylaxis	  in	  the	  event	  of	  a	  tetanus-­‐prone	  injury	  [1C]	  
o We	   suggest	   that	   the	   interval	   between	   booster	   doses	   may	   be	   shortened	   to	   5	   years	   in	  
patients	  older	  than	  50	  years	  [2C]	  
• We	  recommend	  that	  following	  a	  potential	  exposure,	  HIV-­‐positive	  contacts	  receive	  post-­‐exposure	  
prophylaxis	  according	  to	  the	  type	  of	  exposure,	  the	  vaccination	  history,	  and	  the	  CD4	  cell	  count	  [1C]	  
o Subjects	  with	  uncertain	  or	   incomplete	   (<3	  doses)	  vaccination	  history:	  3	  vaccine	  doses	  at	  
monthly	  intervals,	  regardless	  of	  type	  of	  wound	  and	  level	  of	  risk	  
o Subjects	  who	  have	  previously	  received	  ≥3	  vaccine	  doses	  with	  clean	  wound	  and	  negligible	  
risk:	  1	  vaccine	  dose	  if	  the	  last	  dose	  received	  was	  >10	  years	  previously	  	  
o Subjects	   who	   have	   previously	   received	  ≥3	   vaccine	   doses	   with	   tetanus-­‐prone	   wound:	   1	  
vaccine	  dose	   if	   the	   last	  dose	   received	  was	  >10	  years	  previously	  or	  with	  CD4	  count	  <200	  
cells/mL	  
o Subjects	   with	   high-­‐risk	   tetanus-­‐prone	   wounds	   should	   also	   receive	   TIG,	   and	   it	   is	  
recommended	   that	   a	   careful	   assessment	   is	   made	   of	   the	   likely	   immunogenicity	   of	  
vaccination	  as	   the	  sole	  mechanism	  of	  protection	   in	  patients	  with	  poor	   immune	   function	  
and	  a	  significant	  risk	  of	  exposure	  [1B]	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1.	  Infection	  and	  disease:	  Tick-­‐borne	  encephalitis	  (TBE)	  is	  an	  acute	  febrile	  syndrome	  that	  can	  become	  
complicated	  with	  neurological	  symptoms	  ranging	  from	  mild	  meningitis	  to	  severe	  encephalomyelitis	  [1].	  	  
It	  is	  caused	  by	  the	  tick-­‐borne	  encephalitis	  virus	  (TBEV),	  which	  is	  a	  flavivirus.	  TBEV	  can	  be	  divided	  into	  
three	  main	  subtypes:	  European	  (TBEV-­‐Eu),	  Siberian	  (TBEV-­‐Sib),	  and	  Far	  Eastern	  (TBEV-­‐Fe).	  Other	  types	  
also	   circulate	   [2].	   The	   infection	   is	   transmitted	   to	   humans	   by	   the	   bite	   of	   an	   infected	   tick	   or,	   less	  
commonly,	  by	  ingestion	  of	  unpasteurized	  milk	  from	  infected	  animals,	  mainly	  goats.	  Person-­‐to-­‐person	  
transmission	   has	   not	   been	   reported.	   Only	   about	   one	   third	   of	   those	   with	   symptomatic	   infection	  
develop	  neurological	  complications,	  which	  may	  lead	  to	  death	  (1-­‐2%	  or	  higher	  with	  certain	  subtypes)	  or	  
sequelae	  (10-­‐20%).	  	  
	  
2.	  Epidemiology:	  TBE	  is	  an	  emerging	  international	  public	  health	  problem	  [3].	  TBE	  is	  the	  most	  common	  
tick-­‐transmitted	   disease	   in	   Central	   and	   Eastern	   Europe	   and	   Russia,	   and	   is	   endemic	   in	   27	   European	  
countries.	   Infections	  also	  occur	   in	   the	   former	  Soviet	  Union	  and	  Asia	   [2].	   In	   the	  UK,	   Ireland,	  Belgium,	  
the	   Netherlands,	   Luxembourg,	   Spain,	   Portugal	   and	   Malta	   no	   autochthonous	   TBE	   cases	   have	   been	  
registered	   to	   date.	   Climate,	   social,	   economic,	   and	   demographic	   changes	   are	   thought	   to	   have	  
promoted	   the	  expansion	  of	   the	  endemic	   region	  of	   TBE	  viruses	   [3].	   There	  are	   two	   seasonal	  peaks	   in	  
Europe,	   one	   in	   May/June	   and	   the	   second	   in	   September/October.	   Infections	   are	   related	   to	   either	  
leisure	  activities	  such	  as	  hiking,	  walking,	  and	  hunting,	  or	  working	  in	  agriculture	  and	  forestry	  in	  warm,	  
rural	  or	  forested	  parts	  of	  endemic	  regions.	  Vaccination	  remains	  the	  most	  effective	  protective	  measure	  
against	  TBE	  for	  people	  living	  in	  risk	  zones,	  occupationally	  exposed	  subjects,	  and	  travellers	  to	  endemic	  
areas	   [2,4-­‐6].	   The	   risk	   of	   infection	   among	   unvaccinated	   travellers	   to	   a	   highly	   endemic	   region	   is	  
calculated	  to	  be	  1/10,000	  [2].	  For	  countries	  at	  very	  high	  risk	  of	  TBE	  infection,	  introduction	  of	  universal	  
TBE	  vaccination	  in	  children	  >1	  year	  of	  age	  onwards	  has	  been	  advocated.	  For	  countries	  with	  a	  very	  low	  
risk	  of	  TBE,	  vaccine	  recommendations	  apply	  to	  those	  traveling	  to	  endemic	  areas	  [2,5,6].	  
	  
3.	   TBE	   in	  HIV-­‐positive	  adults:	   It	   is	  not	  known	  whether	  the	  natural	  history	  of	  TBE	   is	  modiﬁed	  by	  HIV	  
infection.	  	  
	  
4.	  TBE	  vaccine:	  Two	  non-­‐replicating	  whole	  killed	  vaccines	  are	  currently	  in	  use	  in	  Europe:	  FSME-­‐Immun	  
and	  Encepur,	  which	  are	  given	  by	  parenteral	  administration.	  Three	  doses	  are	  recommended,	  at	  0,	  1-­‐3,	  
and	  6-­‐12	  months	   [2].	  Accelerated	  schedules	  can	  be	   implemented	   in	  emergency	  situations	   (0	  and	  14	  
days,	  followed	  by	  a	  third	  dose	  5-­‐12	  months	  after	  the	  second).	  Booster	  doses	  are	  indicated	  every	  3-­‐5	  
years,	   although	   immunity	   is	   likely	   to	   last	   for	   longer	   [2].	   The	   two	   vaccines	   are	   interchangeable.	   TBE	  
vaccines	  are	  highly	  immunogenic	  in	  adults,	  with	  seroconversion	  rates	  close	  to	  100%	  after	  three	  doses,	  
and	   cross-­‐protection	   against	   different	   subtypes	   [2,4-­‐7].	   The	   rapid	   vaccination	   schedule	   has	   been	  
shown	   to	   elicit	   similar	   rates	   of	   seroconversion	   in	   healthy	   individuals	   and	   is	   practical	   for	   travellers;	  
antibody	  titres	  are	  lower	  and	  decline	  more	  rapidly	  than	  with	  the	  conventional	  schedule	  and	  therefore	  
the	  rapid	  schedule	  is	  best	  suited	  for	  short-­‐term	  travellers.	  The	  TBE	  vaccine	  is	  well	  tolerated.	  Injection	  
site	  reactions	  are	  the	  most	  frequent	  side	  effects.	  The	  vaccine	  however	  is	  contraindicated	  in	  those	  with	  
severe	   allergy	   to	   eggs.	   The	   vaccine	   has	   been	   suspected	   of	   causing	   an	   exacerbation	   of	   autoimmune	  
diseases,	   but	   a	   cause-­‐and-­‐effect	   relationship	   has	   not	   been	   conﬁrmed;	   a	   risk	   assessment	   should	   be	  
made	  before	  administering	  the	  vaccine	  in	  these	  conditions.	  	  
	  
5.	  TBE	  vaccine	  in	  HIV-­‐positive	  adults:	  Two	  published	  studies	  have	  investigated	  the	  immunogenicity	  of	  
TBE	   vaccination	   in	   HIV-­‐positive	   patients	   [8,9].	   These	   studies	   suggest	   that	   the	   vaccine	   is	   less	  
immunogenic	  than	   in	  HIV-­‐negative	  persons,	  particularly	  at	  CD4	  counts	  <400-­‐500	  cells/µL,	  although	  a	  
4-­‐dose	   vaccine	   course	   (given	   at	   0,	   1,	   2,	   and	   9-­‐12	  months)	  may	   improve	   responses.	   The	  duration	  of	  
protection	  in	  HIV-­‐positive	  persons	  is	  unknown,	  but	  may	  be	  reduced	  compared	  to	  healthy	  individuals;	  
however,	  there	  is	  insufﬁcient	  evidence	  to	  guide	  a	  change	  in	  boosting	  recommendations.	  A	  neutralizing	  
antibody	   response	   >126	   Vienna	  Units/mL	   is	   considered	   to	   be	   protective.	   Post-­‐vaccination	   testing	   is	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not	   recommended	   routinely	   in	   healthy	   individuals,	   but	   may	   be	   considered	   in	   some	  
immunocompromised	  persons	  at	   risk	  of	  exposure	   in	  order	   to	  guide	  booster	   requirements.	  Whether	  
rapid	   schedules	   are	   effective	   in	   HIV-­‐positive	   persons	   is	   unknown.	   The	   TBE	   vaccine	   is	   safe	   and	  well	  
tolerated	   in	   HIV-­‐positive	   individuals	   with	   CD4	   count	   >200	   cells/µL	   [8,9;	   H.	   Kollaritsch	   and	   M.	  
Peallabauer,	  personal	  communications).	  	  
	  
6.	  Recommendations	  for	  HIV-­‐positive	  adults	  	  
• We	  recommend	  that	  HIV-­‐positive	  patients	  who	  intend	  to	  walk,	  camp,	  or	  work	  in	  heavily	  forested	  
regions	   of	   TBE-­‐affected	   countries	   during	   late	   spring	   or	   summer	   be	   offered	   TBE	   vaccination,	  
particularly	  if	  staying	  in	  areas	  with	  heavy	  undergrowth	  [1B].	  The	  vaccine	  is	  also	  recommended	  for	  
expatriates	  whose	  principal	  area	  of	  residence	  is	  an	  area	  where	  TBE	  is	  endemic	  and	  this	  should	  be	  
according	  to	  local	  vaccination	  programmes	  [1B]	  
o We	  recommend	  that	  4	  vaccine	  doses	  be	  offered	  in	  order	  to	  improve	  responses,	  and	  these	  
should	  be	  given	  at	  0,	  1,	  and	  2	  months	  (primary	  course),	  followed	  by	  a	  fourth	  dose	  at	  9-­‐12	  
months	  [1B]	  
o We	  recommend	  that	  the	  decision	  to	  offer	  a	  rapid	  vaccination	  schedule	  (2	  doses	  2	  weeks	  
apart,	  followed	  by	  a	  third	  dose	  5-­‐12	  months	  later)	  be	  based	  upon	  an	  evaluation	  of	  risk	  of	  
exposure	  and	  urgency,	  taking	  into	  account	  that	  responses	  may	  be	  reduced	  in	  patients	  with	  
CD4	  counts	  <400	  cells/µL	  [1C]	  
• We	  recommend	  that	  a	  booster	  vaccine	  dose	  is	  offered	  every	  3-­‐5	  years	  to	  those	  at	  continued	  risk,	  
with	  the	  shorter	  interval	  preferred	  for	  patients	  with	  CD4	  counts	  <400	  cells/μL	  [1C]	  	  
• We	  suggest	  that	  where	  available	  serological	  testing	  for	  specific	  antibodies	  may	  be	  used	  to	  guide	  
boosting	  requirements	  [2C]	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1.	   Infection	  and	  disease:	  Salmonella	   is	  a	  gram-­‐negative	  bacillus	  transmitted	  by	  the	  faecal-­‐oral	  route	  
[1].	   Thousands	   of	   serotypes	   are	   recognised,	   and	   most	   cause	   non-­‐invasive	   infections	   of	   the	  
gastrointestinal	  tract.	  Typhoid	  fever	  is	  an	  invasive	  infection	  caused	  by	  S.	  typhi.	  S.	  paratyphi	  A,	  B	  and	  C,	  
and	   in	   HIV-­‐positive	   individuals	   other	   salmonella	   species,	   also	   cause	   invasive	   infections	   which	   may	  
present	   as	   enteric	   fever.	   Disease	   severity	   varies,	   but	   untreated	   infection	   carries	   a	   12-­‐30%	   risk	   of	  
mortality.	  Deaths	  are	   rare	   in	   treated	  persons	   (2%	  or	   less).	  Up	   to	  10%	  of	  patients	  with	   typhoid	   fever	  
excrete	   the	   organism	   for	   three	   months	   following	   the	   acute	   illness.	   A	   chronic	   carrier	   state,	   with	  
excretion	  of	  S.	  typhi	  for	  more	  than	  1	  year,	  occurs	  in	  approximately	  1-­‐6%	  of	  individuals.	  	  
	  
2.	   Epidemiology:	  The	   incidence	  of	   typhoid	   fever	  per	  100,000	  people	   ranges	   from	  <0.1	  cases/year	   in	  
Central	  and	  Eastern	  Europe	  and	  Central	  Asia	  to	  725	  cases/year	  in	  sub-­‐Saharan	  Africa	  [3].	  Paratyphoid	  
incidence	   ranges	   from	   0.8	   cases/year	   in	   North	   Africa/Middle	   East	   to	   77	   cases/year	   in	   sub-­‐Saharan	  
Africa	  and	  South	  Asia.	  The	  adjusted	  estimate	  for	  the	  burden	  of	  typhoid	  fever	  accounting	  for	  the	   low	  
sensitivity	   of	   blood	   cultures	   for	   diagnosis	   is	   about	   27	  million	   episodes.	   In	   the	  UK	  most	   cases	   follow	  
travel	   to	   endemic	   areas;	   about	   7%	   of	   cases	   occur	   in	   individuals	   with	   no	   relevant	   travel	   history.	  
Travellers	   to	   Asia,	   Africa,	   and	   Latin	   America	   who	   have	   prolonged	   exposure	   to	   potentially	  
contaminated	  food	  and	  drink	  are	  especially	  at	  risk	  of	  infection	  [1,2,4].	  In	  these	  regions,	  the	  attack	  rate	  
for	   travellers	   has	   been	   estimated	   at	   10	   per	   100000	   travellers.	   Increasing	   resistance	   to	   available	  
antibiotics,	   including	   fluoroquinolones,	   is	  being	  reported.	  Multidrug-­‐resistant	  strains	  of	  S.	   typhi	  have	  
become	   common	   in	   the	   Indian	   subcontinent,	   the	   Middle	   East	   and	   some	   African	   countries	   [5-­‐7].	  
Typhoid	   vaccination	   is	   an	   important	   component	   of	   typhoid	   fever	   prevention	   and	   control,	   and	   is	  
recommended	   for	   travels	   and	   in	   public	   health	  programmes	   in	   both	   endemic	   and	  outbreak	   settings.	  
Vaccination	  is	  currently	  only	  available	  against	  S.	  typhi.	  
	  
3.	   Typhoid	   fever	   in	  HIV-­‐positive	   adults:	  HIV-­‐positive	  patients	  are	  at	   increased	   risk	  of	   infection	  with	  
Salmonella,	   and	   immunodeficiency	   predisposes	   patients	   to	   bacteraemia,	   antibiotic	   resistance,	  
relapsing	   disease,	   and	   persistent	   infection	   [8-­‐14].	   In	   residents	   of	   endemic	   countries,	   particularly	   in	  
Africa,	   disease	   is	   predominately	   due	   to	   non-­‐typhoidal	   Salmonella	   (NTS),	   rather	   than	   S.	   typhi.	   The	  
burden	  of	  NTS	   in	  HIV-­‐positive	  adults	   is	  declining	  with	   the	   roll-­‐out	  of	  ART	   [15].	  Whether	   the	  disease	  
manifestations	  of	  typhoid	  fever	  among	  HIV-­‐positive	  persons	  differ	  significantly	  from	  those	  observed	  in	  
HIV-­‐negative	  persons	  is	  uncertain.	  
	  
4.	   Typhoid	   vaccine:	   Available	   vaccines	   comprise	   the	   injectable	   non-­‐replicating	   Vi	   capsular	  
polysaccharide	  vaccine	  (ViCPS),	  the	  oral	  replicating	   live	  attenuated	  Ty21a	  vaccine,	  and	  the	   injectable	  
non-­‐replicating	   typhoid	   conjugate	   vaccine	   [TCV]	   [16-­‐18].	   These	   vaccines	   do	   not	   protect	   against	   S.	  
paratyphi	  or	  NTS	  infection.	  A	  NTS	  vaccine	  is	  under	  development	  [17].	  TCVs	  have	  only	  recently	  become	  
available	   and	   experience	   remains	   limited	   [16].	   ViCPS	   is	   38-­‐80%	  protective	   in	   healthy	   people	   after	   a	  
single	  dose	  [16,17,19],	  with	  boosters	  recommended	  every	  three	  years	  for	  those	  at	  risk.	  There	  are	  no	  
major	   safety	   concerns	   with	   the	   ViPS	   vaccine	   in	   healthy	   individuals	   from	   endemic	   or	   non-­‐endemic	  
countries	   [16-­‐19].	   Injection	   site	   reactions	   occur	   in	   up	   to	   7%	   of	  ViCPS	   recipients	   and	   usually	   resolve	  
within	   48	   hours.	   Systemic	   reactions	   such	   as	   headache	   and	   fever	   occur	   in	   up	   to	   20%	   and	   1%	   of	  
vaccinees	  respectively.	  Anaphylaxis	  and	  other	  serious	  adverse	  reactions	  are	  rare.	  There	  are	  no	  major	  
safety	  concerns	  with	  the	  Ty21a	  vaccine	  in	  healthy	  people.	  However,	  the	  Ty21a	  vaccine	  should	  not	  be	  
co-­‐administered	  with	  antibacterials	  or	  antimalarials	  as	  these	  may	  impair	  efficacy.	  
	  
General	  indications:	  The	  vaccine	  is	  indicated	  for	  travellers	  to	  areas	  that	  pose	  a	  risk	  of	  exposure.	  
	  
5.	   Typhoid	   vaccine	   in	   HIV-­‐positive	   adults:	   In	   HIV-­‐positive	   persons,	   the	   induction	   of	   protective	  
antibodies	   is	   impaired,	   particularly	   in	   patients	   with	   CD4	   counts	   <200	   cells/μL	   [20].	   The	   duration	   of	  
protection	  may	  also	  be	  reduced	  in	  HIV-­‐positive	  persons.	  Nonetheless,	  there	  is	  no	  evidence	  for	  dose	  or	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interval	   modification.	   Whether	   the	   Vi-­‐conjugate	   vaccine	   when	   it	   becomes	   available	   will	   be	   more	  
effective	   in	  this	  population	   is	  currently	  unknown.	  The	  ViCPS	  vaccine	   is	  safe	   for	  HIV-­‐positive	  persons.	  
Although	  there	  have	  been	  no	  reports	  of	  adverse	  events	   [21]	   the	  Ty21a	  vaccine	   is	  contraindicated	   in	  
immunocompromised	  persons,	  including	  HIV-­‐positive	  patients	  [13].	  	  
	  
6.	  Recommendations	  for	  HIV-­‐positive	  adults	  
• We	   recommend	   that	   HIV-­‐positive	   patients	   who	   are	   due	   to	   travel	   to	   areas	   in	   which	   there	   is	   a	  
recognized	  risk	  of	  exposure	  to	  S.	  typhi	  be	  offered	  the	  parental	  ViCPS	  vaccine	  [B1]	  
o Efforts	  should	  be	  made	  to	  offer	  vaccination	  to	  those	  at	  particularly	  high	  risk	  of	  exposure:	  
visitors	   to	   friends	   and	   relatives;	   long-­‐term	   travellers;	   and	   those	  with	   likely	   exposure	   to	  
poor	  sanitary	  conditions	  [B1]	  
o These	  patients	  should	  receive	  1	  vaccine	  dose	  at	   least	  2	  weeks	  before	  expected	  exposure	  
[C1]	  
• We	  recommend	  a	  booster	  vaccine	  dose	  is	  given	  every	  3	  years	  in	  those	  who	  remain	  at	  risk	  [1C]	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1.	  Infection	  and	  disease:	  The	  Mycobacterium	  tuberculosis	  complex	  includes	  M.	  tuberculosis,	  M.	  bovis	  
and	  M.	   africanum.	   Transmission	   nearly	   always	   occurs	   through	   airborne	   droplets	   that	   are	   expelled	  
when	  a	  person	  with	  pulmonary	  tuberculosis	  (TB)	  coughs,	  talks,	  sings,	  or	  sneezes.	  The	  most	  infectious	  
persons	  are	  those	  with	  cavitary	  pulmonary	  disease.	  Transmission	  usually	  requires	  prolonged	  exposure	  
and	  close	  contact.	  In	  some	  cases	  transmission	  can	  occur	  through	  unpasteurized	  milk	  or	  milk	  products	  
from	  infected	  cattle.	  Depending	  on	  host	  factors,	  infection	  may	  be	  cleared,	  remain	  latent,	  or	  progress	  
to	  active	  disease	  over	  a	  period	  of	  weeks	  or	  months.	  Disease	  is	  usually	  pulmonary	  (60%	  of	  cases),	  but	  
non-­‐pulmonary	   and	   disseminated	   disease	   can	   occur,	   especially	   in	   young	   children	   and	  
immunocompromised	  persons,	  and	  almost	  every	  tissue	  and	  organ	  can	  be	  affected	  [1].	  Latent	  infection	  
can	  re-­‐activate.	  The	  lifetime	  risk	  of	  re-­‐activation	  is	  5-­‐15%	  for	  immunocompetent	  adults.	  The	  majority	  
of	  re-­‐activations	  occur	  within	  two	  years	  of	  primary	  infection.	  
	  
2.	  Epidemiology:	  In	  the	  UK,	  cases	  of	  TB	  have	  increased	  over	  the	  last	  10	  years.	  A	  large	  number	  of	  cases	  
are	   in	  people	  born	  abroad,	  the	  rate	  being	  higher	   in	  certain	  ethnic	  groups	   in	  the	  first	   few	  years	  after	  
they	  enter	  the	  country,	  and	  rates	  remain	  high	  in	  the	  children	  of	  these	  immigrants	  wherever	  they	  are	  
born.	  The	  risk	  of	   infection	   is	  also	   increased	   in	  persons	  who	  are	  close	  contacts	  of	   infectious	  persons,	  
have	  HIV	  infection,	  are	  homeless,	  have	  hazardous	  alcohol	  use,	  or	  inject	  drugs.	  Risk	  factors	  for	  disease	  
are	   diabetes	  mellitus,	   renal	   failure,	   immunodeficiency,	   latent	   infection	   acquired	   in	   infancy	   or	   early	  
childhood,	   and	   therapy	  with	   immunomodulators	   (especially	   TNF-­‐a	   antagonists).	   The	  mainstay	   of	   TB	  
control	   is	   identifying	   and	   treating	   infectious	   cases	   to	   stop	   transmission,	   skin-­‐testing	   or	   interferon	  
gamma	   release	   assays	   (IGRAs)	   for	   children	   and	   adults	   who	   are	   at	   high	   risk	   for	   TB,	   and	   (where	  
indicated)	   administering	   preventive	   therapy	   to	   persons	   with	   a	   positive	   skin-­‐test	   result.	   Vaccination	  
contributes	   to	   the	   prevention	   and	   control	   of	   TB	   in	   limited	   situations	   and	   is	   contraindicated	   in	   HIV	  
infection.	  
	  
3.	   TB	   in	  HIV-­‐positive	   adults:	  HIV	   infection	  substantially	   increases	   the	   risk	  of	   infection	  and	  active	  TB	  
disease:	   	   worldwide,	   TB	   is	   the	   leading	   cause	   of	   death	   among	   HIV-­‐positive	   people	   [2].	   HIV	   also	  
suppresses	  responses	  to	  the	  tuberculin	  test.	  
	  
4.	  Bacille	  Calmette-­‐Guerin	  vaccine:	  The	  BCG	  vaccine	  is	  a	  live	  attenuated	  vaccine	  containing	  a	  strain	  of	  
M.	  bovis	   isolated	   in	   1908	   from	  a	   cow,	  which	  was	   sub-­‐cultured	  231	   times	  over	   13	   years	   resulting	   in	  
gradual	  attenuation.	  Several	   laboratories	  produce	  vaccine	  derived	  from	  the	  original	  strain	  and	  many	  
different	   BCG	   vaccines	   are	   available	   worldwide,	   with	   different	   production	   techniques	   and	  
characteristics.	   BCG	   Vaccine	   Statens	   Serum	   Institut	   	   (SSI)	   is	   available	   in	   the	   UK.	   It	   is	   administrated	  
intradermally	  in	  the	  later	  aspect	  of	  the	  left	  upper	  arm.	  Studies	  of	  BCG	  vaccine	  are	  difficult	  to	  interpret	  
because	   they	   differ	   in	   design,	   location,	   strains	   used,	   vaccine	   dose,	   population,	   presence	   of	  
mycobacteria	   in	   the	   environment,	   and	   diagnostic	   approach	   [3].	   Protection	   rates	   vary	   widely	   in	  
different	   trials.	   The	   vaccine	   appears	   to	   prevent	   the	   blood-­‐borne	   spread	   of	   M.	   tuberculosis	   from	  
primary	  pulmonary	  foci	  especially	  in	  children,	  but	  the	  protection	  afforded	  against	  pulmonary	  disease	  
is	   more	   uncertain.	   There	   remain	   limited	   data	   concerning	   the	   protective	   efficacy	   of	   vaccination	   in	  
adults,	   but	   overall	   efficacy	   appears	   to	   be	   higher	   in	   persons	   vaccinated	   during	   childhood	   compared	  
with	   persons	   vaccinated	   at	   older	   ages.	   The	   efficacy	   of	   BCG	   vaccine	   in	   children	   and	   adults	   who	   are	  
infected	  with	  HIV	  has	  not	  been	  determined.	  New	  TB	  vaccines	  are	  currently	  under	  investigation	  [4].	  
	  
General	   indications:	   In	   the	   UK,	   a	   single	   BCG	   vaccine	   dose	   is	   given	   to	   selected	   high-­‐risk	   infants	   and	  
children,	   and	   previously	   unvaccinated	   tuberculin-­‐negative	   close	   contacts	   of	   those	   with	   active	  
respiratory	   TB.	   The	   vaccine	   is	   also	   indicated	   for	   previously	   unvaccinated	   tuberculin-­‐negative	   adults	  
below	   the	   age	   of	   35	   years	   if	   they	   are	   at	   occupational	   risk	   of	   exposure	   (e.g.	   healthcare	   workers,	  
laboratory	   staff,	   veterinarians,	   prison	   staff,	   staff	   of	   care	   homes	   for	   the	   elderly,	   staff	   of	   hostels	   for	  
homeless	  people	  and	  facilities	  accommodating	  refugees	  and	  asylum	  seekers)	  or	  intend	  to	  live	  or	  work	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in	  countries	  with	  an	  annual	   incidence	  of	  TB	  of	  40/100,000	  or	  greater.	  The	  BCG	  vaccine	  may	  also	  be	  
considered	   for	  previously	  unvaccinated,	   tuberculin-­‐negative	   individuals	   travelling	   to	  high-­‐prevalence	  
countries	  for	  one	  month	  or	  longer.	  
	  
5.	   Vaccine	   safety:	   The	   BCG	   vaccine	   often	   causes	   local	   adverse	   effects,	   but	   serious	   or	   long-­‐term	  
complications	  are	  rare	  in	  healthy	  individuals.	  Within	  10-­‐14	  days,	  90-­‐95%	  of	  vaccine	  recipients	  develop	  
a	  tender	  erythematous	  papule	  at	  the	  injection	  site,	  which	  may	  ulcerate	  and	  then	  slowly	  subside	  over	  
several	   weeks	   or	   months	   leaving	   a	   flat	   scar	   of	   5-­‐15	  mm.	   There	  may	   be	   enlargement	   (<1	   cm)	   of	   a	  
regional	   lymph	  node.	  Severe	   injection	  site	  reactions	  may	  occur,	  usually	  as	  a	  result	  of	  faulty	   injection	  
technique,	   excessive	   dosage,	   or	   vaccinating	   individuals	   who	   are	   tuberculin-­‐positive.	   Other	   adverse	  
reactions	  include	  headache,	  fever,	  lymphadenopathy	  (>1	  cm),	  allergic	  reactions	  (including	  anaphylaxis)	  
and,	  rarely,	  lymphadenitis,	  and	  disseminated	  BCG	  (e.g.,	  osteitis	  or	  osteomyelitis).	  Fatal	  dissemination	  
has	  been	  described	  in	  immunocompromised	  individuals	  and	  the	  BCG	  vaccine	  is	  contraindicated	  in	  such	  
populations.	  Case	  reports	  indicate	  that	  symptomatic	  HIV-­‐positive	  persons	  are	  at	  a	  greater	  risk	  of	  local	  
and	  systemic	  complications	  including	  disseminated	  BCG	  disease	  than	  HIV-­‐negative	  persons	  or	  persons	  
with	   asymptomatic	   HIV	   infection	   [5-­‐12].	   These	   complications	   can	   occur	   several	   years	   after	   BCG	  
vaccination.	  Overall,	  there	  is	  no	  evidence	  of	  a	  clear	  benefit	  of	  BCG	  vaccination	  in	  HIV-­‐positive	  people	  
that	  may	  offset	  the	  potential	  risk.	  	  
6.	  Recommendations	  for	  HIV-­‐positive	  adults	  
• We	   recommend	   that	   the	   BCG	   vaccine	   be	   absolutely	   contraindicated	   in	   all	   HIV-­‐positive	   persons	  
regardless	  of	  CD4	  cell	  count,	  AT	  use,	  viral	  load,	  and	  clinical	  status	  [1C]	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VARICELLA ZOSTER VIRUS 
	  
1.	   Infection	  and	  disease:	  VZV	  is	  a	  herpes	  virus	  that	  after	  primary	  infection	  establishes	  latency	  within	  
neurons.	   Primary	   infection	   causes	   varicella	   or	   chickenpox.	   Reactivation	   causes	   herpes	   zoster	   or	  
shingles.	  Chickenpox	  is	  highly	   infectious	  and	  can	  be	  transmitted	  by	  respiratory	  droplets	  and	  aerosols	  
up	   to	  48	  hours	  prior	   to	   the	  onset	  of	   the	   rash.	   The	   skin	   lesions	  of	  both	   chickenpox	  and	   shingles	   are	  
infectious	   until	   crusted.	   Chickenpox	   is	   usually	   benign	   and	   self-­‐limiting	   in	   healthy	   children;	   healthy	  
adults	   are	   more	   likely	   to	   develop	   severe	   and	   even	   life-­‐threatening	   infections.	   Complications	   may	  
include	  severe	  cutaneous	  rashes,	  secondary	  bacterial	  infections,	  visceral	  involvement	  (e.g.	  pneumonia,	  
hepatitis),	  and	  neurological	  disease	  (meningitis,	  encephalitis,	  myelitis).	  All	  adults	  with	  chickenpox,	  and	  
especially	  pregnant	  women,	  are	  at	  risk	  of	  VZV	  pneumonia.	  Occasionally,	   infection	  in	  pregnancy	  leads	  
to	   foetal	   injury	   (congenital	   varicella	   syndrome).	   Shingles	   is	   usually	   self-­‐limiting,	   although	   persistent	  
debilitating	  pain	  is	  a	  frequent	  complication,	  particularly	  in	  the	  elderly	  (post-­‐herpetic	  neuralgia,	  PHN);	  
eye	  involvement	  may	  lead	  to	  permanent	  visual	  impairment.	  	  
	  
2.	   Epidemiology:	   In	   temperate	   climates,	   primary	   infection	  with	   VZV	   occurs	  most	   commonly	   during	  
childhood.	  At	  least	  90%	  of	  adults	  in	  England	  and	  Wales	  are	  VZV	  IgG	  seropositive	  [1],	  conﬁrming	  prior	  
infection.	  In	  tropical	  and	  sub-­‐tropical	  climates,	  the	  mean	  age	  of	  primary	  VZV	  infection	  may	  be	  delayed.	  
As	  a	  result,	  a	  signiﬁcant	  proportion	  of	  adults	  raised	  in	  those	  regions	  remain	  VZV	  IgG	  seronegative	  and	  
susceptible	  to	  primary	  infection	  in	  adulthood.	  Among	  HIV-­‐positive	  adults	  in	  the	  UK,	  1.5%	  lack	  evidence	  
of	  VZV	   IgG	   [2].	   Shingles	   is	   common	   in	   the	   general	   population,	  with	   an	  overall	   rate	  of	   2-­‐4	   cases	  per	  
1000	  person-­‐years	  and	  higher	  incidence	  rates	  in	  adults	  ≥50	  years	  of	  age	  and	  in	  immunocompromised	  
people,	  including	  HIV-­‐positive	  individuals	  [3-­‐5].	  	  	  
	  
3.	   VZV	   in	  HIV-­‐positive	   adults:	  HIV-­‐positive	  patients	  who	  acquire	  chickenpox	  are	  at	   increased	  risk	  of	  
severe	  and	  even	  fulminant	  disease	  [6-­‐8].	  Cell-­‐mediated	  immunity	  plays	  a	  major	  role	  in	  controlling	  VZV	  
reactivation,	  and	  impaired	  cellular	  immunity	  also	  increases	  the	  risk	  of	  shingles	  in	  people	  with	  HIV	  [9].	  
Before	  the	  introduction	  of	  effective	  ART,	   incidence	  rates	  of	  shingles	  were	  10-­‐20	  times	  higher	   in	  HIV-­‐
positive	  adults	  than	  in	  the	  age-­‐matched	  general	  population	  [5,10-­‐13].	  While	  disease	  burden	  has	  been	  
reduced	  by	  ART,	   it	   is	  has	   remained	  3-­‐5	   times	  higher	   than	   in	  HIV-­‐negative	  people	   [5,13-­‐17].	   Shingles	  
may	  occur	  and	  may	  recur	  at	  any	  time	  during	  HIV	  infection,	  although	  a	  low	  CD4	  cell	  count	  and	  a	  viral	  
load	   >400	   copies/mL	   have	   been	   associated	  with	   a	   higher	   risk	   [5,12,18].	   Additional	   risk	   factors	  may	  
include	  a	  prior	  episode	  of	  shingles,	  crack	  cocaine	  use,	  and	  age	  >60	  years	  (>40	  years	   in	  crack	  cocaine	  
users)	   [16,18].	  Complications	  of	   shingles	  are	  also	  more	  common	   in	  HIV-­‐positive	  subjects	   than	   in	   the	  
age-­‐matched	   general	   population	   (27%-­‐28%	   vs.	   10%-­‐13%)	   [5,12],	   and	   may	   include	   cutaneous	  
dissemination,	   chronic	   atypical	   skin	   lesions,	   ocular	   and	   neurological	   complications,	   or	   visceral	  
dissemination.	   Acute	   retinal	   necrosis	   and	   neurological	   syndromes	   can	   occur	   as	   a	   result	   of	   VZV	  
reactivation	  in	  the	  absence	  of	  rash.	  Both	  shingles	  and	  VZV-­‐mediated	  cerebral	  vasculitis	  causing	  stroke	  
have	  also	  been	  recognized	  as	  a	  manifestation	  of	  the	   immune	  reconstitution	   inflammatory	  syndrome	  
[19,20].	  
	  
4.	   Chickenpox	   vaccine:	   Two	   varicella	   vaccines	   are	   available	   in	   the	   UK	   -­‐	   Varilrix	   and	   Varivax.	   Both	  
contain	  replicating	  live	  attenuated	  VZV	  (OKA	  strain).	  The	  vaccine	  strain	  can	  establish	  latent	  infection	  in	  
some	  vaccine	  recipients,	  and	  can	  reactivate	  to	  cause	  shingles,	  although	  less	  commonly	  than	  with	  wild-­‐
type	   virus.	   Varilix	   should	   only	   be	   administered	   by	   deep	   subcutaneous	   injection.	   Varivax	   can	   be	  
administered	   by	   either	   intramuscular	   or	   deep	   subcutaneous	   injection.	   In	   healthy	   adults,	   two	   doses	  
give	  75%	  protection	  against	  any	  disease	  and	  95%	  protection	  against	  severe	  disease.	  Waning	  immunity	  
over	   time	   is	  manifested	  by	  mild	  breakthrough	   infections	  with	  wild-­‐type	   virus.	   The	  need	   for	  booster	  
doses	   is	   currently	   under	   investigation.	   The	   vaccine	   is	   safe,	   although	   up	   to	   10%	   of	   healthy	   adults	  
develop	  a	  vaccine-­‐associated	  rash,	   localized	  at	  the	  site	  of	   injection	  or	  generalized,	  within	  one	  month	  
of	   immunization	   [21].	   Transmission	   of	   vaccine	   virus	   from	   vaccine	   recipients	   has	   been	   documented	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only	   rarely	   and	   only	   from	   individuals	   with	   vaccine-­‐associated	   rashes.	   Vaccination	   is	   not	  
contraindicated	  and	  is	  in	  fact	  recommended	  for	  close	  contacts	  of	  HIV-­‐positive	  persons.	  	  
	  
General	   indications:	   In	   the	   UK,	   the	   varicella	   vaccine	   is	   currently	   recommended	   for	   susceptible	  
healthcare	   workers	   and	   close	   contacts	   of	   immunocompromised	   patients.	   Contraindications	   include	  
pregnancy	  and	  significant	  Immunocompromise.	  
	  
5.	  Chickenpox	  vaccine	  in	  HIV-­‐positive	  adults:	  The	  chickenpox	  vaccine	  has	  been	  shown	  to	  be	  safe	  and	  
immunogenic	   in	   susceptible	   children	  with	  asymptomatic	  or	  mildly	   symptomatic	  HIV	   infection,	   and	  a	  
suppressed	  viral	   load	  on	  ART	   is	  associated	  with	   improved	   immunogenicity	   [22-­‐27].	   Severe,	  but	  non-­‐
fatal	   vaccine-­‐associated	   disease	   has	   been	   reported	   in	   some	   children	   with	   undiagnosed	  
immunodeﬁciency	   [28].	   There	   are	   limited	   data	   in	   HIV-­‐positive	   adults.	   Among	   VZV	   IgG	   seropositive	  
persons	  with	  CD4	  counts	  >400	  cells/µL	  and	  stable	  on	  ART	  for	  ≥3	  months,	  the	  vaccine	  has	  been	  shown	  
to	  boost	  VZV-­‐speciﬁc	  cellular	   immune	  responses,	  without	  safety	  concerns	  [29].	  Expert	  opinion	  in	  the	  
US	   advises	   VZV	   vaccination	   in	   susceptible	  HIV-­‐positive	   adults	  with	   CD4	   counts	   >200	   cells/µL,	   based	  
upon	  evidence	  of	  safety	  and	  immunogenicity	  in	  children,	  the	  highly	  contagious	  nature	  of	  the	  infection,	  
and	  the	  significant	  risk	  of	  severe	  disease	  resulting	  from	  primary	  VZV	  infection	  [30].	  Further,	  patients	  
who	   develop	   complications	   from	   the	   vaccine	   strain	   can	   be	   managed	   with	   antiviral	   therapy	   (e.g.,	  
aciclovir	  800	  mg	  5	  times	  daily,	  or	  valaciclovir	  1g	  3	  times	  daily).	  	  
	  
6.	   Shingles	   vaccine:	   The	   available	   shingles	   vaccine	   (Zostavax)	   contains	   high	   dose,	   replicating	   live	  
attenuated	  VZV	   (Oka/Merck	   strain).	   The	   shingles	   vaccine	   is	   at	   least	   14	   times	  more	   potent	   than	   the	  
chickenpox	   vaccine	   [31].	   It	   is	   given	   as	   a	   single	   dose	   by	   subcutaneous	   injection	   and	   is	   licensed	   for	  
immunocompetent	   adults	   aged	   ≥50	   years	   [32].	   Vaccination	   of	   immunocompetent	   adults	   aged	   ≥60	  
years	  boosts	  natural	  immunity	  and	  reduces	  the	  incidence	  of	  shingles	  by	  half	  and	  the	  incidence	  of	  PHN	  
by	  two	  thirds	  [33].	  The	  vaccine	  is	  also	  efficacious	  in	  immunocompetent	  adults	  aged	  50-­‐59	  years,	  and	  
protection	  against	  shingles	  lasts	  for	  at	  least	  5	  years	  [34-­‐36].	  The	  need	  for	  boosting	  doses	  has	  not	  been	  
clearly	  determined.	  A	  systematic	  review	  concluded	  that	  there	  is	  a	  clear	  benefit	   in	  vaccinating	  elderly	  
patients,	   with	   no	   major	   safety	   concerns	   [36].	   Inactivated	   subunit	   vaccines	   based	   on	   the	   VZV	  
glycoprotein	  E	  (gE)	  antigen	  are	  in	  clinical	  development	  [37].	  
	  
General	   indications:	   In	   the	  UK,	   shingles	   vaccination	   is	   recommended	   for	   adults	  without	   a	   history	   of	  
immunodeficiency	   aged	   70	   years,	   and	   a	   ‘catch-­‐	   up’	   programme	   currently	   targets	   those	   aged	   70-­‐79	  
years.	  Contraindications	  include	  pregnancy	  and	  breast	  feeding	  and	  significant	  immunocompromise.	  	  
	  
7.	   Shingles	   vaccine	   in	   HIV-­‐positive	   adults:	   The	   shingles	   vaccine	   was	   safe	   and	   immunogenic	   in	   a	  
randomised	   trial	   (ACTG	   5247)	   of	   392	   HIV-­‐positive	   patients	   who	   were	   VZV	   IgG	   seropositive	   and	  
receiving	  ART	  with	  a	  CD4	  count	  >200	  cells/µL.	  There	  was	  greater	  incidence	  of	  injection	  site	  reactions	  in	  
the	   vaccine	   group	   (42%)	   versus	   the	   placebo	   group	   (12%).	   The	   greatest	   antibody	   response	   was	  
observed	   in	   patients	   with	   CD4	   counts	   >350	   cells/µL	   [38].	   Duration	   of	   response	   and	   clinical	  
effectiveness	  are	  unknown.	  Although	  these	  data	  are	  promising,	  further	  studies	  are	  required	  to	  define	  
the	  cost-­‐effectiveness	  of	  shingles	  vaccination	  in	  HIV-­‐positive	  adults,	  including	  the	  appropriate	  age	  cut-­‐
off.	   Expert	  opinion	   is	   that	   it	   is	   reasonable	   to	  vaccinate	  patients	  ≥60	  years	  of	  age	   (provided	   the	  CD4	  
count	  is	  >200	  cells/µL)	  [39].	  Meanwhile,	  efforts	  are	  required	  to	  overcome	  barriers	  to	  the	  vaccination	  
of	   HIV-­‐positive	   people	   with	   good	   immune	   status	   who	  meet	   age-­‐related	   indications	   for	   vaccination	  
based	  upon	  general	  indications	  [40].	  As	  a	  future	  alternative	  to	  a	  replicating	  vaccine,	  a	  recent	  phase	  1/2,	  
randomised,	  placebo-­‐controlled	  study	  evaluated	   the	   immunogenicity	  and	  safety	  of	   a	  non-­‐replicating	  
adjuvanted	  subunit	  shingles	  vaccine	  in	  123	  HIV-­‐positive	  adults	  that	  were	  predominantly	  on	  ART	  with	  
CD4	  counts	  ≥200	  cells/µL	   [37].	  After	   two	  doses,	   the	  vaccine	  proved	  to	  be	  strongly	   immunogenic;	  no	  
vaccination-­‐related	  serious	  adverse	  events	  were	  reported.	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8.	   Post-­‐exposure	   prophylaxis:	   Protective	   immunity	   develops	   within	   four	   days	   of	   chickenpox	  
vaccination,	   and	   Varivax	   (but	   not	   Varilrix)	   is	   licensed	   for	   post-­‐exposure	   prophylaxis	   in	   susceptible	  
individuals	   exposed	   to	   VZV,	  when	   it	   should	   be	   administered	  within	   three	   days	   and	   up	   to	   five	   days	  
post-­‐exposure	  in	  order	  to	  prevent	  or	  attenuate	  the	  infection.	  Available	  evidence	  supports	  the	  use	  of	  
vaccination	  as	  post-­‐exposure	  prophylaxis	  in	  healthy	  individuals	  [41,42].	  There	  are	  currently	  no	  data	  in	  
HIV	  infection,	  where	  the	  risk	  of	  any	  vaccine-­‐related	  adverse	  event	  must	  be	  balanced	  against	  the	  risk	  of	  
severe	   complications	   resulting	   from	   natural	   infection.	   Varicella-­‐zoster	   immune	   globulin	   (VZIG)	   is	  
indicated	   for	   susceptible	   immunocompromised	   patients	   (and	   pregnant	   women)	   who	   have	   had	   a	  
signiﬁcant	   exposure	   to	   VZV,	   and	   this	   includes	   symptomatic	  HIV-­‐positive	   patients	   and	   asymptomatic	  
patients	  with	   CD4	   count	   <400	   cells/µL.	   VZIG	   should	   be	   given	  within	   seven	  days	   and	  up	   to	   ten	  days	  
after	  exposure	  by	  intramuscular	  injection.	  The	  duration	  of	  protection	  is	  three	  weeks.	  In	  the	  event	  of	  a	  
second	   exposure	   after	   three	   weeks,	   repeat	   administration	   is	   recommended.	   Where	   intramuscular	  
injection	   is	   contraindicated	   in	   individuals	  with	   bleeding	  disorders,	   intravenous	   immunoglobulin	  may	  
be	   given	   instead.	   VZIG	   given	  within	   three	  weeks	   of	   a	   live	   attenuated	   vaccine	   (except	   Yellow	   Fever)	  
may	   interfere	  with	   the	   vaccine	   immunogenicity.	   Replicating	   vaccines	   should	   likewise	   be	   postponed	  
until	  three	  months	  after	  the	  administration	  of	  VZIG.	  Published	  evidence	  for	  the	  efficacy	  of	  aciclovir	  as	  
post-­‐exposure	   prophylaxis	   indicate	   that	   chickenpox	  may	   be	   prevented	   or	   attenuated	   in	   children	   by	  
administration	  of	   aciclovir	   starting	  between	   seven	  and	   ten	  days	  after	  exposure,	   for	   a	   total	  of	   seven	  
days	   [43,44].	   The	   equivalent	   dose	   of	   aciclovir	   in	   adults	   is	   800	   mg	   four	   times	   daily.	   There	   are	   no	  
published	  controlled	  trials	  comparing	  antiviral	  prophylaxis	  directly	  with	  VZIG.	  	  
	  
9.	  Recommendations	  for	  HIV-­‐positive	  adults	  	  
• We	   recommend	   HIV-­‐positive	   adults	   with	   a	   negative	   or	   uncertain	   history	   of	   chickenpox	   or	  
shingles	   undergo	   VZV	   IgG	   testing	   to	   determine	   susceptibility	   to	   primary	   infection	   and	  
reactivation	  [1B]	  
• We	   recommend	   VZV	   IgG	   seronegative	   patients	   who	   have	   a	   CD4	   count	   >200	   cells/µL	   and	  
preferably	  are	  established	  on	  ART	  are	  offered	  2	  doses	  of	  the	  chickenpox	  vaccine	  3	  months	  apart	  
[1B]	  
o Serological	  testing	  for	  evidence	  of	  VZV	  IgG	  seroconversion	  should	  be	  performed	  4-­‐6	  weeks	  
after	  the	  second	  vaccine	  dose	  [GPP]	  
• We	  recommend	  VZV	  IgG	  seropositive	  patients	  who	  have	  a	  CD4	  count	  >200/µL	  and	  preferably	  are	  
established	  on	  ART	  be	  offered	   1	   dose	   of	   the	   shingles	   vaccine	   in	   line	  with	   national	   age-­‐related	  
indications	  [1B]	  
o We	   recommend	  prior	   serological	   testing	   for	   evidence	   of	   VZV	   IgG	   seropositivity	   in	   those	  
lacking	  a	  reliable	  history	  of	  chickenpox	  or	  shingles	  [1C]	  
o We	  recommend	  efforts	  be	  made	  to	  overcome	  barriers	  to	  the	  vaccination	  of	  HIV-­‐positive	  
people	  with	   CD4	   count	   >200	   cells/µL	  who	  meet	   the	   age-­‐related	   indications	   for	   shingles	  
vaccination	  based	  upon	  national	  guidance	  [1B]	  
• We	  suggest	  that	  VZV	  IgG	  seropositive	  patients	  who	  have	  a	  CD4	  count	  >200/µL	  and	  preferably	  are	  
established	  on	  ART	  may	  benefit	  from	  shingles	  vaccination	  from	  the	  age	  of	  60	  years	  [2B]	  
• We	   recommend	   HIV-­‐positive	   recipients	   of	   replicating	   VZV	   vaccines	   be	   advised	   to	   report	   post-­‐
vaccine	   rashes	   or	   other	   symptoms	   promptly,	   and	   following	   medical	   evaluation,	   be	   offered	  
appropriate	  antiviral	  therapy	  against	  VZV	  if	  required	  [1B]	  
• We	   recommend	   that	   following	   a	   signiﬁcant	   exposure	   to	   VZV,	   the	   VZV	   IgG	   status	   of	   the	   HIV-­‐
positive	   contact	   be	   ascertained	   regardless	   of	   vaccination	   history	   (although	   prophylaxis	   should	  
not	  be	  delayed	  waiting	  for	  the	  results)	  and	  VZV	  IgG	  seronegative	  patients	  be	  considered	  for	  post-­‐
exposure	   prophylaxis	   and	   monitored	   closely	   for	   symptoms	   to	   facilitate	   prompt	   institution	   of	  
antiviral	  therapy	  [1A]	  
o We	   recommend	   VZV	   IgG	   seronegative	   contacts	   with	   CD4	   counts	   <400	   cells/µL	   receive	  
post-­‐exposure	  prophylaxis	  with	  VZIG	  as	  soon	  as	  possible,	  preferably	  within	  7	  days	  and	  not	  
later	  than	  10	  days	  after	  exposure	  [1B]	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o We	  recommend	  that	  where	  VZIG	  is	  not	  available	  VZV	  IgG	  seronegative	  contacts	  be	  offered	  
antiviral	   prophylaxis	  with	   aciclovir	   (800mg	  4	   times	  daily)	   [1B]	   or	   valaciclovir	   (1g	   3	   times	  
daily)	  [1C]	  starting	  from	  day	  7	  after	  exposure	  and	  continuing	  for	  7	  days	  
o We	  suggest	  VZV	  IgG	  seronegative	  contacts	  with	  CD4	  count	  <200	  cells/µL	  be	  considered	  for	  
both	  VZIG	  and	  antiviral	  prophylaxis	  with	  aciclovir	  (800mg	  4	  times	  daily)	  or	  valaciclovir	  (1g	  
3	  times	  daily)	  [2C]	  starting	  from	  day	  7	  after	  exposure	  and	  continuing	  for	  7	  days	  
o We	   recommend	   VZV	   IgG	   seronegative	   contacts	   with	   CD4	   counts	   >400	   cells/µL	   receive	  
post-­‐exposure	   prophylaxis	   with	   the	   Varivax	   vaccine	   within	   3	   and	   up	   to	   5	   days	   after	  
exposure	  [1C].	  The	  second	  dose	  should	  normally	  be	  scheduled	  after	  3	  months	  
• We	  recommend	  that	  VZV	  seronegative	  close	  contacts	  of	  HIV-­‐positive	  adults	  with	  CD4	  count	  <200	  
cells/µL	  are	  proactively	  offered	  chickenpox	  vaccination	  [1B]	  
• We	  recommend	  that	  whenever	  possible	  HIV-­‐positive	  patients	  receiving	  VZV	  replicating	  vaccines	  
are	  not	  given	  treatment	  doses	  of	  antiviral	  drugs	  with	  anti-­‐herpetic	  activity	  (e.g.,	  aciclovir)	  at	  the	  
time	  of	  vaccination	  and	  for	  4	  weeks	  subsequently	  as	  it	  may	  reduce	  vaccine	  immunogenicity	  [1D]	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YELLOW FEVER VIRUS 
	  
1.	  Infection	  and	  disease:	  Yellow	  fever	  virus	  (YFV)	  is	  a	  flavivirus	  spread	  by	  the	  bite	  of	  an	  infected	  Aedes	  
aegypti	   mosquito.	   Severity	   varies.	   Most	   infections	   are	   asymptomatic	   or	   cause	   a	   non-­‐specific,	   self-­‐
limited	  influenza-­‐like	  illness.	  Severe	  cases	  are	  characterised	  by	  hepatitis,	  jaundice,	  and	  haemorrhage,	  
and	   carry	   a	   risk	   of	  mortality	   of	   up	   to	   50%	   in	   non-­‐immune	   adults	   travelling	   to	   endemic	   areas	   [1-­‐3].	  
There	  is	  no	  specific	  antiviral	  treatment	  available.	  	  
	  
2.	   Epidemiology:	   YFV	   is	   prevalent	   in	   tropical	   and	   sub-­‐tropical	   regions	   of	   Africa	   and	   South	   America,	  
where	   it	   is	  endemic	  and	   intermittently	  epidemic.	   It	  does	  not	  occur	   in	  Asia.	  Two	  forms	  of	  YF	  –	  urban	  
and	  jungle	  –	  are	  epidemiologically	  distinguishable.	  In	  South	  America,	  sporadic	  infections	  occur	  almost	  
exclusively	  as	  a	  result	  of	  occupational	  exposure	  in	  or	  near	  forested	  areas.	  In	  Africa,	  YFV	  is	  transmitted	  
mainly	   in	   the	  moist	  savannah	  zones	  of	  west-­‐central	  Africa,	  especially	  during	   the	   late	   rainy	  and	  early	  
dry	  season	  (July-­‐October).	  For	  travellers	  to	  endemic	  areas	  the	  risk	  of	  acquiring	  YF	  has	  been	  estimated	  
to	  be	  0.4-­‐4.3	  cases	  per	  million	  travellers	  [2].	  The	  risk	  of	  disease	   is	  ~10	  times	   lower	   in	  South	  America	  
than	   in	   rural	   West	   Africa,	   but	   varies	   greatly	   according	   to	   specific	   location	   and	   season.	   Under	  
regulations	  set	  out	  by	   the	  World	  Health	  Organization	   (WHO),	  anyone	  travelling	   to	  a	  country	  or	  area	  
where	  the	  Aedes	  aegypti	  mosquito	   is	   found	  must	  have	  an	   International	  Certificate	  of	  Vaccination	  or	  
Prophylaxis,	  which	  is	  compulsory	  for	  entry	  to	  several	  countries	  in	  these	  regions.	  The	  certificate	  is	  valid	  
for	  10	  years	  from	  the	  tenth	  day	  after	  primary	  vaccination	  and	  immediately	  after	  revaccination	  [1].	  
	  
3.	  Yellow	  fever	  in	  HIV-­‐positive	  adults:	  It	  is	  not	  known	  whether	  the	  natural	  history	  of	  YF	  is	  modified	  by	  
HIV	  infection.	  
	  
4.	  YFV	  vaccine:	  YF	  vaccine	  is	  a	  replicating	  live	  attenuated	  preparation	  of	  the	  YFV	  17D	  strain	  grown	  in	  
embryonated	   chick	   eggs.	   The	   YF	   vaccine	   is	   given	   as	   a	   single	   dose	   by	   deep	   subcutaneous	   or	  
intramuscular	  injection.	  In	  healthy	  recipients,	  a	  single	  dose	  of	  the	  YF	  vaccine	  has	  a	  protective	  efficacy	  
of	  90%	  after	  10	  days	  and	  99%	  after	  30	  days	  [3].	  The	  protection	   lasts	   for	  at	   least	  10	  years	  (for	  which	  
duration	  the	  certificate	  of	  vaccination	  is	  valid),	  after	  which	  a	  booster	  is	  required	  for	  those	  at	  continued	  
risk.	  However,	  with	  some	  exceptions,	  immunity	  is	  thought	  to	  persist	  for	  at	  least	  35	  years	  and	  probably	  




General	  indications:	  The	  YF	  vaccine	  is	  offered	  to	  travellers	  to	  specific	  regions.	  Vaccination	  can	  only	  be	  
given	  at	  designated	  vaccination	  centres	  as	  established	  by	  the	  International	  Health	  Regulations	  of	  WHO.	  	  
	  
5.	   Vaccine	   safety:	   Adverse	   reactions	   are	   generally	   mild	   with	   headache,	   myalgia,	   low-­‐grade	   fever	  
and/or	  soreness	  at	  the	  injection	  site	  occurring	  in	  10-­‐30%	  of	  vaccine	  recipients.	  More	  serious	  adverse	  
events	  are	  very	  rare	  and	  more	  likely	  to	  occur	  in	  persons	  who	  have	  no	  prior	  immunity	  to	  YFV.	  These	  are	  
principally	   urticarial,	   bronchospasm	   or	   anaphylaxis	   (occurring	   in	   one	   per	   130,000-­‐250,000	   vaccine	  
doses),	   which	  may	   be	   related	   to	   reactions	   to	   the	   egg	   protein	   in	   the	   vaccine.	   Yellow	   fever	   vaccine-­‐
associated	  neurological	  disease	   (YEL-­‐AND)	  has	  an	  estimated	   incidence	  overall	  of	  0.4-­‐0.8	  per	  100,000	  
with	  a	  higher	  rate	   in	  person	  aged	  over	  60	  years	   (1.4-­‐1.8	  per	  100,000)	   [1].	  Presentation	   is	  with	   fever	  
and	   headache	   progressing	   to	   confusion,	   focal	   neurological	   deficits,	   coma,	   and	   Guillain-­‐Barré	  
syndrome;	   complete	   clinical	   recovery	   is	   the	   usual	   outcome.	   Yellow	   fever	   vaccine-­‐associated	  
viscerotropic	  disease	  (YEL-­‐AVD)	  was	  first	  described	  in	  2001	  and	  has	  an	  estimated	  incidence	  of	  0.4	  per	  
100,000,	   increasing	   to	   1-­‐2.3	   per	   100,000	   in	   persons	   aged	   ≥60	   years	   [1,4,5].	   It	   resembles	   naturally	  
acquired	  YF	  clinically	  and	  pathologically,	  and	  is	  characterized	  by	  multi-­‐organ	  involvement	  and	  50%	  risk	  
of	  mortality.	  Studies	  are	  being	  conducted	  to	  clarify	  the	  cause	  and	  risk	  factors	  for	  these	  rare	  adverse	  
events	  associated	  with	  the	  YF	  vaccines.	  A	  history	  of	  thymic	  dysfunction	  may	  be	  a	  risk	  factor.	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The	  main	  groups	  of	  adult	  people	  for	  whom	  the	  vaccine	  is	  contraindicated	  are:	  
• People	  with	  severe	  egg	  allergy	  or	  previous	  anaphylactic	  reaction	  to	  a	  previous	  YF	  vaccine	  or	  to	  
any	  components	  of	  the	  vaccine	  	  
• Pregnant	  women	  and	  breast	  feeding	  mothers	  
• Those	  with	  a	  thymus	  disorder	  
• Persons	  with	  immunodeficiency	  caused	  by	  disease	  or	  treatment	  
	  
People	  with	  any	  of	  these	  conditions	  can	  obtain	  a	  waiver	  letter	  prior	  to	  travel,	  although	  some	  countries	  
may	   not	   accept	   waiver	   documents.	   Since	   it	   is	   recognised	   that	   older	   recipients	   are	   more	   at	   risk	   of	  
developing	   YF	   vaccine-­‐associated	   neurotropic	   and	   viscerotropic	   disease,	   older	   travellers	   are	   usually	  
advised	  not	  to	  undergo	  vaccination	  and	  instead	  receive	  a	  certificate	  of	  exemption	  when	  the	  absolute	  
risk	  of	  infection	  is	  low.	  	  
	  
6.	   YFV	   vaccine	   in	   HIV-­‐positive	   adults:	   A	   Cochrane	   review	   evaluated	   the	   risk	   and	   benefits	   of	   YFV	  
vaccination	  in	  HIV-­‐positive	  patients	  [6].	  The	  review	  included	  3	  cohort	  studies	  [7-­‐9]	  and	  reported	  that	  
vaccination	  can	  produce	  protective	   levels	  of	  neutralising	  antibodies	   in	  HIV-­‐positive	  people,	  although	  
immunogenicity	  is	  less	  than	  in	  HIV-­‐negative	  people.	  In	  one	  of	  the	  included	  studies,	  83%	  of	  HIV-­‐positive	  
people	   had	   protective	   YFV	   neutralizing	   antibodies	   titres	   (NT)	   one	   year	   after	   vaccination,	   compared	  
with	   97%	  of	   HIV-­‐negative	   people	   [8].	   NT	  were	   significantly	   lower	   and	   declined	  more	   rapidly	   during	  
follow-­‐up	  in	  HIV-­‐positive	  patients.	  Another	  study	  demonstrated	  high	  NT	  one	  year	  after	  immunization	  
(98%)	  with	  a	  marginal	  decrease	  after	  10	  years	  (92%)	  [9].	  Having	  a	  higher	  CD4	  count	  (>200	  cells/μL)	  and	  
lower	   viral	   load	   at	   the	   time	   of	   vaccination	   were	   key	   associations	   with	   development	   of	   NT.	   The	  
Cochrane	  review	  reported	  that	  none	  of	  the	  484	  HIV	  positive	  persons	  included	  in	  the	  review	  suffered	  
serious	   adverse	   events	   as	   a	   result	   of	   vaccination	   [6].	   The	   data	   cautiously	   support	   the	   safety	   of	   YF	  
vaccination	  in	  HIV-­‐positive	  patients	  with	  CD4	  counts	  >200	  cells/μL	  and	  following	  viral	  load	  suppression	  
on	  ART.	  The	  small	  numbers	  of	  patients	  included	  limits	  conclusions,	  particularly	  the	  very	  low	  numbers	  
(n=21)	  with	  a	  CD4	  count	  <200	  cells/μL.	  There	  has	  been	  only	  one	  report	  of	  death	  after	  receiving	  YF	  17D	  
vaccine	  in	  a	  Thai	  man	  with	  symptomatic	  HIV	  infection	  and	  a	  CD4	  count	  of	  108	  cells/μL,	  probably	  from	  
YEL-­‐AND	  [10].	  	  
	  
7.	  Recommendations	  for	  HIV	  positive	  adults	  
• We	  recommend	  that	  HIV-­‐positive	  persons	  aged	  <60	  years	  and	  with	  CD4	  counts	  >200	  cells/μL	  who	  
are	   due	   to	   travel	   to	   countries	   in	  which	   there	   is	   a	   recognized	   risk	   of	   exposure	   to	   YFV	   should	   be	  
offered	  the	  choice	  of	  vaccination	  [1C]	  
o We	  recommend	  patients	  receive	  counselling	  about	  the	  benefits	  and	  risks	  of	  vaccination	  in	  
relation	  to	  the	  risk	  of	  exposure,	  emphasising	  that	  a	  high	  CD4	  cell	  count	  and	  a	  suppressed	  
viral	  load	  on	  ART	  are	  likely	  to	  maximize	  safety	  and	  efficacy	  of	  vaccination	  [1C]	  
o If	   international	   travel	   requirements	   and	   not	   true	   exposure	   risk	   are	   the	   only	   reasons	   to	  
vaccinate,	  a	  certificate	  of	  exemption	  can	  be	  given	  (some	  countries	  may	  not	  accepts	  waiver	  
certificates)	  [1C]	  
o We	  recommend	  1	  vaccine	  dose	  at	   least	  2	  weeks	  before	  travel.	  Vaccine	  recipients	  should	  
be	  monitored	  closely	  after	  vaccination	  [1C]	  
• We	   recommend	   a	   booster	   after	   10	   years	   for	   those	   at	   continued	   risk,	   providing	   the	   recipient	  
remains	   aged	   <60	   years,	   the	   CD4	   count	   is	   >200	   cells/μL,	   and	   following	   risk	   assessment	   and	  
counselling	  [1C]	  	  
o We	   suggest	   that	   a	   serological	   test	   may	   precede	   vaccination	   and	   guide	   boosting	  
requirements	  in	  those	  at	  greater	  risk	  of	  side	  effects	  [2C]	  
• We	  recommend	  that	  until	  more	  data	  are	  available	  on	  vaccine	  safety,	  HIV-­‐positive	  adults	  with	  CD4	  
counts	   <200	   cells/μL	   or	   >60	   years	   of	   age	   should	   not	   receive	   YFV	   vaccination,	   and	   should	   be	  
discouraged	  from	  travel	  to	  destinations	  that	  present	  a	  true	  risk	  of	  infection	  [1C]	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